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The influenza virus still causes hundreds of thousands of deaths globally, on top of morbidity 
and associated economic burden. We are currently at the height of efforts surrounding the 
ĚĞǀĞůŽƉŵĞŶƚ ĂŶĚ ĞŵƉůŽǇŵĞŶƚ ŽĨ  ‘ƵŶŝǀĞƌƐĂů ? ǀĂĐĐŝŶĞƐ ĂŐĂŝŶƐƚ ƚŚŝƐ ǀŝƌƵƐ ?ǁŝƚŚ ĐůŝŶŝĐĂů ƚƌŝĂůƐ
commencing on the most promising candidates. Despite this, the influenza virus poses more 
of a threat to human life than it ever has previously, with multiple subtypes of pandemic 
potential circulating around the globe. The key to current efforts lies in the priming of the 
immune system towards generating long lasting defences against conserved epitopes and 
conferring heterosubtypic immunity against the surface glycoprotein haemagglutinin. While 
vaccine strategies have expanded rapidly over recent years with ƚŚĞ ĂĚǀĞŶƚ ŽĨ  ‘ŚĞĂĚůĞƐƐ ?
constructs as well as those derived from consensus, mosaic or chimeric sequences, the 
serological techniques to test how effective these vaccines are, have advanced less rapidly. 
Classical serological assays have been shown to be ineffective at detecting the antibodies 
ǁŚŝĐŚ ŵŽĚĞƌŶ  ‘ƵŶŝǀĞƌƐĂů ? ǀĂĐĐŝŶĞƐ ƐƚƌŝĨĞ ƚŽ ĞůŝĐŝƚ ? ƌĞƉůĂĐĞĚ ďǇ >/^ ďĂƐĞĚ ĂƉƉƌŽĂĐŚĞƐ
combined with mouse models measuring in vivo protection. In this thesis, an alternative 
method for the detection of heterosubtypic antibodies is used in depth across multiple 
platforms. Influenza pseudotypes have been employed using chimeric haemagglutinin 
constructs in a comprehensive project aimed at dissecting head and stalk directed 
antibodies present in human serum. Characterised broadly neutralising monoclonal 
antibodies have been tested on panels of influenza pseudotypes including divergent bat 
influenza viruses which hitherto have not been encountered in humans. A further aspect of 
influenza immunity has been covered in the detection of anti neuraminidase antibodies 
which have an important role to play in influenza heterosubtypic immunity. Finally, 
influenza pseudotypes bearing the glycoproteins from the less studied influenza B virus have 
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Chapter 1 : Introduction 
1.1 Influenza virus basics and disease 
Influenza is a respiratory syndrome caused by three of six genera in the orthomyxoviridae 
family, influenza A, B and C. A putative fourth genus (Influenza D) has recently been 
characterised and proposed (Hause et al. 2014). Influenza A virus (IAV) is the most 
widespread, its various subtypes are classified according to their antigenically variable 
surface glycoproteins: haemagglutinin (HA, H1-H18) and neuraminidase (NA, N1-N11). The 
virion consists of a segmented negative sense genome encapsidated within 
ribonucleoprotein complexes (vRNP), which are surrounded by a matrix shell and lipid 
envelope containing the two surface glycoproteins and the M2 ion channel. Influenza A is 
the primary source of the seasonal form of the disease, responsible for up to 500,000 
deaths per annum as well as deaths caused by pandemics such as those occurring in 1918, 
1957, 1968, and 2009 (WHO factsheet N°211, 2014). Influenza B is also of importance, with 
two antigenically distinct lineages co-circulating worldwide causing 20-30% of global 
morbidity (Ambrose and Levin 2012; Glezen et al. 2013; Mccullers et al. 2004). Vaccines 
against influenza need to be regularly updated to match predicted circulating strains that 
are constantly escaping from vaccine protection through a mechanism known as antigenic 
drift. Influenza A is primarily associated with wild fowl/birds in the case of the majority of 
subtypes and can reassort with human strains through antigenic shift to yield human 
compatible viruses with previously un-encountered surface epitopes. Pigs are usually 
considered to be the mixing vessel for rĞĂƐƐŽƌƚŵĞŶƚĂƐƚŚĞǇĞǆƉƌĞƐƐĂŵŝǆƚƵƌĞŽĨɲ-2,3 and 
ɲ-2,6 sialic acid linkages which are the preferred receptor for avian and human influenza 
viruses respectively (Skehel and Wiley 2000). Research on influenza viruses is often hindered 
by the requirement for expensive bio safety level (BSL) precautions, especially in the case of 
the Highly Pathogenic Avian influenza (HPAI, e.g. H5N1, H7N1) or pandemic strains. 
Symptoms caused by influenza virus infection range from a non-febrile upper respiratory 
tract illness to severe or fatal pneumonia. The majority of infections have been reported to 
be self-limiting fevers with respiratory symptoms and many cases have been 
indistinguishable from the common cold. (Komiya et al. 2009; Liang et al. 2009; Ong et al. 




2009; S. I. Park et al. 2010; Plessa et al. 2010). However as many as one third of the infected 
are thought to be asymptomatic (Carrat et al. 2008; C. J. Williams et al. 2010). Nevertheless, 
the WHO estimates suggest that influenza A and B seasonal epidemics cause between 3-5 
million severe cases of influenza disease and 250 to 500,000 deaths per annum (WHO 2003). 
1.2 Influenza virus molecular biology 
The influenza A virus is contains a segmented genome consisting of 8 genes, coding for up to 
14 proteins which are described briefly here, and in further detail in the following sections. 
Segments 1, 2 and 3 form the components of the viral RNA polymerase which associates 
with the vRNP, and the influenza negative sense RNA (-ssRNA) in complex with 
nucleoprotein (NP). Segment 4 is the HA glycoprotein which is the main focus of this thesis. 
Segment 5 codes for the NP and segment 6 the NA glycoprotein which is involved in 
destruction of the HA-receptor sialic acids on infected cells, allowing release of nascent 
virions. Segment 7 codes for the M1 matrix protein, also involved in nuclear export of newly 
synthesised vRNPs, and the M2 ion channel. Segment 8 codes for non-structural proteins 
NS1 and the Nuclear Export Protein (NEP). These various genes are shown in schematic 
format in Figure 1.1. 
 
Figure 1.1. Schematic representation of the influenza virus. Surface glycoproteins HA, NA and M2 
are embedded in the cell membrane, the latter taken from the host cell. The Matrix protein forms 
the core or the virus which encapsidates the viral ribonucleoproteins complexed with viral RNA 
polymerases, on each segment of the multi-partite genome. 
 




The influenza virus infects target ciliated epithelial cells in the respiratory tract through the 
binding and fusion protein HA, which will bind to terminal sialic acids of glycoproteins or 
glycolipids on the surface of its target cells (DuBois et al. 2011). Binding initiates endocytosis 
of the influenza virus and acidification of the resulting endosome, allowing pH mediated 
conformational changes in the HA trimer and facilitating fusion of the viral and host 
endosomal membranes, releasing the viral core into the cytoplasm. Endocytosis has been 
shown to occur both by clathrin-mediated and clathrin/caveolin independent pathways 
(Lakadamyali et al. 2004; Matlin et al. 1981). The viral core then dissociates after M2 
mediated acidification of the viral core, allowing the release of vRNPs coding for the genes 
which make up the influenza virus (Holsinger et al. 1994; Yoshimura and Ohnishi 1984). 
vRNPs are transported to the nucleus via interaction with importin-ɲĂŶĚ ŝŵƉŽƌƚŝŶ-ɴ ?ĂŶĚ
resulting translocation through nuclear pores (Eisfeld et al. 2014). The negative sense 
genome segments are then transcribed into mRNAs by the transcription complex associated 
with every vRNP. ĂƉ ƐŶĂƚĐŚŝŶŐ ƚŚĞŶ ŽĐĐƵƌƐ ? ĐŽŶƐŝƐƚŝŶŐ ŽĨ ƚƌĂŶƐĨĞƌ ŽĨƚŚĞ  ? ? ĞŶĚ ĨƌŽŵ
cellular mRNAs, including the cap, to the influenza mRNA. This allows viral mRNA stability 
and transcription after export from the nucleus (Dias et al. 2009; Fechter and Brownlee 
2005). Polyadenylation of these mRNAs occurs as a result of transcription from the vRNA. 
Viral mRNAs subsequently form a template for the production of negative sense viral gene 
segments as well as being exported to the cytoplasm for translation via the nuclear export 
protein (NEP) and matrix protein (M1) (Bui et al. 2000; Eisfeld et al. 2014; Martin and 
Helenius 1991). Viral proteins are translated and trafficked through the endoplasmic 
reticulum (ER) and golgi apparatus, mediating correct folding and exposure to proteases for 
post-translational cleaving where necessary (HA protein)(Braakman et al. 1991; Doms et al. 
1993; Skehel and Waterfield 1975). Viral glycoproteins are then targeted to the surface of 
the cell, gathering on lipid rafts and promoting the formation of mature viral particles 
exiting the cell (D. P. Nayak et al. 2009; Rossman et al. 2010). Exit is facilitated by the action 
of NA, destroying HA receptors on the surface of the cell and allowing release of viral 
particles. A life cycle diagram is shown in Figure 1.2. 





Figure 1.2. Life cycle diagram for the influenza virus. 1) Attachment to target cells is mediated by the 
HA glycoprotein interaction with terminal sialic acid molecules on the cell surface. 2) Virus 
internalisation, pH dependent fusion mediated by the HA glycoprotein and influenza virus core 
acidification mediated by M2 enable release of vRNPs into the cell cytoplasm. 3) Influenza genome 
replication and protein production is initiated after vRNP nuclear import. 4) Post-translational 
processing of proteins and packaging occurs, producing progeny viruses. 5) Budding of progeny is 
facilitated by influenza proteins, allowing viral egress which is further enabled by NA mediated 
cleavage of surface sialic acid molecules. 6) Cleavage of HA glycoproteins, within the cell or at the 
cell surface allows maturation of new virions. Figure adapted from (Krammer and Palese 2015)  
1.3  HA 
The trimeric attachment and fusion protein HA is the principal constituent of the influenza 
virus envelope, alongside NA and M2. Attachment to sialic acid residues on target cell 
membranes triggers endocytosis and pH dependent exposure and engagement of the fusion 
peptide, mediating entry of the virus (Wiley and Skehel 1987). This process is the basis on 




which influenza neutralisation assays are founded  W the exploitation of attachment and 
entry for the study of HA-directed antibodies and their neutralising ability. Sequence 
analysis has permitted classification of influenza A subtypes into two distinct groups: group 
1 containing HA subtypes 1, 2, 5, 6, 8, 9, 11, 12, 13, 16, 17 and 18 and group 2 containing 3, 
4, 7, 10, 14, and 15. (Fouchier et al. 2005; Tong et al. 2012, 2013). Subtypes within each 
group are often subdivided into clades with further sequence dissimilarity. A phylogeny of 
current influenza HA types and subtypes are shown in Figure 1.3. 
 
Figure 1.3. Phylogeny of current influenza HA subtypes. Influenza A subtypes form two distinct 
groups, group 1 consists of subtypes 1, 2, 5, 6, 8, 9, 11, 12, 13, 16, 17 and 18 while group 2 contains 
subtypes 3, 4, 7, 10, 14, and 15. Influenza B lineages Yamagata and Victoria, Influenza C and 
influenza D show divergence from influenza A based on this phylogenetic analysis. Figure from 
(Carnell et al. 2015)  
 
1.3.1 Structural and antigenic properties of HA 
There are four primary antigenic sites proximal to the binding site of the HA trimer, to which 
neutralising antibodies are generally directed. For H1N1, sites Sa, Sb and Cb are found on a 
single protomer of the HA trimer, and Ca (Ca1 and Ca2) are found in a cleft between two 
receptor binding domains (RBD) (Brownlee and Fodor 2001; Caton et al. 1982; DuBois et al. 
2011; Wiley et al. 1981). These are extensively reviewed and in great detail by Skehel and 
Wiley (Skehel and Wiley 2000). It has been reported in these cited articles that single amino 




acid mutations in these antigenic sites will give rise to drift mutants. For H3N2, the antigenic 
site A consists of a loop of amino acids from residues 140-146, B consists of the outside 
residues of an ɲ-helix between residues 187-196, site C is reported from a bulge between 
cysteine residues 52 and 277 which are linked by a disulphide bridge and the subject of 
techniques to produce chimeric (or hybrid) HAs (chapter 3). Site D is reported between 
residues 207 and 220 (Wiley et al. 1981). Aside from these, there are other epitopes on the 
HA trimer, most notably in the stalk region such as the F domain (Fusion peptide) and 
membrane proximal stem (Corti et al. 2011; Ekiert et al. 2012; T. T. Wang et al. 2010). Other 
sites include Pa and Pb on the HA trimer stalk (A. Wu et al. 2010). It would seem that while 
head proximal antibodies would be involved in obstruction of the RBC, making them 
haemagglutination inhibition (HI) competent antibodies, stalk antibodies work by 
preventing unfolding of the HA trimer and neutralising the action of HA in this fashion. 
These antibodies would not be detected by the HI assay. Despite the notion that high 
densities of glycoproteins can obscure this stalk region, research has suggested, at least in 
the case of pandemic H1N1 (pH1N1) that HA are not packed so tightly as to evade stalk 
reactive antibodies completely. This is partly due to the fluid nature of the influenza 
envelope in which HA, NA and M2 are embedded. ~75% of HAs were shown to be bound by 
bnmAb C179 at the membrane proximal stem (A. K. Harris et al. 2013). See Figure 1.4 for a 
schematic representation of the HA trimer alongside neutral pH and fusion pH 
conformations, discussed in (Y. Zhou et al. 2014). 
1.3.2 Proteases used for cleavage of HA proteins 
As HA is produced and trafficked through the secretory pathway it requires proteolytic 
cleavage in order to become fusion competent. Proteolytic cleavage is mediated by certain 
host cell proteases and subsequently restricts certain subtypes to epithelial cells where 
these required proteases are expressed. Newly folded HA0 precursors are cleaved by trypsin 
or serine proteases (E.g. Human Airway Trypsin) into HA1 and HA2 subunits (S Bertram et al. 
2010; Böttcher et al. 2006; Chaipan et al. 2009).  Cleavage is necessary for fusion 
competence of the HA and its resulting role in and viral infectivity (Klenk et al. 1975; Klenk 
and Rott 1988; Lazarowitz et al. 1973; Lazarowitz and Choppin 1975). 





Figure 1.4. Schematic representation of an HA trimer. A) Globular head domain, Stalk domain and region proximal to the viral envelope are shown. B) The 
conformational changes each HA monomer undergoes are shown, from Neutral pH to Fusion pH whereupon membrane fusion is mediated by HA. Figure 
adapted from Y. Zhou et al. 2014.





The NA protein is an enzyme composed of four identical monomers, each 470 amino acid 
residues in length. They form a homotetramer of which the N-terminal regions form a 
transmembrane region anchoring the glycoprotein in the membrane and associating with 
the viral core (matrix, section 1.5). Each influenza virus typically contains 50 NA tetramers 
on its surface, often arranged in clusters (A. Harris et al. 2006). There are 11 known 
influenza NA subtypes, arranged into two distinct phylogroups based on nucleotide 
sequence analysis. N10 and N11, derived from newly described bat species of influenza are 
divergent with a currently uncharacterised substrate and are discussed in further depth in 
chapter 7. The N-terminal region forms a cytoplasmic tail which is highly conserved among 
all NA subtypes of influenza A, but divergent in influenza B (Shtyrya et al. 2009). NA has a 
globular, mushroom shaped head domain containing the enzymatic active site nestled 
within a pocket in the space within each NA monomer, shown in Figures 1.5 and 1.6. A thin 
stalk region extends this head outwards from the virus envelope. NA is an exosialidase, 
cleaving sialic acid from the surfacĞŵŽůĞĐƵůĞƐŽĨŝŶĨĞĐƚĞĚĐĞůůƐďǇďƌĞĂŬŝŶŐƚŚĞɲ-ketosidic 
linkage between sialic acid and its adjacent sugar molecule (Varghese and Colman 1991). 
This allows release of new virions from the cell surface (Lentz and Air 1986; Palese et al. 
1974). Sialidase function also aids the virus in evading the heavily sialylated glycoproteins 
present in the mucus of the respiratory tract, allowing the virus to reach its target cells 
(Cohen et al. 2013; Matrosovich et al. 2004). In a similar fashion, sialic acid residues on 
infected cells are cleaved, preventing superinfection (I. C. Huang et al. 2008). The active site 
of NA is pictured in Figure 1.6, located at the N-terminal end of central parallel strands 
ůŽĐĂƚĞĚǁŝƚŚŝŶƚŚĞɴ-ƐŚĞĞƚ ‘ƉƌŽƉĞůůĞƌ ? folds of the NA protein (Colman 1994). The active site 
is conserved among all influenza A and B NAs, with only small differences observed between 
divergent sequences (Russell et al. 2006).The length of the NA stalk has been associated 
with pathogenicity in certain highly pathogenic avian influenza (HPAI) strains. These viruses 
with NAs containing truncated stalk regions showed enhanced replication and shedding in 
avian species but not other animals tested (Blumenkrantz et al. 2013; T. W. Hoffmann et al. 
2012; Y. Li et al. 2014). Further studies have confirmed the relationship of NA stalk deletions 
with pathogenicity outside of the avian model, showing an increase in lethality to mice 
resulting from infection by pH1N1 with a truncated NA (S. Park et al. 2017). 





Figure 1.5. Schematic representation of influenza A (N2) tetramer. Each monomer is arranged 
symmetrically around a central axis. Amino acid ribbon structures coloured from blue to red from N- 




Figure 1.6. Schematic representation of influenza A (N2) NA in complex with 2,3 linked sialic acid 
(black), with the functional amino acid residues of NA shown in red. Figure from (Shtyrya et al. 2009) 
  




In recent years a binding property of NA has been characterised after discovery that 
treatment of influenza virus with NA inhibitors reduced its infection efficiency by 1/4 and 
1/8 in Madin Darby Canine Kidney (MDCK) and A549 cells respectively (Ohuchi et al. 2006). 
Mutations (such as D151G and G147R) within the NA of H3N2 viruses have been reported, 
that increase the receptor-binding activity of NA, also compensating for weaker affinity of 
the HA glycoprotein for its receptor.  Despite this, these NAs still carry out their function in 
releasing HA from sialic acids in order to mediate release of new particles (Hooper and 
Bloom 2013; Y. P. Lin et al. 2010). It has been shown that in the presence of non-functional 
NA, mutations can arise in the HA to reduce its binding affinity, allowing release of viral 
particles. This shows that HA and NA affinities are carefully balanced to enable the 
continuation of the influenza life cycle (Mitnaul et al. 2000).  
NA is the target for various antiviral drugs which are widely used. Zanamivir, oseltamivir and 
laninamivir are antivirals which block the action of NA by mimicking its substrate. The latter 
two are prodrugs, taken in by ingestion or inhalation respectively; these drugs are converted 
into the active form of the drugs in the liver (oseltamivir) or respiratory tract (laninamivir). 
Until January 2008 the consensus was that misuse of NA inhibitors would not lead to the 
rise of resistance mutations, until the first instance occurred with the H274Y mutation 
conferring resistance to oseltamivir but not zanamivir (Yen et al. 2007). The 2009 pH1N1 
strain entering circulation and replacing currently circulating seasonal strains was found to 
be susceptible to oseltamivir (Shtyrya et al. 2009).  However, a recent mutation (H275Y) has 
arisen, conferring oseltamivir resistance to pH1N1 strains, despite it still being susceptible to 
zaninamivir and laninamivir (Kamali and Holodniy 2013; Pinilla et al. 2012).  
1.5 M1 
The matrix protein (M1) of the influenza virus forms the core which acts as a shell 
interacting closely with the plasma membrane, acting as a bridge between internal proteins, 
vRNPs and the transmembrane proteins HA, NA and M2, the latter of which interacts with 
M1 via cytoplasmic tail domains (Gómez-Puertas et al. 2000; K. Zhang et al. 2012). M1 pH 
dependent dissociation of the influenza virus core, releases vRNPs into the cell cytoplasm 
upon M2 mediated acidification. M1 is also involved in nuclear import and accumulation of 
viral structural proteins, and the nuclear export of vRNPs (Akarsu et al. 2003; Whittaker et 
al. 1996). M1 is a 242 amino acid long protein with a flexible C-terminal domain which may 




be responsible for the proteins multiple roles in virion shape/stability and interactions 
within the viral life cycle (Gómez-Puertas et al. 2000; Shtykova et al. 2013). To date, 
attempts to determine its full structure have been unsuccessful  W no high resolution model 
has been determined for the entire protein.  
1.6 M2 
The M2 ion channel is responsible for acidification of the influenza virus core after 
internalisation by endocytosis, mediating the dissociation of influenza proteins and release 
of vRNPs into the cell cytoplasm after HA based fusion (Lamb et al. 1985), reviewed in detail 
by Pinto & Lamb 2006. It is also responsible for regulation of the pH within the Golgi 
apparatus or endosome, stabilising the pH sensitive HA protein while it is trafficked to the 
cell surface (Ciampor et al. 1992). M2 is composed of four monomers, each of which is 96 
amino acids in length. This resulting homotetramer is a transmembrane protein with an 
extracellular N-terminal domain 23 amino acids in length, a 19 amino acid transmembrane 
domain and a cytoplasmic tail 54 amino acids long (Lamb et al. 1985; Pinto et al. 1992). This 
protein is not only essential for release of vRNPs through its action as a proton channel, but 
it is also involved in the mediation of virus budding through the action of an amphipathic 
helix located within its cytoplasmic tail. This 17 amino acid long helix has been shown to be 
essential for membrane scission, promoting membrane curvature in a cholesterol-
dependent manner (Rossman et al. 2010). It is also associated with the M1 protein in its 
involvement in viral packaging and budding. Mutations in the cytoplasmic region of M2 have 
been shown to lead to incomplete incorporation of genomc RNA into new viruses, as well as 
defective budding of new particles (B. J. Chen et al. 2008; Imai et al. 2004, 2008; McCown 
and Pekosz 2006; Rossman and Lamb 2011). The pore located in the space within the M2 
homotetramer contains two essential pore-lining residues which are important for proton 
selectivity, allowing unidirectional conductance of the M2 ion channel (Y. Tang et al. 2002; 
C. Wang et al. 1995). M2 is a target for influenza antiviral drugs, discussed in section 1.15. 
1.7 vRNP and polymerase 
The genetic material of the influenza virus is packaged into eight viral ribonucleoprotein 
complexes (vRNP) which consist of viral RNA packaged in multiple nucleoprotein (NP) 
segments and a single trimeric polymerase complex. vRNPs are transported into the host 




cell nucleus via nuclear pore complexes (NPC), allowing transcription and genome 
replication to occur. The NP protein is 498 amino acid residues in length with a positive 
charge at neutral pH (Ng et al. 2009). It binds to the negative sense single stranded RNA (-
ssRNA) gene segment as well as interacting with other NP proteins, and the polymerase 
basic 1 and 2 (PB1 and PB2) parts of the viral polymerase (Biswas et al. 1998; Eisfeld et al. 
2014; Poole et al. 2004). 
The viral polymerase complex is composed of PB1 and PB2 alongside the Polymerase acidic 
protein (PA) in influenza A and B, or Polymerase 3 (P3) in influenza C (Fodor 2013; Resa-
Infante et al. 2011; te Velthuis and Fodor 2016). It is complexed to each individual genome 
segment within the influenza virus, allowing transcription and replication of each vRNA after 
translocation to the nucleus (Area et al. 2004; Fodor 2013; Hutchinson and Fodor 2013). 
Transcription occurs in a primer-ĚĞƉĞŶĚĞŶƚ ŵĂŶŶĞƌ ? ƉƌŽĚƵĐŝŶŐ ŵZEƐ ǁŝƚŚ  ? ? ĐĂƉ ĂŶĚ Ă
poly(A) tail (Plotch et al. 1981) ?dŚĞĐĂƉŝƐ ‘ƐŶĂƚĐŚĞĚ ?ĨƌŽŵŚŽƐƚŵZEƐ by action of the PB2 
cap-binding domain, that allows the cap to be cleaved 8-14 nucleotides downstream by PA 
or P3 (Dias et al. 2009; Guilligay et al. 2008; Yuan et al. 2009). The resulting cap and 
nucleotides are used to prime synthesis of mRNA transcripts for influenza gene segments. 
Replication of influenza gene segments is primer independent, new vRNAs being produced 
via a replicative complimentary RNA (cRNA) intermediate. The polymerase complex is 
intimately linked to host specificity, Nucleoproteins have been shown to co-evolve with the 
other proteins making up the vRNP complex, possibly as a result of functional restrictions 
between proteins (Naffakh et al. 2008). Incompatibility between vRNP proteins is a likely 
hurdle impeding the ability of reassortant influenza viruses from crossing species barriers, 
limiting interspecies transmission (Cauldwell et al. 2014; Long et al. 2013; Obenauer et al. 
2006). 
1.8 NEP 
The Nuclear Export Protein (NEP), previously known as Non Structural Protein 2 (NS2) is 
another key protein involved in the cellular functions of the life cycle of the influenza virus. 
Aside from facilitating the export of vRNPs from the host cell nucleus, NEP also has roles in 
regulating vRNA, viral mRNA and cRNA accumulation (Inglis et al. 1979; Lamb and Choppin 
1979; Lamb and Lai 1980). This role is important as mutations in NEP have been shown to 
compensate for lack of viral polymerase efficiency when infecting cultured human cells with 




avian HPAI viruses (H5N1) (Mänz et al. 2012; Robb et al. 2009). NEP has also been shown to 
have a role in the budding of progeny viruses through recruitment of a cellular ATPase to 
the cell membrane for this purpose (Gorai et al. 2012). 
1.9 NS1 
NS1 is the key influenza protein involved in host cell interactions where it acts to antagonize 
antiviral responses mediated by interferon (IFN) (Hale et al. 2008). It is expressed at high 
levels in the nucleus of infected cells where it carries out its primary function in the blocking 
of cellular innate immunity (Krug and Etkind 1973). In Influenza A viruses, NS1 is typically 
230 amino acid residues in length, with distinct genetically divergent clades named A and B, 
and a third clade for the bat influenza subtypes H17N10 and H18N11 (Tong et al. 2013). 
Clade B NS1 is mainly found in avian strains whereas Clade A NS1 are the most frequently 
encountered. Influenza B and C viruses have their own respective NS1 (281 and 246 amino 
acid residues respectively) variants (Alamgir et al. 2000; Yin et al. 2007). NS1 is a homodimer 
composed of two distinct structural domains, connected by a flexible linker region (Qian et 
al. 1994). An RNA-binding domain makes up the first 73 amino acids and an effector domain 
(ED) completes the protein from residues 80-230. The RNA-binding domain contains six ɲ 
helices which are involved in the binding of double stranded RNAs (dsRNA) (Cheng et al. 
2009). NS1 acts as an IFN antagonist by preventing Retinoic acid inducible gene 1 (RIG-I) 
activation, preventing the triggering of antiviral responses by recognised viral dsRNAs 
(Mibayashi et al. 2007; Rehwinkel et al. 2010; Schmidt et al. 2009). It also acts to block the 
RIG-I signal transduction pathway through its interaction with TRIM25 and Riplet as well as 
preventing RIG-I ubiquitination (Gack et al. 2009; Rajsbaum et al. 2012). NS1 has been 
shown to abrogate activation of the protein kinase PKR, preventing this further activation of 
cellular defensive pathways (S. Li et al. 2006; Lu et al. 1995; Min et al. 2007; Min and Krug 
2006). Further capabilities of this dynamic protein include reducing the expression of type I 
IFN system proteins (such as MxA), delaying or reducing its antiviral effects (García-Sastre et 
al. 1998; Haye et al. 2009). 
1.10 Alternative splicing of Influenza mRNAs 
Various novel proteins have been discovered in recent years, produced from alternative 
splicing of influenza virus mRNAs. PB2-S1 is spliced from Segment 1 mRNA, producing a 




protein localized to the mitochondria which acts to inhibit the RIG-I dependent interferon 
signalling pathway (Yamayoshi et al. 2015). Segment two contains two further non-
structural genes, PB1-F2 and N40, the latter which is currently poorly characterised. PB1-F2 
is involved in induction of cell death in immune cells and together with N40 these proteins 
are beneficial to viral replication, but not essential for the viability of influenza virus, as 
determined by mutational studies (W. Chen et al. 2001; H. M. Wise et al. 2009). 
Segment 3 codes for three further non-structural genes, PA-N182, PA-N15S and PA-X.  All 
three proteins are important for viral replication but not essential, as their absence only 
reduced the efficiency of viral replication and lowered pathogenicity. PA-X plays a role in the 
regulation of host mRNA degradation. Loss of PA-X was shown to increase inflammatory, 
apoptotic and T-lymphocyte signalling pathway kinetics (Jagger et al. 2012; Muramoto et al. 
2013). 
Segment 7 codes for a further ion channel M42 which has an antigenically distinct 
ectodomain to M2. This protein replaced M2 in an M2 null-mutant virus, through a 
compensatory mutation inducing an upregulation in M42 synthesis (H. M. Wise et al. 2012). 
A schematic diagram of all the genes listed in the previous sections is shown in Figure 1.7. 
 
 
Figure 1.7. Schematic diagram showing the eight gene segments of the influenza virus. Segment 1, 2 
and 3 code for PB1, PB2 and PA, the components of the viral polymerase. Segment 4 and 6 code for 
the glycoproteins HA and NA while segment 5 codes for the nucleoprotein. M1 and M2 are coded for 
by segment 7 and NS1 and NEP coded for by segment 8. Schematic adapted from Viral Zone, Swiss 
Institute of Bioinformatics. 




1.11 Epidemiology of Influenza virus 
1.11.1 Seasonal influenza 
Seasonal influenza is the term given to the constant spread of influenza virus around the 
globe, peaking in seasons each year between September and March in temperate countries. 
Seasonal influenza viruses are currently composed of human strains of the virus in the H1 
and H3 subtypes. Vaccination remains the most effective way to reduce mortality and 
morbidity against seasonal influenza viruses. The WHO Global Influenza Surveillance and 
Response System (GISRS), a network of laboratories worldwide, works towards bi-yearly 
update of vaccine strains to predict and match circulating strains as they evolve (WHO 
2003). Due to the dynamics surrounding the circulating strains of influenza, the multiple 
circulating subtypes and lineages and the time required to produce stocks of vaccine, there 
are often mismatches in circulating strains and current vaccines (de Jong et al. 2000; Dos 
Santos et al. 2016; Hoa et al. 2016). This problem is compounded by the elicitation of HA 
head reactive antibodies (Also HI compatible antibodies) by the traditional inactivated 
influenza vaccines used globally. The predisposition of the viral polymerase to inducing 
mutations in progeny influenza virions, alongside the selective pressure on IAVs caused by 
natural infection, drives antigenic drift in this hyper variable head region, leading to the 
need for constant updates of the vaccine strain (L. Du, Zhou, et al. 2010; Mossad 2007, 
2008; Tosh et al. 2010). Despite this, studies have shown that repeated vaccination or 
exposure to seasonal influenza can lead to an increase in cross protective antibodies 
(Pichyangkul et al. 2014). 
1.11.2 Pandemic influenza 
Upon global spread of a novel strain of influenza to which the human population is naive or 
lacking immunity to, a pandemic strain is designated. There have been several influenza 
pandemics in recent human history, the first of note being the H1N1 pandemic (pH1N1) 
 ‘ƐƉĂŶŝƐŚ ĨůƵ ? ? ǁŚŝĐŚ ĐĂƵƐĞĚan estimated 40 million deaths worldwide (WHO 2003). 
^ƵďƐĞƋƵĞŶƚƉĂŶĚĞŵŝĐƐĂƌŽƐĞĨƌŽŵ, ?E ? ?ƚŚĞ  ‘ƐŝĂŶ ŝŶĨůƵĞŶǌĂ ?ŽĨ  ? ? ? ? ?, ?E ? ?  ‘,ŽŶŐ<ŽŶŐ
ŝŶĨůƵĞŶǌĂ ? ŽĨ  ? ? ? ? ĂŶĚ ƚŚĞ  ? ? ? ? ƉĂŶĚĞŵŝĐ  ‘ƐǁŝŶĞ ĨůƵ ? ? Pandemic influenza is generally 
brought about through antigenic shift, a process by which a virus with novel characteristics 
but the ability to infect humans results from co-infection of two or more strains/subtypes 




within the same cell. It has been reported that infection with pH1N1, whether the 1918 or 
2009 strains, leads to increased titres of stalk-directed antibodies which have a role in the 
pH1N1 strain replacing currently circulating seasonal strains (Pica et al. 2012; Thomson et al. 
2012). Also, cross-protection against the 2009 strain was provided by previous infection 
with the 1918 strain (Medina et al. 2010). This phenomenon has been attributed in part to 
protection provided by the Fc region (FcR) of stalk antibodies and subsequent protection 
through antibody dependent cell-mediated cytotoxicity (ADCC) (Tete et al. 2016). The 
heterosubtypic nature of antibodies elicited by pH1N1 viruses lead to an increased 
protection against seasonal strains among the elderly, it has been shown that dominant 
heterosubtypic antibody responses against the HA stalk correlate with absence of memory B 
cells providing immunity against the HA head. Therefore exposure to a pH1N1 strain early 
ŽŶ ŝŶ Ă ƉĂƚŝĞŶƚ ?Ɛ ŝŵŵƵŶĞ ŚŝƐƚŽƌǇ ƐĞĞŵƐ ƚŽ ƉƌŽǀŝĚĞ ƚŚĞŵ ǁŝƚŚ ůŽŶŐ ůĂƐƚŝŶŐ ŚĞƚĞƌŽƐƵďƚǇƉŝĐ
immunity (Thomson et al. 2012).  
 
The 2009 pandemic virus is a triple reassortant influenza virus with internal gene segments 
from Eurasian and North American Swine, Classic Swine and H3N2 triple reassortant viruses 
which were circulating in North America (Garten et al. 2009; G. J. D. Smith et al. 2009). The 
virus itself emerged in Mexico and the United States, spreading rapidly worldwide and 
becoming pandemic. The virus itself has since evolved, the current WHO recommended 
vaccine strain originating from the 2009 pandemic being A/Michigan/45/2015 (H1N1) 
pdm09-like virus. However, this current strain has only 13 amino acid differences in the HA 
gene with the 2009 strain A/Texas/06/2009, shown in the multiple sequence alignment 
generated using Clustal Omega (Sievers et al. 2011). See Figure 1.8. 
 





Figure 1.8. Multiple HA amino acid sequence alignment between pH1N1 strains A/Texas/06/2009 
and A/Michigan/45/2015 13. Amino acid differences are displayed. Amino acid alignment carried out 
using Clustal Omega (Sievers et al. 2011).  
1.12 Innate immunity to Influenza virus 
After the influenza virus reaches the respiratory mucosa, it must overcome the protective 
layer of mucus which lines the respiratory tract. The first defence of the innate immune 
system, influenza viruses will be caught up in the mucociliary escalator and evacuated into 
the stomach for disposal. Some viruses will manage to penetrate this layer, avoiding the 
heavily sialylated mucins present in the mucus through the action of the NA (Cohen et al. 
2013; Matrosovich et al. 2004). Once the virus has finally encountered its target cell and 
initiated an infection, the other aspects of the host cell innate immune system are the next 
line of defence. Upon initiation of replication, single stranded RNA (ssRNA) and double 
stranded RNA (dsRNA) will be produced as the virus carries out its life cycle. These will be 
recognised as pathogen associated molecular patterns (PAMPs), alongside other influenza 




life cycle products, by pathogen recognition receptors (PRRs) (Akira et al. 2006; Medzhitov 
and Janeway 2000; Thompson et al. 2011). 
1.12.1 IFN 
There are four IFN families of which type I is the most important in regards to the influenza 
virus, activating key pathways of the innate and adaptive immune system after activation of 
PRRs (Takeda and Akira 2004). Type I IFN is a multi-gene cytokine family composed of 
multiple IFN-ɲƐƵďƚǇƉĞƐ ?ŽŶĞ /&E-ɴƐƵďƚǇƉĞĂŶĚƐĞǀĞƌĂůŽƚŚĞƌŐĞŶĞƉƌŽĚƵĐƚƐ (Pestka et al. 
2004). Type II IFN consists of IFN-ʄ which is produced by T cells and Natural Killer (NK) cells, 
acting on cells which contain the IFN-ʄ receptor (Schoenborn and Wilson 2007). Type III IFN 
consists of IFN-ʄ1 IFN-ʄ2 and IFN-ʄ3 and IFNʄ ? ?K ?ƌŝĞŶĞƚĂů ? ? ? ? ? ?WƌŽŬƵŶŝŶĂ-Olsson et al. 
2013). These act in a similar manner to Type I IFN cytokines, but are restricted in activity due 
to their receptor only being found on epithelial cells surfaces (Witte et al. 2010). Type I IFN 
are able to induce an antiviral state in infected and bystander cells, interfering with viral 
replication (Yan and Chen 2012). Almost all cell types are able to produce IFN-ɲŽƌ/&E-ɴĂƐĂ
result of stimulation of PRRs by PAMPs. A variety of sensors are present in cells for the 
detection of different PAMPs, recognising ligands or DNA/RNA in different conformations 
(McNab et al. 2015). Toll like receptor (TLRs) activation also leads to IFN-ɲ ?/&E-ɴƉƌŽĚƵĐƚŝŽŶ
of which the relevant TLRs are described in this section (Leber et al. 2008; Pandey et al. 
2009). As well as inducing an antiviral state, IFN also has a direct antiviral action, by 
increasing the expression of IFITM3, MxA and PKR genes described in subsequent sections, 
among others such as the Ribonuclease L and ISG15 ubiquitin-like pathways (Julkunen et al. 
2000; Anthony J. Sadler and Williams 2008). Type I IFNs are extensively reviewed by McNab 
et al. 2015, the remainder of this innate immunity subsection will be devoted to the 
receptors relevant for innate immunity and influenza virus. 
1.12.2 TLR7 and TLR8 
TLR7 recognises ssRNA influenza genomes within endosomes, resulting in nuclear factor ੦B 
(NF-੦B) or interferon regulatory factor 7 (IRF7) activation (Diebold et al. 2004; Lund et al. 
2004). These transcription factors stimulate further expression of pro-inflammatory 
cytokines and type I IFN respectively, blocking viral replication (Honda et al. 2005; Lande et 
al. 2007; Sasai et al. 2010). TLR8 also recognises ssRNA within endosomes  and is involved in 




the innate immune response to viruses such as HIV (Heil et al. 2004). It is expressed in 
human monocytes and macrophages, producing IL-12 upon stimulation by ssRNA (Iwasaki 
and Pillai 2014). 
1.12.3 RIG-I 
RIG-I is a protein that is crucial for viral detection as well as the production of type I IFN in 
infected cells (Kato et al. 2005). /ƚƌĞĐŽŐŶŝƐĞƐ ? ?ƚƌŝƉŚŽƐƉŚĂƚĞǀŝƌĂůƐƐZEŐĞŶĞƌĂƚĞĚĂĨƚĞƌƚŚĞ
start of viral replication (Baum et al. 2010; Hornung et al. 2006; Pichlmair et al. 2006; 
Rehwinkel et al. 2010). RIG-I comes into contact with vRNAs in antiviral stress granules, 
where it co-localises with viral RNA and interferon stimulated gene (ISG) products such as 
PKR. Its encounter with vRNA leads to activation of the mitochondrial antiviral signalling 
protein (MAVS). This results in the production of pro-inflammatory cytokines downstream 
of NF-੦B, and also the production of type I IFNs and ISGs through its activation of IRF3 
(West et al. 2011). 
1.12.4 ISG 
Genes stimulated by IFN which control influenza virus infection include MxA, PKR, IFITM3 
(and other IFITM proteins) as well as TRIM22, Viperin and several other genes, reviewed by 
Iwasaki & Pillai 2014. The Mx proteins were among the first ISGs with anti-influenza roles 
discovered (Ichinohe et al. 2009). MxA is present in the cytosol, acting against influenza A 
and other viruses (Hefti et al. 1999; Pavlovic et al. 1995; Turan et al. 2004). It prevents post-
transcriptional events in the cytoplasm as well as interacting with NP and the influenza 
polymerase (Haller et al. 2009; Pavlovic et al. 1992). 
 IFITM3 acts to block virus-host cell membrane fusion following endocytosis in the first stage 
of infection. It is expressed constitutively in epithelial and endothelial cells as well as in 
macrophages (Brass et al. 2009; Desai et al. 2014). 
The protein kinase PKR blocks translation of influenza genes through its action in 
ƉŚŽƐƉŚŽƌǇůĂƚŝŶŐƚŚĞɲƐƵďƵŶŝƚŽĨĞƵŬĂƌǇŽƚŝĐŝŶŝƚŝĂƚŝŽŶĨĂĐƚŽƌ ?ɲ ?/& ?ɲ ? ? It also activates the 
NF-੦B pathway and stabilises IFN-ɲĂŶĚ/&E-ɴŵZEƐ(Balachandran et al. 2000; Kumar et 
al. 1994; A J Sadler and Williams 2007). 
The tripartite motif 22 (TRIM22) is located in the nucleus and its mRNA and protein levels 
are highly unregulated upon influenza virus infection in epithelial cells. It interacts with 




influenza NP and this results in NP polyubiquitination and degradation through the 
proteasome pathway (Di Pietro et al. 2013). 
1.13 Cell based immunity 
Innate cell based immunity comes in the form of alveolar macrophages, monocytes, 
neutrophils, and NK cells. Alveolar macrophages secrete chemokines and cytokines in order 
to recruit further innate cells, as well as initiating an adaptive immune response (Tripathi et 
al. 2015). These, together with monocytes and neutrophils are recruited to the site of 
influenza infection and, with macrophages, aid in the clearance of virus-infected cells by 
recruited phagocytes (Y. Hashimoto et al. 2007). Neutrophils have been shown to produce 
reactive oxygen species which are responsible for part of the pathology associated with 
influenza virus infection, through tissue damage (Tripathi et al. 2015). Efforts have been 
made to reduce this damage, such as investigation of the compound apocynin, which acts to 
inhibit the NADPH oxidase system involved in neutrophil mediated tissue damage (Vlahos et 
al. 2011). NK cells act to destroy infected cells alongside the activation of cytotoxic T 
lymophocytes. They also regulate the production of IFN-ʄ and interleukin-2 (IL-2). The 
presence of pre-existing influenza virus specific T cells has been shown to increase NK-
mediated innate immunity (He et al. 2004). 
1.14 Adaptive immunity 
Adaptive immunity is instigated by antigen presenting cells (APC), in particular dendritic cells 
(DC) which stimulate T cells. DCs encounter viral antigens either through phagocytosis of 
infected cells, or by being infected. Subsequently, DCs will present viral antigens/peptides 
on the major histocompatability complexes I or II (MHC I and II) and migrate to the lymph 
nodes, allowing interaction with CD4+, CD8+ T lymphocytes as well as B lymphocytes 
(Mildner and Jung 2014). The peptide-MHC complexes will be presented to T cells via the T 
cell receptor (TCR), mediating their activation.  
CD4+ T cells induce the proliferation of CD8+ T cells and B cells, the effectors of the adaptive 
immune system (Sant et al. 2007). Once activated in the lymphatic system by APC antigen 
presentation, CD4+ T cells contribute to viral clearance through induction of IFN pathways, 
described in section 1.12. CD4+ cells can differentiate into two different functional classes of 




helper T cells (TH1, TH2). TH1 cells secrete IFN- ʄǁŚŝůĞdH2 secrete interleukin 4 (IL-4) which is 
critical for the initiation of humoural immunity (Smiley and Grusby 1998). 
CD8+ T cells are activated upon presentation of viral antigens in complex with MHC I, 
allowing their migration to the site of infection (Cerwenka et al. 1999). Memory CD8+ T cells 
present in the lymphatic system from a previous exposure to influenza virus will be re-
activated, allowing a more rapid protective response to a previously encountered, 
antigenically similar virus (Tamura and Kurata 2004). These antigen-experienced CD8+ T 
cells have been shown to immediately degranulate upon recognition of an influenza 
infected cell, killing them, whereas naive cells have a cytotoxic effect without immediate 
degranulation (Wolint et al. 2004).  
Upon activation, B lymphocytes differentiate into plasma cells and begin to produce antigen 
specific immunoglobulin (Ig, antibodies). Depending on the epitope or specific protein to 
which an antibody has been produced, these will either neutralise the action of said protein 
or act as a primer for the induction of cell-directed immunity, for example through Fc 
mediated activation leading to ADCC (Zhong et al. 2016). Alternatively, complement 
mediated cytotoxicity can be induced (Quinnan et al. 1980). 
The humoral immune response at the level of the mucosa involves IgA, which is produced 
locally and transported to the upper respiratory tract via the mucosal epithelium (Palladino 
et al. 1995; Renegar et al. 2004).The lower respiratory tract is where IgG is primarily found, 
this class of Ig has been found to diffuse into the blood where it can be collected and 
analysed as serum. As mentioned previously, the outcome of the production of antibodies is 
dependent on the epitope and protein presented to B cells.  
Antibodies directed against the HA glycoprotein either act to neutralise the virus through 
masking its RBS, or by preventing its ability to unfold and mediate membrane fusion 
(Brandenburg et al. 2013). Anti HA antibodies are further detailed in section 1.18 with 
multiple examples.  
Antibodies against the NA have been shown to block viral replication through the inhibition 
of viral release at the cell surface. Anti NA antibodies therefore have a similar mechanism of 
action to NA antivirals which do not prevent infection but limit symptoms and further 
transmission of the virus (Marcelin et al. 2011, 2012; Wohlbold and Krammer 2014). 




Antibodies against the M2 channel have been associated with poor protection against 
infection, but represent a promising target due to the conserved nature of this protein in 
comparison to other humoral immune targets (B. Nayak et al. 2010; Schotsaert et al. 2009; 
Treanor et al. 1990). 
Anti NP antibodies have been shown to aid cellular immunity against influenza (Carragher et 
al. 2008). This conserved protein has been targeted alongside other influenza proteins that 
are conserved between strains, with safety and T cell mediated immunogenicity reported in 
an NP + M1 MVA vaccine produced and tested in phase I clinical trials by Berthoud et al. 
2011. 
ƵĞƚŽƚŚĞǀŝƌƵƐ ?ĂďŝůŝƚǇƚo drift and shift, evading humoral immune responses, efforts have 
been made to study the effect of immunological memory against the influenza virus. The 
Memory B cell populations plays an essential role in prevention of re-infection against 
similar strains (Ellebedy and Ahmed 2012; K.-Y. Y. A. Huang et al. 2014; Quan et al. 
2007).However this immunological memory puts the viral proteins under pressure, driving 
mutational selection on a global scale and rendering efforts to produce effective vaccines 
fruitless. A further aspect to consider is the phenomenon of original antigenic sin, in which 
exposure to an antigen leads to the generation of a sub optimal immune response to a 
related antigen, such as a from a previously encountered influenza strain (de St.Groth and 
Webster 1966a, 1966b; Francis 1960; Pan 2011). Due to the worldwide circulation of 
multiple subtypes and strains of influenza, characterisation of the effects of original 
antigenic sin on immunity, whether natural or induced by vaccination, is crucial to the future 
of influenza virus research. 
  




1.15 Influenza virus vaccines and antivirals 
Influenza vaccines are available in many forms. Inactivated influenza virus vaccines have 
been produced in trivalent (TIV) or quadrivalent forms (QIV). In general the TIV will contain 
one strain from seasonal H1N1 and H3N2 viruses as well as the predicted dominant 
influenza B lineage strain, whether Yamagata or Victoria. The QIV will generally contain a 
representative from both influenza B lineages. Alternative vaccines include live attenuated 
influenza vaccines (LAIV), available commercially as FluMist or Fluenz, consisting of a live 
and functional influenza virus, attenuated for virulence, often through cold-adaptation 
(Glezen 2004). Protein based vaccines are produced by recombinant technology  W 
production of HA immunogens or truncated versions of HA, often in bacteria. Finally, 
reverse genetics based systems utilise cells to grow viruses with desired characteristics 
(Neumann et al. 2012).  
There are various antivirals available against the influenza virus, intercepting the virus in its 
life cycle at various points. NA inhibitors such as oseltamivir and zanamivir prevent the 
action of the NA enzyme, reducing the ability of nascent viruses to escape infected cells and 
thereby slowing down infection and associated symptoms. These are extensively reviewed 
by De Clercq, 2004 and Moscona, 2005. However, there are NA-inhibitor resistant strains of 
Influenza circulating, with amino acid changes such as E119V or R292K in the NA gene 
resulting in decreased sensitivity to the inhibitor. However, some ferret model studies show 
the drug is still working as intended by reducing spread between ferrets (Herlocher et al. 
2002, 2004; Yen et al. 2005). M2 inhibitors are also available, such as amantadine, 
rimantadine and adamantanamine, which share common features. These block the M2 
protein, preventing its action in acidification of the viral core, preventing dissociation and 
release of vRNPs (Shuck et al. 2000). Various other antivirals are in the process of being 
characterised and are reviewed by De Clercq, 2006. While this field is currently neglected, 
research continues to produce novel M2 inhibitor candidates as well as working efforts to 
overcome resistance mutations in circulating strains of influenza viruses (F. Li et al. 2016; 
Sulli et al. 2013). 
1.16 Universal vaccines and Heterosubtypic immunity: HA 
Universal vaccines aim to induce long lasting immunity, generally by eliciting antibodies 
against conserved regions of the influenza virus. These regions include the HA stalk region in 




order to create pan-subtype or pan-group/multi-lineage vaccines, or conserved epitopes 
between seasonal strains to produce multi-seasonal vaccines (Graham, WHO report). Due to 
the constraints involved with the active machinery of the HA glycoprotein and its 
requirement to change conformation to allow membrane fusion, this target is less amenable 
to antigenic drift and therefore likely less able to evolve around a targeted stalk immune 
response. However, it is possible that the immunodominance of the head region drives its 
evolution, and that conservation seen in the stalk is a result of ƚŚĞ ŝƚ ?Ɛ ƌĞĚƵĐĞĚ
immunogenicity. 
Various methods have been employed in order to design and test universal vaccines. One of 
the most exciting developments in the universal vaccine section of influenza virus research 
is the progress being made on utilisation of chimeric HA (cHA) based vaccines, reviewed by 
Kramer and Palese over recent years (Krammer 2016; Krammer and Palese 2013, 2014, 
2015). These vaccines employ cHA, originally developed and published by Hai and 
colleagues (Hai et al. 2012; Krammer et al. 2013) and developed by this group since 2012 in 
ǀĂƌŝŽƵƐĂƌƚŝĐůĞƐƐŚŽǁŝŶŐƚŚŝƐĂƉƉƌŽĂĐŚ ?ƐĂďŝůŝƚǇƚŽŝŶĚƵĐĞďƌŽĂĚůǇŶĞƵƚƌĂůŝƐŝŶŐĂŶƚŝďŽĚŝĞƐ ŝŶ
mouse models. Cryo EM tomography on these cHAs has shown them to be structurally 
different to native HAs, with a 60° rotation between stalk and head regions. This leads to a 
ŵŽƌĞ ‘ŽƉĞŶ ?ĂƌƌĂŶŐĞŵĞŶƚĂůůŽǁŝŶŐĂĐĐĞƐƐƚŽƚŚĞƐƚĂůŬƌĞŐŝŽŶ ? Despite these differences, the 
cHA is still functional and viruses bearing it has been shown to be infectious in the reverse 
genetics system (Tran et al. 2016). Early work aimed to characterise and build cHAs and 
utilise them as a serological platform through the production of PV (Hai et al. 2012). This 
was followed by a study utilising H6/H1 and H9/H1 cHAs to test for bnAbs in serum from 
H5N1 vaccine clinical trials (Nachbagauer et al. 2014). The H5N1 vaccine elicited bnAbs 
which were effective in a mouse passive transfer model. A similar approach to the cHA 
system was evaluated by Eggink et al., 2014, utilising hyperglycosylation as a tool to shield 
epitopes in the HA head, dampening the immune response elicited against the 
immunodominant head and redirecting immunity to the stalk region. Mice vaccinated with 
hyperglycosylated HA vaccines were better protected against mortality and morbidity than 
those vaccinated with the wild type (WT) HA. dŚŝƐ ĚĂƚĂ ůĞŶĚƐ ĐƌĞĚĞŶĐĞ ƚŽ ƚŚĞ  ‘ƵŶŝǀĞƌƐĂů
ǀĂĐĐŝŶĞ ? ŝĚĞĂ ?ďƵŝůĚŝŶŐƵƉĞǀŝĚĞŶĐĞƚŚĂƚƐƚĂůŬĚŝƌĞĐƚĞĚ ŝŵŵƵŶĞƌĞƐƉŽŶƐĞƐĂƌĞƚŽďĞĂŝŵĞĚ
for. cHAs were further evaluated to be used as vaccines in a system employing head regions 
from multiple subtypes and stalks ĨƌŽŵ ƚŚĞ ƐĂŵĞ , ? ƐƵďƚǇƉĞ ? ĂŝŵĞĚ Ăƚ  ‘ƌĞĚŝƌĞĐƚŝŶŐ ? ƚŚĞ




immune system to the stalk. A panel of influenza viruses were produced bearing cHAs with 
intra or intergroup head/stalk combinations and examined for growth kinetics and the 
preservation of epitopes. cHAs were shown to behave in a similar fashion to WT HAs, 
maintaining stalk epitopes (C.-J. Chen et al. 2016). A vaccine regimen was designed by 
Nachbagauer et al. whereupon a three stage vaccine regimen using H1N1 followed by cHAs 
with H5 and then H8 head domains and the same H1N1 stalk. The vaccine regimen induced 
higher stalk neutralising antibody titres than the seasonal vaccine, with long lasting cross-
reactivity observed alongside protection in vivo (Nachbagauer, Kinzler, et al. 2016). Similarly, 
a more recent study achieved the same results, this time using cHAs with influenza A head 
domains (H5/H7/H8) and an influenza B stalk, mice were protected from lethal challenge 
post vaccination to a diverse set of influenza B strains (Ermler et al. 2017). The cHA system 
has also been employed as a vaccine through the use of VSV vectors, administered via 
intramuscular and intranasal routes  W inducing protective heterosubtypic immunity in mice 
(Ryder et al. 2016).  
A different approach has focused ŽŶƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨ ‘ŚĞĂĚůĞƐƐ ?,ĐŽŶƐƚƌƵĐƚƐĂƐƉƌŽƚĞŝŶ
vaccines allowing the host to produce an immune response against the conserved stalk 
region in the absence of the immunodominant globular head. This approach has been 
followed by several research groups with varying levels of success (Mallajosyula et al. 2014; 
Steel et al. 2010; Valkenburg et al. 2016). Headless HAs, otherwise known as stem 
constructs or mini HAs were born from early work describing the ability to remove the HA1 
region of the influenza HA through acid treatment (Graves et al. 1983). The ability to 
remove the head of the HA trimer allowed access to the stalk and when used as an 
immunogen, generating cross-reactive antibodies. Steel et al. produced a headless HA 
construct and used it to immunize mice, eliciting immunity with broader reactivity than the 
full length HA tested. They also showed full protection from mortality, and partial protection 
from morbidity in a lethal challenge experiment (Steel et al. 2010). H1 stem headless HAs 
designed by the Crucell Vaccine Institute showed structural and bnAb binding properties 
similar to the full length HA tested (Impagliazzo et al. 2015). This construct was used to 
vaccinate mice, inducing complete protection in a lethal challenge experiment using 
heterologous and heterosubtypic strains. This immunogen was also shown to reduce 
morbidity after sublethal challenge in a primate model. A further headless HA immunogen 
designed at the National Institutes of Health (NIH) conferred heterosubtypic protection in 




mice and ferrets. This design employed a stabilised H1 stem with conserved epitopes, also 
conferring protection through serum transfer in mice (Yassine et al. 2015). Similarly to 
previously cited examples, broadly neutralising, yet group 1 specific antibodies were 
generated by an H5 headless HA generated by Valkenburg et al. Once again, passive transfer 
of serum protected mice tested from influenza challenge (Valkenburg et al. 2016) 
1.17 Other universal vaccines 
Influenza vaccine research groups or projects have had success in the elicitation or 
detection of heterosubtypic immunity to influenza. While seasonal vaccination has been 
shown to primarily induce head directed antibody responses, some level of heterosubtypic 
immunity has also been shown (Ding et al. 2011). It is important to note differences 
between age groups infected with influenza viruses and the immune complement 
depending on previous exposure history. The elderly are known to have higher stalk 
directed antibodies due to sequential exposure to strains over the years, as opposed to the 
young who may have a more head-dominated response. This data was further validated by 
a recent study (Nachbagauer, Choi, et al. 2016). Sequential sH1N1 vaccination has also been 
shown to induce heterosubtypic immunity, in a similar fashion to the cHA system utilising 
divergent HA heads. Kirchenbaum et al showed that sequential vaccination of ferrets with 
sH1N1 lead to protection from pH1N1 challenge and resulted in poor transmission between 
ferrets (Kirchenbaum et al. 2015). In 2010, heterosubtypic immunity was elicited through a 
bivalent H1/H3 vaccine, allowing recipients to produce a bnAb which was able to neutralise 
an H5 strain (Corti et al. 2010). This group isolated 20 heterosubtypic mAbs which were able 
to bind group 1 influenza viruses, including the recent pH1N1 strain. bnAbs were found to 
bind the acid sensitive epitopes in the stalk. Attempts at using exotic H5N1 strains as 
vaccine candidates has also given rise to heterosubtypic antibodies, for example in the use 
of a H5N1 DNA vaccine candidate followed by an inactivated vaccine (Joyce et al. 2016). A 
different approach utilising an MVA delivered recombinant vaccine using a mosaic H5N1 
was also successful in generating protection to the matched H5N1 subtype as well as H1N1 
(Kamlangdee et al. 2016). 
Several recent articles have recently shown that natural infection by G2 subtypes H3 or H7 
lead to increases in heterosubtypic antibodies in patients. H3N2 infection was reported to 
elicit more cross-reactive antibodies than through inactivated virus or HA DNA vaccination 




(Margine et al. 2013; Moody et al. 2011). Similarly, natural infection to H7N9 influenza virus 
has been reported to induce both G1 and G2 specific bnAbs (L. Liu et al. 2017). 
Attempts to induce antibodies against the conserved M2 protein ectodomain (M2e) are 
ongoing, with vaccines in clinical development (Ramos et al. 2015). While the M2 protein is 
poorly immunogenic, being shielded by HA and NA glycoproteins on the surface of the 
influenza virion, this protein is present in higher numbers on infected cells and may induce 
immune responses in the form of ADCC (Nachbagauer and Krammer 2017; Schotsaert et al. 
2009). Vaccines against the M1 and NP proteins are also aimed at eliciting heterosubtypic 
immunity due to their conserved nature between strains. While these proteins are usually 
shielded from antibodies, they can provide protective immunity in the form of T-cell 
epitopes (M. Zheng et al. 2014). Vaccination with NA or NA + M2e VLPs from 2009pdm 
influenza protected mice from subsequent challenge by H3N2 influenza through CD8+ 
reactive T cell responses, while this was not observed in HA vaccinated mice (Schotsaert et 
al. 2016). Part of the effectiveness of whole virus vaccines can be attributed to NA targeting 
antibodies, which have been shown to also contribute to heterosubtypic immunity 
(Eichelberger and Wan 2014; W.-C. Liu et al. 2015). Various universal vaccines are discussed 
by Nachbagauer & Krammer 2017 with clinical trial information reported. Figure 1.9 shows a 
variety of universal vaccine approaches. 
1.18 Stalk antibodies 
Much of the work in identification of influenza HA epitopes has been carried out using mAbs 
and associated crystal structures of mAbs bound to their epitopes, via x-ray crystallography. 
This section will describe some of the main stalk-directed mAbs discovered over recent 
years. CR9114 was produced by the Crucell Vaccine Institute (now Janssen Pharmaceutical 
Companies of Johnson and Johnson), binding at the HA stem and was shown to protect mice 
from lethal challenge with Influenza A and B strains (Dreyfus et al. 2013). This mAb 
competed with CR6261 which binds to the membrane proximal stem of HA  W both of these 
antibodies therefore act on HA by preventing conformational changes required for the 
fusion process (Ekiert et al. 2009). The F16 mAb was characterised in 2011 by Corti et al., 
2011, binding to the F sub domain of the fusion peptide of influenza HA, neutralising all 16 
subtypes of influenza A tested. Another important mAb of note is C179, generated after 
mice were immunized with A/Okuda/1957 (H2N2) by a group in Japan. This mAb recognises 




group 1 influenza viruses, binding two monomers of the HA trimer in the stalk region 
(Okuno et al. 1993). Finally, yet another stalk binding mAb was characterised, F10. This mAb 
binds ƚŽŚǇĚƌŽƉŚŽďŝĐ  ‘ƉŽĐŬĞƚƐ ?ǁŝƚŚŝŶƚŚĞ,ƐƚĂůŬ ?ŶĞĂƌƚŚĞĨƵƐŝŽŶ peptide. This mAb was 
shown to neutralise a broad range of group 1 influenza viruses (Jianhua Sui et al. 2009). 
Interestingly, part of the immunity provided by stalk directed mAbs has been associated 
with protection through promotion of ADCC through the Fc portion of the bnAb. One study 
managed to enhance Fc engagement, leading to increased cytotoxicity (DiLillo et al. 2014). 
Alternative approaches have employed nanobodies  W derived from camelids (reviewed by 
Muyldermans, 2013)  W in a similar fashion to mAbs. Nanobodies which bind to HA stalk 
regions in overlapping epitopes with CR6261 and F10 (fusion peptide) have been 
characterised and employed successfully in binding and neutralisation assays (Gaiotto and 
Hufton 2016). 
 
Figure 1.9. Various universal vaccine approaches to the influenza virus. A) Vaccines targeting the HA 
head are strain specific and neutralising while those targeting the stalk are cross-reactive as well as 
inducing ADCC based immunity. B) M2 ion channel vaccines targeting the M2 ectodomain are non-
neutralising but may induce ADCC. B-D) M2e, M1 and NP vaccine approaches confer broadly cross-
reactive immunity due to the conserved nature of these proteins. Figure from (Nachbagauer and 
Krammer 2017). 





1.19.1 Basic introduction 
Serology takes the form of many different assays when dealing with influenza virus 
immunity. The primary protein to which antibodies are generated (HA) is used in the 
majority of assays aimed at detecting immune responses to the virus. Serological 
experiments for influenza have been reviewed in depth by Trombetta et al., 2014. The HI 
assay was designed based on the ability of influenza viruses to agglutinate erythrocytes (red 
blood cells, RBC) through action of its RBS, forming a lattice of RBCs in lieu of a pellet when 
added to a V-bottom micro titre well. ĚĚŝƚŝŽŶŽĨĂŬŶŽǁŶŶƵŵďĞƌŽĨ,/ ‘ƵŶŝƚƐ ?ƚŽĂ ? ?-well 
micro titre plate with serial dilutions of serum allowed measurement of neutralising 
antibody titres to different strains of influenza virus. This assay is still widely used to 
measure immunogenicity of vaccines and immunity after natural infection; however several 
caveats have arisen since its inception. An HI titre above 40 has been shown to be a good 
correlate of protection in adults, but not children, the latter of which have a reduced 
capacity to mount an immune response leading to elicitation of HI competent antibodies (de 
Jong et al. 2003; Hobson et al. 1972). Currently there is an issue with the type of red blood 
cell used; with viruses derived from different hosts giving dissimilar results based on the 
ƐƚƌĂŝŶ ŝŶ ƉĂƌƚŝĐƵůĂƌ ?Ɛ ĂǀŝĚŝƚǇ ĨŽƌ ƚŚĞ ǀĂƌŝŽƵƐ ƐŝĂůŝĐ ĂĐŝĚ ŵŽŝĞƚŝĞƐ ŽŶ ZƐ ? As well as this, 
certain human seasonal strains within the H3N2 subtype have changed their avidity to RBC 
receptors over the years. For example, H3N2 strains have  lost the ability to bind to chicken 
RBCs used in the 1990s, but since 2003 have regained the ability to bind them (Gulati et al. 
2013; Kumari et al. 2007; Yi Pu Lin et al. 2012; Medeiros et al. 2001; Nobusawa et al. 2000). 
Research suggests amino acid changes in residues 190 and 226 in the HA trimer RBS was 
involved in the reduction of HI ability of these viruses (Medeiros et al. 2001; Nobusawa et al. 
2000). Various groups have also shown that alongside a reduction in binding affinity of the 
H3 HA over recent years, the NA has compensated and become involved in the infection 
process by reduced ability to cleave sialic acids and subsequent change in the balance 
between receptor destroying and receptor binding properties of NA or HA (Y. P. Lin et al. 
2010). The balance between HA and NA binding and affinities has further reaching 
implications, anti NA antivirals are now required to test for HA antigenicity using the HI 




assay, in order to prevent false positives arising from NA mediated haemagglutination (Y. P. 
Lin et al. 2010). 
Viral neutralisation or microneutralisation (MN) enables a direct observed response against 
the cytopathic effect (CPE) of the influenza virus tested (44). Neutralisation is observed by 
all antibodies which block viral entry and therefore will include stalk as well as head directed 
antibodies. For this reason this assay is an excellent tool for the detection of antibodies. 
However, due to the requirement for live virus, this experiment must be carried out under 
higher BSL conditions when using highly pathogenic or hazardous strains of influenza, 
reducing the ease at which data can be generated. Furthermore, viruses must be grown for 
this experiment and therefore must be amenable to growth in eggs or cell based systems. A 
recent study was carried out in order to compare MN protocols and resulted in a large scale 
study (Laurie et al. 2015). Single Radial Haemolysis was developed in 1975, utilising antibody 
diffusion within an agar gel and complement mediated haemolysis induced by antibody-
antigen complexes (Schild et al. 1975). This forms zones of haemolysis that can be measured 
and thus compared between sera (Morley et al. 1995; Schild et al. 1975; Vaerman, J 1981). 
The Enzyme-linked lectin assay (ELLA) is an ELISA based assay aimed at detecting NA activity 
through NA-mediated digestion of Foetal bovine serum (FBS) derived Fetuin, which is pre-
coated on compatible microtitre plates. This assay is the focus of Chapter 5 where it is 
described in further detail. ELISA based approaches are used regularly in influenza virus 
research. Microneutralisation ELISA combines the elements of viral neutralisation and ELISA 
detection, by detecting NP produced after viral infection, which can be knocked down using 
serum (de Boer et al. 1990; Rowe et al. 1999; WHO 2011). Other uses of ELISA include using 
HA or inactivated virus to coat wells as capture antigens for antibodies, with subsequent 
ELISA colorimetric readout. The ADCC assay measures the effect of the antibody region FcR 
role in cellular cytotoxicity through its relationship with NK cells. In this way, antibodies 
which do not neutralise influenza in the traditional assays can be assayed for an in vivo role 
in protection through ADCC (Greenberg et al. 1978; G. Hashimoto et al. 1983a, 1983b; 
Jegaskanda et al. 2014; Vella et al. 1980; Zhong et al. 2016). See Figure 1.10 for a life cycle 
diagram of the influenza virus alongside each point in which antibodies can neutralise the 
virus. 
 




Figure 1.10. Simplified life-cycle diagram for the influenza virus with methods of neutralisation 
highlighted by bound antibodies. 1) NA targeting antibodies can prevent release of incoming or 
outgoing influenza viruses from mucins. 2) HA mediated binding of influenza viruses to target cells 
can be prevented by HA targeting antibodies. 3) HA fusion with endosomal membranes can be 
prevented by HA stalk targeting antibodies. 4) Nascent influenza viruses can be neutralised during 
egress from the cell. 5) Maturation of HA through proteolytic cleavage can be prevented by HA stalk 
bound antibodies. 6-7) Influenza directed antibodies can prime ADCC through FcR interactions as 
well as NK cells and complement cascade. Figure from (Krammer and Palese 2015)  
  





The consortium for the standardization of influenza seroepidemiology (CONSISE) is a group 
of laboratories with the goal of standardising serological techniques in order to inform 
public health and improve the consistency of intra and inter laboratory data. The CONSISE 
group will be mentioned in chapter 5 where ELLA was attempted with PV in accordance to 
CONSISE approved protocols. 
1.21 Introduction to influenza virus and pseudotypes 
In this section, the methods used for the production and use of PV will be described in the 
context of the current published literature utilising them, detailed in (Carnell et al. 2015). 
1.21.1 Influenza pseudotypes 
PV ĂƌĞĐŚŝŵĞƌŝĐ ‘ǀŝƌƵƐĞƐ ?ĐŽŶƐŝƐƚŝŶŐŽĨĂƐƵƌƌŽŐĂƚĞǀŝƌƵƐĐŽƌĞƐƵƌƌŽƵŶĚĞĚďǇĂůŝƉŝĚĞŶǀĞůŽƉĞ
with the surface glycoproteins of another virus, such as HA. By removing the genetic 
element of the virus being studied and replacing it with a suitable reporter, these viruses 
can be studied in this safer, single cycle system. The comparative safety of PV circumvents 
the need for restrictive, expensive and widely unavailable BSL facilities, increasing access to 
research groups interested in highly pathogenic or hazardous viruses.  
PV are defined as a replication deficient viruses containing a viral core from one species and 
bearing glycoproteins from another that are not represented in the genome, in respect to 
this thesis.  
1.21.2 Cores and reporters 
The core and its associated genome containing a reporter are the backbone of the PV 
system which can be used to study the properties of selected entry glycoproteins. The use 
of cores from lentiviral Human Immunodeficiency Virus 1 (HIV-1) and gammaretroviruses 
such as Murine Leukemia virus (MLV) predominate in the influenza pseudotype literature. 
Recent use of systems involving rhabdoviruses, in particular the vesicular stomatitis virus 
(VSV) has also been used to produce pseudotype cores with promising results (Cheresiz et 
al. 2014). 
  




1.21.3 Retroviral cores and vectors 
Retroviral (including lentiviral) vectors are complex systems which will be explained in 
simple terms specific to the production and use of pseudotypes. Core and vector systems 
have been reviewed in great detail (Blesch 2004; Sakuma et al. 2012). The primary genes 
provided by retroviral or lentiviral systems are gag and pol. In the case of HIV, gag provides 
the structural proteins p18, p24 and p15, whereas pol provides the integrase and reverse 
transcriptase enzymes in conjunction with the p10 protease required for maturation of each 
distinct protein from their respective polypeptide chain (Engelman and Cherepanov 2012; 
Jacks et al. 1988). Reporter constructs are associated with their respective cores based on 
the packaging signal element (Psi, Ɏ ? incorporated in the vector design process, making 
them specific to the surrogate species used. HIV-1 cores are derived from several different 
origins between laboratory groups. First generation pNL4-3 vectors are well represented in 
the literature, the pNL4-3-Luc.E-R- variant is the most commonly used (Stephanie Bertram 
et al. 2012; M. W. Chen et al. 2008, 2011; Labrosse et al. 2010; Pappas et al. 2014; Zmora et 
al. 2014). This replication deficient proviral HIV-1 clone is derived from the pNL precursor 
but has inhibitory frame shifts in the env and vpr genes as well as a luciferase reporter gene 
cloned into the nef gene, the entire construct is incorporated into progeny pseudotypes. Its 
life cycle mimics that of HIV-1, using the ɎĞůĞŵĞŶƚƚŽĂůlow encapsidation ŽĨƚŚĞ ‘ŐĞŶŽŵĞ ? 
into nascent PV and Long Terminal Repeat (LTR) regions  ?ĐŽŶƐŝƐƚŝŶŐŽĨ ? ?ĂŶĚ ? ?ƵŶƚƌĂŶƐůĂƚĞĚ
regions U3/U5 and transcription regulatory region R) bearing the U3 promoter, which with 
the aid of tat, permit the expression of the viral proteins after integration into the host 
genome. The rev responsive element (RRE) allows nuclear export of viral mRNA, including 
the reporter gene transcript which is the measure of output for this system. Due to the 
incorporation of the HIV core genes into the same integrated construct as the reporter, 
transduced cells may possibly produce luciferase containing cores alongside its transcribed 
enzyme which could potentially interfere with luciferase activity output. Another commonly 
used HIV-1 ĐŽƌĞǀĞĐƚŽƌŝƐƉDsȴZ ? ? ? ?ĂƌĞůĂƚŝŽŶŽĨƉDsȴZ ? ? ?ǁŚŝĐŚƐƚŝůůĐŽŶƚĂŝŶƐŝŶƚĂĐƚ
vif, vpr, vpu and nef genes (Ding et al. 2011; Hashem et al. 2010; Wei Wang et al. 2008; S. 
Zhang et al. 2008; F. Zhou et al. 2012; Zufferey et al. 1997).  
A further approach uses the second generation HIV vector p8.91 that originates from pCMV 
ȴZ ? ? ? ĂŶĚ ȴZ ?(Naldini et al. 1996; Zufferey et al. 1997) which is the vector used in the 




projects reported in this thesis. The p8.91 vector is a modified HIV-1 clone, lacking the Ɏ
sequence as well as the env, vif, nef, vpu and vpr genes and is widely used in the published 
literature (Ahmed et al. 2015; Smith et al. 2013; Molesti et al. 2014; Benfield et al. 2015). 
The human cytomegalovirus (hCMV) promoter is used in lieu of LTR based promotion, 
meaning that p8.91 provides the necessary genes for the production of the core but the 
ƉƌŽǀŝƌĂů ĂŶĚ ƉĂĐŬĂŐŝŶŐ ĞůĞŵĞŶƚƐ  ?>dZƐ ? ZZ ? Ɏ ? ĂƌĞ ƚƌĂŶƐĨĞƌƌĞĚ ƚŽ Ă ƐĞƉĂƌĂƚĞ ƉůĂƐŵŝĚ
bearing the reporter gene. Thus the reporter construct will be incorporated into nascent PV 
ĂŶĚŝŶƚĞŐƌĂƚĞĚŝŶƚŽƚŚĞƚƌĂŶƐĚƵĐĞĚĐĞůů ?ƐŐĞŶŽŵĞ ?ǁŚĞƌ ƵƉŽŶƚŚĞ>dZƐĂŶĚZZǁŝůůĂĐƚƚŽ
enhance expression. In the case of the commonly used firefly luciferase or green fluorescent 
protein (GFP) containing plasmids pCSFLW or pCSGW, a safety component is incorporated 
ƚŚƌŽƵŐŚ Ă ĚĞůĞƚŝŽŶ ŝŶ ƚŚĞ  ? ? >dZ  ?h ? ƉƌŽŵŽƚĞƌ ƌĞŐŝŽŶ ? ? ĐƌĞĂƚŝŶŐ ƐŽ ĐĂůůĞĚ ƐĞůĨ-inactivating 
(SIN) vectors (E. Wright et al. 2010; Zufferey et al. 1998). Third generation vectors have also 
been used, in this instance HIV-1 structural and accessory genes are separated from rev, 
which is provided in cis on an additional plasmid. The third generation Invitrogen ViraPower 
Lentiviral Expression System has been used in published research articles, using the 
plasmids pLP1 and pLP2 (Sawoo et al., 2014; McKay et al., 2006; Finer et al., 1994; Farrell et 
al., 2002). 
MLV cores are less widely used but provide similar gag and pol elements to HIV-1 vectors 
(Hatziioannou et al. 1999; Haynes et al. 2009; I. C. Huang et al. 2011; Oh et al. 2009; Tao et 
al. 2013; Wallerstrom et al. 2014; S.-Y. Wang et al. 2009). One available MLV core used 
consists of gag and pol under the effect of a CMV promoter (Bock et al. 2000; Soneoka et al. 
1995; Towers et al. 2000). In this instance the vector originates from MLV expression vectors 
pCI G3 N, B or NB which are differentially restricted in certain murine cells based on the 
mouse resistant gene alleles Fv1N and Fv1B (Hartley et al. 1970). The reporters used in this 
system are derived from CLONTECH vectors LNCX and pIRES2-EGFP (Bock et al. 2000; 
Towers et al. 2000). Another described MLV plasmid, pkatgagpolATG originates from 
ecotropic Moloney MLV and strain 4070A (Wei Wang et al. 2008). Minor differences have 
been observed when pseudotyping HIV or MLV cores with influenza glycoproteins 
(Temperton et al. 2007). Therefore the question of which core to use to produce 
pseudotypes is often down to choice, preference and availability (Garcia and Lai 2011). See 
Figures 1.11-1.14 for schematic diagrams of the types of PV cores, as well as HIV-1 and MLV 
packaging constructs and reporters compared to retroviral proviruses.  





Figure 1.11. Schematic representation of different PV cores.. Components of influenza pseudotypes 
can be varied according to need. Pseudotypes have been produced with HA, NA, and M2 influenza 
envelope proteins, with a range of core packaging constructs (HIV, MLV, VSV shown) as well as 
different reporters. Figure from (Carnell et al. 2015). 
1.21.4 VSV PV 
Recombinant VSV viruses are produced expressing GFP in lieu of the resident VSV envelope 
glycoprotein (VSV-G). In certain cases, HA and NA or simply HA are also added to the VSV 
genome. These additions produce a replication-competent virus which will promote GFP 
production in infected cells (Zimmer et al. 2014). As these recombinant viruses are not 
limited to a single cycle of replication, they lack the safety element found within other 
pseudotypes. A safer VSV based alternative involves transfection of surface protein 
encoding plasmids (HA/NA) into cells and subsequent infection with a recombinant VSV. In 
this way one can produce VSV pseudotyped with influenza surface proteins which lack 
entry-glycoproteins in its resident genome, rendering the second generation of virus 
infection incompetent (Cheresiz et al. 2014). 
 
 





Figure 1.12. Schematic diagram comparing the HIV-1 provirus with first generation HIV-1 packaging 
constructs. First generation packaging constructs are composed of the HIV-1 provirus with a 
disrupted glycoprotein gene and often an inserted reporter gene. In this system, the HIV-1 genome 
depicted is incorporated into PV and transduced into target cells. 
 
Figure 1.13. Schematic diagram of an MLV provirus and example MLV packaging system. Genes are 
separated into two plasmids to allow packaging genes gag and pol to be expressed and a separate 
retroviral vector containing a reporter gene incorporated into PV. 





Figure 1.14. Schematic diagram of second and third generation HIV packaging constructs. These 
differ from first generation packaging constructs as HIV-1 genes have been separated into two 
plasmids, allowing the expression of gag and pol structural genes in cis while the genome 
incorporated into PV (shown in figure 1.6) lacks complete HIV-1 genes. The third generation 
separates rev into a third plasmid, preventing the incorporation of rev into PV. 
 
 
Figure 1.15. Schematic diagram of lentiviral vectors used with second or third generation HIV-1 
packaging constructs. Vectors enable the expression of the reporter gene in transduced cells, while 
limiting the involvement of HIV-1 genes in the use of PVs. Top vector includes HIV-1 LTR regions 
involved in replication and integration. Lower vector prevents replication through deletion of the U3 
region of the LTR, producing self-inactivating 
 
  




1.21.5 Reporter systems 
The output of the PV system is based on the incorporated reporter which mimics the 
genome of the surrogate virus. In the case of HIV-1 or MLV surrogates, the reporter will 
often be incorporated into the pseudotype in RNA form, which upon transduction will be 
reverse transcribed, translocated to the nucleus and integrated into the host cell genome. 
The reporter will then be transcribed and translated by the host cell and its action used to 
measure transduction efficiency. The primary reporter used in influenza pseudotypes is 
firefly luciferase (Mullarkey et al. 2013; Lingwood et al. 2012; Su et al. 2008; Rao et al. 2010; 
Loureiro et al. 2011; Wei et al. 2012; Ledgerwood et al. 2013; Wei et al. 2008; Wang et al. 
2014). Relative luminescence units (RLU) or relative luciferase activity (RLA) are used as 
output, measured by lysing transduced cells and adding substrate for the luciferase enzyme, 
the signal from which is then read using a luminometer. GFP is also commonly used, in 
which case transduction efficiency is determined by counting the number of fluorescing cells 
via epifluorescence microscopy or fluorescence-activated cell scanner (FACS) (Ao et al. 2008; 
J. Wu et al. 2010). Other reporters such as lacZ (Ao et al. 2008; Hatziioannou et al. 1998; 
Konishi et al. 2008; McKay et al. 2006) as well as Gaussia (Hai et al. 2012) and Renilla 
(Ascione et al. 2009; B. Su et al. 2009) luciferase are also used to a lesser extent in the 
published PV literature.  
See Figure 1.16 for a comparison of published influenza strains used in the production of PV 
in comparison to the total number of HA sequences in NCBI GenBank. Figure 1.17 shows the 
various PV production parameters used in the published studies using PV.  






Figure 1.16. Comparison of influenza HA strains described against published HA strains incorporated 
into PV. Out of a total of 60693 HA sequences extracted from NCBI GenBank, the vast majority come 
from subtypes H1, H3, H5 and influenza B. Conversely, the current number different subtypes and 
strains of HA used to produce pseudotypes is 82. The majority of PV strains come from subtypes H1, 
H3 and especially H5. Figure from (Carnell et al. 2015). 







Figure 1.17. Pseudotype production methods. Various parameters including method of HA cleavage 
(A), PV release (B), retroviral cores used (C), reporter used (D) and transfection reagent used (E) for 
the production of influenza PV. Figure from (Carnell et al. 2015). 
 
  




1.21.6 Titration methods 
With luciferase reporter PV the RLU can be used as a secondary measure of pseudotype 
quantity within a sample, but this is dependent on many variables surrounding the cells and 
the particular luminometer used. Pseudotypes are typically 2-fold serially diluted down or 
across 96-well plates from a starting 100 µL of harvested supernatant. After an incubation of 
48 or 72 hours, RLU can be measured by lysing the transduced cells and adding luciferin 
(luciferase substrate). This can then be used to calculate the RLU per well and the RLU/ml of 
the original sample. Reverse transcriptase quantative PCR (RT-qPCR) has also been 
employed in order to estimate transduced gene copies as well as messenger RNA (mRNA) 
copies in cells. This method is often used in conjunction with others described in this section 
in order to have comparative measurements of pseudotype quantity (Wu et al., 2010; Zhang 
et al., 2010; Du et al., 2010b). In many studies, PV input is normalized via enzyme-linked 
immunosorbent assay (ELISA) detection of the principal component of the HIV-1 core, p24 
(Sawoo et al. 2014; Du et al. 2010; Su et al. 2009; Zhou et al. 2012; Ao et al. 2008; 
Schmeisser et al. 2013; Wang et al. 2010; Wang, Xie, et al. 2010; Wei et al. 2011; Chaipan et 
al. 2009; Wang et al. 2008; Zhao et al. 2011; Nefkens et al. 2007; Bosch et al. 2001; Basu et 
al. 2014). However, as core budding is independent of surface HA, this method will also 
detect cores lacking envelope glycoproteins as well as cores belonging to replication 
competent pseudotype viruses. PV HA has also been detected using ELISA and used to 
normalize pseudotype input (Yang et al. 2014; Wang et al. 2013; Li et al. 2011). 
Quantification through HI assay has also been used frequently (Hai et al. 2012; Whittle et al. 
2014; Yang et al. 2014; Zheng et al. 2012; Zhang et al. 2009; Tisoncik et al. 2011; Zhang et al. 
2010; Hultberg et al. 2011; Sawoo et al. 2014; Yang et al. 2007; Wu et al. 2010; Wei et al. 
2011). Western blotting is used in some cases to determine the amount of glycoprotein or 
HIV-1 p24 in a PV sample (Du et al. 2010a; Su et al. 2009; Wang et al. 2011). It is also used in 
a wider range of studies to ascertain glycoprotein or HIV-1 p24 expression (N. Du et al. 2010; 
Sawoo et al. 2014; Wei Wang et al. 2008; J. Wu et al. 2010; Y. Zhang et al. 2010). 
  




1.21.7 Cell Input  
The vast majority of studies involving neutralisation assays titrate and transduce in 96-well 
plates with 1x104 cells (HEK293, HEK293T/17 or MDCK) per well. However, the amount of 
cells can range from 5x103 to 1x105. In some instances, 293A and MDCK-London cells are 
also used, whereas BHK-21 cells are frequently used for VSV-based pseudotype infection 
due to their comparative susceptibility (Hanika et al. 2005; Wei et al. 2011; Kong et al. 2006; 
>ĞĚŐĞƌǁŽŽĚĞƚĂů ? ? ? ? ? ?K ?ŽŶŶĞůůĞƚĂů ? ? ? ? ? ?>ĞĚŐĞƌǁŽŽĚĞƚĂů ? ? ? ? ? ?>ŝŶĞƚĂů ? ? ? ? ? ?ZĂŽ
et al. 2008). Specialised cells over-expressing ɲ ? ? ?-linked sialic acid (MDCK-SIAT) have also 
been used and compared to parental cells in the presence of soluble HA (Tang et al. 2012).  
The importance of pseudotype input in batch to batch variation is highlighted by Garcia et 
al. 2010, this study suggests that using an RLU input of at least 105 per well should be used 
to ensure that antibody titer is independent of pseudotype input. 
1.21.8 Substrates 
Steady-Glo and Bright-Glo (Promega) are the most common sources of luciferin, the 
substrate required by the luciferase enzyme to produce light. Whilst expensive, these two 
substrates also serve a secondary purpose of lysing cells and releasing any expressed 
luciferase enzyme. 
1.21.9 High-throughput approaches 
PVs are amenable to high-throughput approaches and this has been used to evaluate 
antiviral compound effects on pseudotype transduction, testing a wide range of unique 
compounds in a single assay performed with 96 or 384-well plates (Wang et al. 2013; Basu 
et al. 2014). High-throughput assays have also been used for PVs bearing the glycoproteins 
of different viruses, such as for the identification of HIV-1 inhibitors or other BSL-4 viruses 
(Basu et al. 2010; Garcia, Gao, et al. 2009; Talekar et al. 2012). 
1.21.10 Increased transduction efficiency  
Polybrene and polyfect (Qiagen) are used in several studies in order to increase transduction 
efficiency (Krammer et al. 2012; Hai et al. 2012; Lin & Cannon 2002; McKay et al. 2006; Pica 
et al. 2012; Sandrin & Cosset 2006; Tsai et al. 2009; Wang et al. 2008; Yang et al. 2014). 1 
µg/ml, 8 µg/ml or 16 mg/ml of polybrene is added to virus or virus/antibody mixes before 




the addition of cells in titration and neutralisation assays or during incubation. In two 
studies, spinoculation was used to increase transduction, centrifuging cells and pseudotype 
at 1250 RPM for 2 hours or 3000 RPM for 1 hour (Cheresiz et al. 2014; Chaipan et al. 2009). 
1.22 Pseudotype based neutralisation assays  
1.22.1 Protocol 
Pseudotype based neutralisation assays (pMN) are usually carried out in 96-well white 
plates. A measured amount of antibody is incubated with a set amount of quantified virus in 
a total volume of medium, usually at a 1:1 virus: media ratio. Incubation is carried out at 
between 20 and 37°C for between 30 minutes to 2 hours (Garcia et al. 2010; Mallajosyula et 
al. 2014; Schmeisser et al. 2013; Shelton et al. 2013; Temperton et al. 2007; L. Zheng et al. 
2011). 1x104 target cells are then added to each well, subsequently the plate is left to 
incubate at 37°C in 5% CO2 for 48 or 72 hours. A cell only control as well as known positive 
and negative sera standards should be used as benchmarks for the neutralisation assay 
(Wei, Boyington, Dai, et al. 2010; Zhao et al. 2011). See Figure 1.18 for a depiction of the 
pMN assay. 
1.22.2 PV input 
The quantities of PV used in neutralisation assays which were normalised based on p24 
ELISA ranged from 6.25 to 50 ng/ml (Wei Wang et al. 2008). RLU or RLA values of between 
10,000 and 1,000,000 per well (96-well plate) have been used in the influenza PV literature, 
sometimes in conjunction or normalized with p24 or qPCR methods (Hultberg et al. 2011; 
Mather et al. 2014; Wei Wang, Xie, et al. 2010). Estimates of copy number per set volume of 
original viral supernatant can also be used. It is important to note that RLU based values are 
affected by the make-up of the plasmid bearing the HA gene, as well as a multitude of 
factors from the luminometer used to cells transduced and substrate added. A further 
method for quantification of PV involves the dilution expected for the infection of 50% of 
cells (TCID50, Reed and Muench 1938) which can be used with GFP PV. 
1.22.3 Serum/antibody dilutions and start points  
Antibody input varies depending on availability, especially when taking into account the 
possibility of repeats and replicates. Antibodies are primarily diluted 2-fold in Dulbecco's 




Modified Eagle Medium (DMEM), with or without FBS, across a 96-well plate, with the 
occasional three, four or five-fold dilution experiment published (Alberini et al. 2009; 
Cheresiz et al. 2014; Ding et al. 2011; Hai et al. 2012; Mahallawi et al. 2013). Where 




Figure 1.18. Pseudotype based neutralisation assay (pMN). Serial dilutions are carried out down 96-
well microtitre plates, whereupon a known quantity of PV is added. Plates are centrifuged to 
consolidate well contents and incubated for 1h at 37°C, 5% CO2. Approximately 1x10
4 HEK293T/17 
cells in 50 µl of DMEM are added per well. Plates are incubated for 48h at 37°C, 5% CO2 before 
reporter-specific plate readout. Figure from (Carnell et al. 2015). 
1.22.4 Incubation times and time periods 
When stated, serum inactivation varies from 30 minutes to 1 hour at 56°C (Garcia et al. 
2010; Tsai et al. 2009). PV-antibody incubation times are generally consistent between 
studies, at 37°C for 1 hour. Transduction times vary in 24 hour increments at 24, 48 and 72 
hours, after which output is measured. The total length of each neutralisation assays varies, 
especially regarding measurement methodologies. Output is measured at 48 or 72 hours 




post-transduction yet occasionally output is measured 48 or 72 hours after the first wash or 
medium replenishment. 
1.22.5 Controls  
Positive sera or specific commercial antibodies are required as positive controls which can 
be compared to tested sera and used to normalise between assays (see section 1.22.11 on 
standardisation). Reference sera from the National Institute for Biological Standards and 
Control (NIBSC), Office International des Epizooties (OIE), Animal and Plant Health Agency 
(APHA, previously AHVLA) and US Food and Drug Administration (FDA) are regularly used as 
controls (Hultberg et al. 2011; Molesti et al. 2013; J Sui et al. 2009; Wei Wang et al. 2011; 
Wei Wang, Castelán-Vega, et al. 2010; Wei Wang, Xie, et al. 2010). 
1.22.6 Neutralising antibody titer determination 
Antibody effect is displayed using one of many inhibitory concentrations (IC50, IC80, IC90, and 
IC95). The numerical value relates to the percentage point each particular study is 
calculating, for example the IC50 value can represent the concentration of an antibody that 
reduces RLU reading by 50%, when compared to 100% and 0% transduction controls (Gorres 
et al. 2011; Kanekiyo et al. 2013; Rao et al. 2010; Tsai et al. 2009). These controls are 
essential to the calculation. 100% inhibition can be benchmarked by a cell only control and 
0% by incubation of cells and virus in the absence of sera. 
1.22.7 HI assay 
HI assays using PV utilise the same procedures as with WT virus. Viral samples are diluted in 
phosphate buffered saline in a 96-well plate, to which 50 µl of a 0.5-1% chick/turkey red 
blood cell suspension is added. After between 30minutes to 1 hour, the HI plates are scored 
for agglutination. PV input is adjusted according to WHO guidelines at 4 HI units and sera is 
treated with receptor destroying enzyme to inactivate nonspecific inhibition of agglutination 
(Yang et al. 2014; Haynes et al. 2009). 
1.22.8 Post-attachment neutralisation assay 
The post-attachment neutralisation assay is used to identify antibodies that neutralise HA 
after it has bound to sialic acid. Oh et al. 2010 modified the post-attachment assays, 
originally developed by Edwards & Dimmock 2001, to allow WT influenza virus to be 




replaced by influenza PV. In this assay, PV are incubated at 4°C with cells to enable the 
synchronisation of the attachment of virus to sialic acid on the cell surface and to block viral 
endocytosis. Diluted sera is then added, and following another 4°C incubation, plates are 
incubated at 37°C to permit transduction (Oh et al. 2010). Transduction is then measured 
using the same approach as that taken in a neutralisation assay. Antibodies detected by this 
assay have neutralising activity via their ability to impede the endocytosis step and 
subsequent HA conformational changes necessary for virus-endosome fusion (Edwards and 
Dimmock 2001; Hsueh-Ling et al. 2010). Antibodies that have neutralising activity through 
impeding viral attachment will produce negative results in this assay. The post-attachment 
assay is useful for evaluating the neutralising capacity of stalk-directed antibodies that do 
not inhibit viral attachment (Corti et al. 2011; Hsueh-Ling et al. 2010).  
1.22.9 Reproducibility 
Reproducibility is a major issue in the field of serology. Serum samples are often finite, 
leading to an inability to reproduce experiments or results in the same context as they were 
originally published. However, by standardising methods for production, titration and 
neutralisation and the use of common reference standards it is possible to minimize 
variation between experiments and research groups. The members within the laboratories 
of the CONSISE group (section 1.20) have carried out several studies aimed at reducing or at 
least measuring the amount of variation between laboratories utilising the same techniques. 
They have also established CONSISE consensus protocols for ELISA and other assays in an 
effort to further improve inter and intra-laboratory correlation of data generated using 
these same assays (Laurie et al. 2015; Van Kerkhove et al. 2013). Similar efforts should be 
made to standardise PV based assays worldwide. 
1.22.10 Correlation with other serological assays  
Comparisons have been made between pMN assays and traditional serological assays with 
mixed results. Several articles report increases of between 31.9% and 200% in H5 PV IC50 
antibody titers in comparison to MN based results with WT virus (Buchy et al. 2010; Garcia, 
Pepin, et al. 2009). Buchy et al. 2010 show a correlation between H5 PV and MN (spearman 
0.79, p<0.001), which was also reported by Du et al., 2010a and W. Wang, Xie, et al. 2010, 
the latter presenting r2 values of 0.9802 for A/Vietnam/1203/2004, 0.8193 for 




A/Anhui/1/2005 and 0.5244 for A/turkey/Turkey/1/2005 strains. Alberini et al. 2009 
compared pMN assays to HI, SRH and MN assays using 226 different serum samples. The 
Pearson correlation test showed significant correlation (p<0.001) between the antibody 
titers calculated from each assay. The correlation coefficients between pMN and HI, SRH 
and MN assays were 0.73, 0.70 and 0.78 respectively. Furthermore the correlation between 
H5 and H5 pMN allowed the establishment of a threshold from which pMN titers could be 
based. pMN data was then analysed based on the threshold which showed protective titers 
in patients of 38-43%, 54% and 79% after adjuvanted vaccination, second dose and booster 
respectively (Alberini et al. 2009). Qiu et al. 2012 showed a range of correlations between HI 
and pMN using different HA subtypes. A/Moscow/10/1999 (H3N2) correlates well 
(r=0.8454, p<0.0001), A/Brisbane/59/2007 (H1N1) and A/Japan/305/57 (H2N2) poorly (r= 
0.1171, p=0.7472 and r=0.1171, p=7472) whereas A/Viet Nam/1203/ 2004 (H5N1) 
correlates (r=0.7921, p=0.0029). In an additional study, HI and pMN (IC50) correlate well in 
Qiu et al. 2013 in the case of A/ Shanghai/4664T/2013 (H7N9) (spearman r=0.88, p<0.0001) 
as well as in Whittle et al. 2014 (r2=0.6491, p<0.0001). A significant correlation (p=0.002) of 
65% (r= 0.65) was also been reported between SRH and pMN in equine influenza PV and a 
further study showed the relationship between RLU and HA content (Scott et al. 2012; C. Y. 
Su et al. 2008). 
1.22.11 Approaches towards validation and standardisation 
Approaches towards the standardisation of pMN should follow the procedure that was 
required for MN standardisation. Standardisation of MN in general has focused on the use 
of pooled serum samples as reference standards. A/California/7/2009 (H1N1) pdm standard 
was established by the WHO in 2010 with an assignment of potency of 13000 International 
Units (IU) per ml. A second pooled sera reference standard for H5N1 exists and has 
successfully been used in a number of studies (Alberini et al. 2009; Stephenson et al. 2009). 
A cut off value for positive and negative H5N1 neutralising sera exists for this set of H5N1 
reference standards (Alberini et al. 2009).  
1.22.12 cHA 
There has been considerable research into the stalk region of the HA in relation to vaccine 
design and immunity to influenza. Various stalk-directed mAbs such as CR6261 have been 




characterised, opening up the use of cHA to test for the presence of similar antibodies in 
serum samples (Ekiert et al. 2009; Throsby et al. 2008). Stalk directed antibodies were first 
identified in 1994 when the cross-reactive C179 mouse monoclonal antibody (mAb) was 
identified and found to inhibit fusion of several HA subtypes (Okuno et al. 1994). Since then 
many studies have focused on stalk directed antibodies and their neutralisation of multiple 
diverse subtypes of influenza (Corti et al. 2010, 2011; Ekiert et al. 2012; Throsby et al. 2008; 
Wrammert et al. 2011). However this range of heterosubtypic immunity is dependent on 
the characteristics of the epitope of each antibody tested, which will influence which 
subtypes, clades and whether they neutralise group 1 or 2 influenza virus HAs. The stalk 
region of HA is more conserved than the variable globular head, to which the vast majority 
of neutralising antibodies are directed. While residues in the head mediate attachment of 
the virus to target cells by binding to sialic acid, the fusion peptide in the stalk of HA is just 
as crucial to the HA function (Jianhua Sui et al. 2011; Wei, Boyington, McTamney, et al. 
2010). In order to test for neutralising stalk antibodies, studies have employed a variety of 
cHA constructs bearing stalks and heads from different subtypes. The concept behind this 
revolves around the use of HA heads which are largely non-reactive to the antibodies used 
in the assay. In this way a neutralising response can be detected in the absence of head 
directed neutralisation. Classical serological assays are insensitive to the detection of stalk-
directed mAbs when compared to pMN. In order to more efficiently test for stalk-
neutralising antibodies, some studies have employed a variety of cHA constructs bearing 
stalks and heads from different subtypes. Several hybrids have been constructed and 
pseudotyped using HIV-1 cores, these are generally constructed through PCR amplification 
and incorporation of complimentary restriction sites, allowing ligation of different segments 
of HA genes together in one plasmid. The presence of a conserved disulfide bond linking 
cysteines 52 and 277 in influenza A HAs (H3 Aichi numbering), separating the globular head 
from the stalk region, make production of these cHAs relatively straight forward (Ferrara 
2015; Hai et al. 2012). However, when cHAs are produced with influenza B components, the 
52-277 delineation is not present, making efforts to produce influenza B cHAs more difficult. 
One approach successfully swapped cysteines with alanines from a similar location in the 
influenza B HA (57-366), producing functional cHAs with an influenza B stalk and influenza A 
head (Ermler et al. 2017). However this study employed the cHA in the production of RG 
viruses as well as recombinant protein, their use in PV system would require optimisation. A 




wider variety of different cHA have been used in reverse genetics approaches towards 
development of wild type virus bearing cHAs (Krammer et al. 2013; Krammer, Hai, et al. 
2014; Krammer, Margine, et al. 2014). These cHA are also promising candidates for 
 ‘ƵŶŝǀĞƌƐĂů ? ǀĂĐĐŝŶĞƐ ? ĚŝƐĐƵƐƐĞĚ ĞĂƌůŝĞƌ ŝŶ ƚŚŝƐ ĐŚĂƉƚĞƌ ? Table 1.1 displays the regions and 
subtypes used in the construction of cHAs in the listed literature. 
Table 1.1 Examples of cHAs originating from divergent subtypes and used for pseudotype 
production. Article source and composition of cHA are detailed. 
Article Head Stalk 
Hai et al. 2012 H5 A/Vietnam/1203/04 H1 A/Puerto Rico/8/1934 
H1 A/California/04/09 H1 A/Puerto Rico/8/1934 
H7 A/mallard/Alberta/24/01 H3 A/Perth/16/2009 
H5 VN/05 HA H3 A/Perth/16/2009 
Pica et al. 2012 H6 A/mallard/Sweden/86/02  H1 A/Puerto Rico/8/1934 
H9 A/guinea fowl/Hong 
Kong/WF10/99 
H1 A/Puerto Rico/8/1934 
 HA1 HA2 
Wang et al. 2011 A/Brisbane/59/ 2007 A/New Caledonia/20/1999 
A/New Caledonia/20/1999 A/Brisbane/59/ 2007 
1.23 The future of influenza PV 
pMN offers the safety of using pseudotypes and the sensitivity of the MN assay. Further 
validation and standardisation of the assay is required, but once established, this assay 
should offer a robust and sensitive means of interrogating influenza vaccine trials for head 
and stalk targeting antibodies. The production of vaccines that elicit stalk-targeting 
antibodies may in time lead to a universal vaccine, preventing the mortality and morbidity 
resulting from seasonal influenza and the emergence of pandemic strains, most recently the 
pH1N1, which caused an estimated 284,500 deaths in its first 12 months of circulation 
(Dawood et al. 2012). pMN currently offers the opportunity to batch test vaccines or 
commercialized antibodies in the absence of standardisation. Furthermore, the ability of 
pMN assay to include PVs bearing cHA, NA and M2 allows the pMN to be used to explain the 
pathogenicity of seasonal and pandemic influenza strains and perhaps elucidate the 
antigenic evolution of influenza further. Such information will prove useful for the 
generation of future vaccines.  




1.24 Other uses of influenza PV 
1.24.1  Gene therapy 
As the field of gene therapy progresses, influenza pseudotyping will benefit from the design 
of even safer and more effective vectors. As more sophisticated systems are developed they 
may become more easily standardised and comparable to WT virus. One aspect of gene 
therapy which may benefit from the field of influenza is the use of viral entry proteins to 
target delivery of nucleic acids into specific cells. One study used influenza PV to transduce 
the respiratory epithelial cells of mice after nasal administration with promising results 
indicating that the method could be used in the treatment of cystic fibrosis (Patel et al. 
2013). 
1.24.2 PV as Vaccines 
PV based vaccines are also becoming more widespread, with several candidates already 
cited in this thesis. Baculovirus pseudotyped with VSV-G has been used successfully to 
express HA genes in mammalian cells and provided an efficacious vaccine when tested in 
chickens and mice (Q. Wu et al. 2009). The VSV-G glycoprotein enabled entry of baculovirus 
into target cells whereupon the delivered HA gene was expressed. While originally a popular 
vector for transgene expression in insect cells, VSV-G has been shown to be a useful tool for 
vaccine production in mammalian cells (Hofmann et al. 1995). In Wu et al. 2009 delivery was 
achieved through VSV-G incorporation into baculovirus under the effect of the polyhedron 
promoter and HA under the effect of the CMV promoter in order to achieve expression in 
insect cells and subsequent infection and expression of HA in mammalian cells. This is an 
interesting system which could be used as a method for the introduction of PV genes into 
cells through a VSV-G bearing baculovirus in lieu of cytotoxic transfection reagents. H5 
bearing PV have been tested in mice as candidate vaccines, eliciting high levels of anti-HA 
antibodies as determined by HI. Mice that were vaccinated survived despite weight loss of 
approximately 12.8 W21.1% whereas the non-vaccinated group lost approximately 25.5 W
26.2% of their bodyweight and died 6 days after H5N1 virus challenge (S. Zhang et al. 2008). 
A further PV vaccine has been developed which contains a modified HA gene, allowing 
expression in transduced cells but lacking the viral RNA sequences required for replication. 
This yields a particle bearing the desired glycoproteins, in this case A/Puerto Rico/8/1934 




(H1) that consequently induces a robust T-cell response when given to mice via inhalation. 
Reduction in the severity of symptoms was also seen in mice infected with a different 
subtype: H3N2 A-X31 (Powell et al. 2012). Influenza PV could also be used in vaccine design 
through the use of integrase defective lentiviral vector technology. Defective lentiviral 
vector technology allows transduction of target cells through maintenance of an episomal 
reporter construct without integration into the genome. This approach may bring benefits 
by reducing the chance of interrupting host genes and the eventual dilution of the delivered 
gene (Banasik and McCray Jr 2010; Farazmandfar et al. 2012). 
1.25 Thesis aims and objectives 
The aim of the projects reported in this thesis were primarily to make use of HA and NA 
bearing PV as surrogates for neutralisation assays aimed at the detection of bnAbs. This was 
to be achieved through the use of panels of human sera as well as mAbs on a library of PV 
bearing glycoproteins from a range of G1 and G2 influenza subtypes, including divergent 
subtypes such as H17. Furthermore, the cHA system was to be employed using PV in a 
comprehensive study in collaboration with the Jenner Institute Laboratories, University of 
Oxford. This study was aimed at firmly establishing and making use of the pMN cHA system 
to detect HA stalk-directed antibodies which may be elicited from universal vaccines. Due to 
the nature of the pMN assay and its requirement of a functional glycoprotein to mediate 
membrane fusion, this assay should hold advantages over the commonly used ELISA based 
approaches and pave the way for the detection of binding and neutralising antibodies. 
Due to the importance of the viral NA in the viral life cycle and vaccines, efforts were made 
to establish PV as a source of NA using the ELLA system, allowing comparison of ELLA and 
pMN data using the same antigen source. The aim of this project was to enable correlation 
between HA and NA responses detected using PV systems, both of which only provide 
positive data in the absence of function of the HA and NA proteins: neutralisation of HA or 
inhibition of NA. 
1. Development of cHA with pandemic H1N1 2009 stalk 
2. Utilisation of cHA to detect bnAbs in human sera 
3. Establishment of pELLA 
4. Correlation  of gold standard assays (HI and SRH) with pMN 
5. Production of H17 bat influenza PV and neutralisation with bnAbs. 




Chapter 2 :  Materials and Methods  
General materials and methods will be reported in this chapter, with sources, catalogue and 
accession numbers where necessary. Deviations of these protocols in regards to variables 
and reagents changed will be detailed in each individual results chapter thereafter. 
2.1 DNA Methods 
2.1.1 Plasmids, vectors and genes 
A variety of different plasmids were used in the projects reported in this thesis, all of them 
were used for the production of PV and fall within three different types of plasmid. First, 
eukaryotic expression plasmids were used in order to express relevant influenza genes (HA, 
NA, M2) for incorporation into PV. Second, lentiviral vectors were used to provide a PV core 
and genome with desired reporter output. Lastly, accessory plasmids designed to express 
various different proteases in PV producer cells were used, depending on the requirements 
of each HA used in PV production. The primary eukaryotic expression plasmid used in this 
project, pI.18 was derived from influenza DNA vaccine research (Cox et al. 2002). This 
plasmid contains an hCMV immediate early promoter (IE) and intron A, a CMV enhancer 
region which enhances expression in eukaryotic cells. This region precedes the multiple 
cloning site (MCS) which contains sites for DNA cloning via restriction digestion. A CMV 
terminator sequence is located after the MCS allowing polyadenylation of mRNAs produced 
from genes expressed at the MCS region. The plasmid also contains a standard pUC origin of 
replication (Ori) ĂŶĚɴ-lactamase gene allowing selection of bacteria transformed with this 
plasmid for molecular biology purposes. The expression of ƚŚŝƐ ŐĞŶĞ ŝƐ ƉƌŽŵŽƚĞĚ ďǇ Ă ɴ-
lactamase promoter; both of these are antisense to the eukaryotic region containing CMV 
genes and MCS. The plasmid backbone (ȴ insert) is ~4.3 kb in length, depicted in Figure 2.1. 
  





Figure 2.1. Simplified schematic of the eukaryotic expression plasmid pI.18. This plasmid contains a 
ŚDsƉƌŽŵŽƚĞƌ ?ŚDsA? ?ĂůŽŶŐƐŝĚĞƚŚĞŚDs ‘/ŶƚƌŽŶ ?ĞŶŚĂŶĐĞƌ ?ĂůůŽǁŝŶŐĞǆƉƌĞƐƐŝŽŶŽĨĐůŽŶĞĚ
genes in eukaryotic cells. Bacterial Ori ĂŶĚɴ-lactamase are also present to allow transformation and 
selection of bacterial transformants. This Plasmid is ~4,3kb in length. 
 
A second eukaryotic expression plasmid was used, phCMV1. This was used due to the 
acquisition of a variety of cloned HA genes from Dr Davide Corti at the Institute for Research 
in Biomedicine, Bellinzona, Switzerland. This plasmid contains a hCMV promoter to drive 
expression of genes cloned into the MCS, and bacterial transformants can be selected 
through a kanamycin/neomycin resistance cassette. phCMV1 is also ~4.3kb in length, see 
Figure 2.2 for a simplified schematic of this plasmid. 
 





Figure 2.2. Simplified schematic of the eukaryotic expression plasmid phCMV1. This plasmid contains 
a hCMV+ alongside an Ori for transformation into competent bacteria. Selection of transformants is 
possible through a Neomycin/Kanamycin resistance cassette. 
2.1.2 HIV-1 packaging construct 
HIV- ? ĚĞƌŝǀĞĚ ƉĂĐŬĂŐŝŶŐ ƉůĂƐŵŝĚ ƉDsȴZ ? ? ? ?  ?Ɖ ? ? ? ? ? ǁĂƐ ŽďƚĂŝŶĞĚ ĨƌŽŵ Professor Greg 
Towers, University College London, originating from the laboratory of Dr Didier Trono 
(Naldini et al. 1996; Zufferey et al. 1997). This lentiviral packaging plasmid contains the 
relevant genes (gag, pol, tat, and rev) for the production of HIV-1 packaging proteins 
required for PV production. These are produced as a single transcript under the control of a 
hCMV promoter, which will then be exported in various spliced states in an HIV-1 
dependent manner. This yields suitable ratios of proteins for the production of particles 
containing core proteins from gag (p17, p24, p7, p6) and enzymes from pol (protease, 
reverse transcriptase, integrase, p15). Other elements included in this plasmid allow 
replication (Ori) and selection of bacterial transformants (ɴ-lactamase, ampicilin resistance). 
See Figure 2.3 for a simplified schematic of the p8.91 plasmid. 





Figure 2.3. Simplified schematic of lentiviral packaging plasmid p8.91. This plasmid contains gag, pol, 
tat and rev genes, all other HIV-1 genes are disrupted through deletions and/or insertions. HIV-1 
genes are under the control of a hCMV promoter (hCMV+) and a polyadenylation site is present 
downstream to allow stable functional mRNAs to be transcribed. The RRE remains intact in order to 
allow export of unspliced mRNA from the nucleus. An Ori and ɴ-Lactamase gene are also present for 
transformation of competent bacteria and ampicillin based selection of transformants. 
2.1.3 Luciferase containing vector constructs 
A firefly luciferase bearing lentiviral vector was used as a mock genome for incorporation 
into PVs in order to quantify PV based on RLU. The WůĂƐŵŝĚ Ɖ^'t  ?^ǇŶŽŶǇŵƐ Ɖ,Z ?^/E-
cPPT-SE & pHR-SIN-CSGW) was obtained from Dr A Thrasher (Institute of Child Health, 
London, UK) and has been characterised in detail (Demaison et al. 2002). The eGFP gene 
was replaced with firefly luciferase by Novartis vaccines, Italy, now GlaxoSmithKline, Italy, 
giving us plasmid pCSFLW. This lentiviral vector contains a truncated HIV-1 genome and is 
designed to be incorporated into PV via the PSI packaging signal, and to express the firefly 
luciferase gene after incorporation into the target cell genome after PV mediated 
transduction. The firefly luciferase gene is under the control of the spleen focus-forming 




virus (SFFV) LTR promoter and is enhanced by the Woodchuck hepatitis post-regulatory 
element (WPRE). >dZƐĂƌĞƉƌĞƐĞŶƚǁŝƚŚĂĚĞůĞƚŝŽŶ ŝŶ ƚŚĞh ? ƌĞŐŝŽŶŽĨ ƚŚĞ  ? ?hdZ ?ŵĂŬŝŶŐ
ƚŚŝƐ ǀĞĐƚŽƌ  ‘ƐĞůĨ-ŝŶĂĐƚŝǀĂƚŝŶŐ ? ŝŶ ƌĞgards to possible replication. Other elements of this 
plasmid enable replication in bacteria through the Ori and selection through the ɴ-
lactamase gene (Amp resistance) and its relevant bacterial promoter. See Figure 2.4. 
 
Figure 2.4. Simplified schematic of the lentiviral vector pCSFLW. This construct contains a truncated 
HIV-1 genome with functional LTRs and firefly luciferase under the control of SFFV LTR promoter and 
enhanced by the WPRE. Incorporation into PV is enabled by the presence of the packaging signal 
(PSI).  




2.1.4 Protease encoding expression plasmids 
In order to mediate maturation of the HA protein, a protease element is required for strains 
lacking the HPAI polybasic cleavage site. It appears that HEK293T/17 cells do not have 
adequate proteases or protease concentrations within the cell to mediate this cleavage to a 
sufficient degree to produce high titre PVs. Therefore, protease-encoding plasmids have 
been employed in order to mediate maturation of the translated HA0 to HA1 and HA2 
subunits, a functional HA protein. Various proteases have been used in PV production and 
some of this work has been published (Ferrara et al. 2012; Sawoo et al. 2014; Scott et al. 
2012; Wei Wang et al. 2008). Type 2 Transmembrane protease, serine 3 (pcDNA3.1 -
TMPRSS3) and Type 2 Transmembrane protease, serine 4 (pCMV-Tag3 -TMPRSS4 (ECD)  W 
myc, (Jung et al. 2008) were obtained from Prof. Stefan Pöhlmann (Infection Biology Unit, 
German Primate Center, Germany). pCAGGS-HAT was obtained from Eva Böttcher-
Friebertshäuser, Institute of Virology, Philipps University, Marburg, Germany. The HAT gene 
was extracted by RT-PCR from 6-week old cell cultures of human airway epithelial cells 
(Böttcher-Friebertshäuser et al. 2013; Böttcher et al. 2006, 2009). For the sake of simplicity, 
the pCMV-Tag3 -TMPRSS4 (ECD)  W myc plasmid will be referred to as pCMV-TMPRSS4 in the 
remainder of this thesis. 
2.1.5 HA/NA/M2 gene containing plasmids 
A library of expression plasmids bearing the HA and NA genes has been established by the 
Viral Pseudotype Unit for use in the production of PV. Table 2.1 shows the current list of 
functional plasmids which were used in the projects that form this thesis. This table also 
includes information such as the accession numbers for each gene, the plasmid in which it 
has been cloned and the source. 
  




Table 2.1. List of HA, NA and M2 genes used in this thesis, alongside accession numbers, plasmid in 
which gene has been cloned and source. 
Subtype/ 
Gene Strain Accession Plasmid Source 
H1 A/California/7/2009 CY121680.1 pI.18 Synthesised: Genscript 
H1 A/New Caledonia/20/1999 EU103824.1 phCMV1 Dr. Davide Corti 
H1 A/Brisbane/59/2007 CY163864.1 pI.18 Dr. Kajia Hoschler 
H1 A/South Carolina/1/1918 AF117241.1 phCMV1  Dr. Davide Corti 
H1 A/Solomon Islands/3/2006 EU124177.1 pI.18 Prof. Sarah Gilbert 
H1 A/Puerto Rico/8/34 AF389118.1 pI.18 Viral Pseudotype Unit 
H1 A/Texas/05/2009 GQ457487.1 pI.18 Prof. Sarah Gilbert 
H3 A/Texas/50/2012 KC892952.1 pi.18 Synthesised: Genscript 
H3 A/Udorn/307/1972  DQ508929.1 pi.18 Viral Pseudotype Unit 
H5 A/Vietnam/1194/2004 EF541402 pI.18 Viral Pseudotype Unit 
H5 
A/gyrfalcon/Washington/41088-
6/2014 KP307984 pI.18 Synthesised: Genscript 
H7 A/Shanghai/2/2013 KF021597 pI.18 Synthesised: Genscript 
H11 A/duck/Memphis/546/1974 AB292779 phCMV1 Dr. Davide Corti 
H17 
A/Little shouldered 
bat/Guatemala/060/2011 CY103892.1 pI.18 Synthesised: Genscript 
B B/Bangladesh/3333/2007 CY115255.1 pi.18 Viral Pseudotype Unit 
B B/Brisbane/60/2008 KX058884.1 pi.18 Viral Pseudotype Unit 
B B/Yamagata/16/1988 CY018765.1 phCMV1 Dr. Davide Corti 
B B/Victoria/2/1987 ABL77244.1 phCMV1 Dr. Davide Corti 
B B/Hong Kong/8/1973 K00425 phCMV1 Dr. Davide Corti 
B B/Florida/4/2006 EU515992 phCMV1 Dr. Davide Corti 
N1 A/Puerto Rico/8/34 CY033579 pI.18 Viral Pseudotype Unit 
N1  A/California/7/2009 KU933487.1 pI.18 Synthesised: Genscript 
N2  A/Udorn/307/1972   M879361.1 pI.18 Viral Pseudotype Unit 
N2  A/Texas/50/2012 KC892281.1 pI.18 Synthesised: Genscript 
N10 
A/Little shouldered 
bat/Guatemala/060/2011 CY103894.1 pI.18 Synthesised: Genscript 
M2 A/Hong Kong/156/97 AAC32091.1 pcDNA3 Prof. Wendy Barclay 
2.1.6 Nucleic acid quantification and purity  
Plasmid concentration and purity data is required prior to transfection of HEK293T/17 cells, 
production of PV. To this end, purified nucleic acids were analysed using a Nanodrop 2000 
 ?EĂŶŽƌŽƉ ? ?dŚĞƌŵŽ&ŝƐŚĞƌ^ĐŝĞŶƚŝĨŝĐ ? ?ĞŶĂďůŝŶŐƚŚĞŵĞĂƐƵƌĞŵĞŶƚŽĨĐŽŶĐĞŶƚƌĂƚŝŽŶ ?ŶŐ ?µl) 
as well as purity via absorbance values at 260/280 and 260/230 nm. The Nanodrop 2000 
was first cleaned with  ? ?A?ĞƚŚĂŶŽů ?ĂŶĚƚŚĞŶ ‘ďůĂŶŬĞĚ ?ǁŝƚŚ ? µl of either dH2O or EB buffer 
(Qiagen) depending on plasmid extraction DNA elution solution used. Subsequently, 1 µl of 
plasmid containing solution (in EB buffer or dH2O) was pipetted onto the Nanodrop 2000 
reader, and nucleic acid concentration and purity measured. 




2.1.7 Primers for PCR, mutagenesis, cloning and sequencing 
A range of primers were designed and ordered for this study. Project specific primers will be 
reported within relevant chapters. Generic primers used for sequencing of pI.18 and 
phCMV1 genes were designed by previous students in the laboratory, located on either side 
of the MCS site, allowing amplification and sequencing of the gene of interest for each 
plasmid, regardless of nucleotide differences. These primers are listed in Table 2.2. 
Table 2.2. Primers used for the amplification of cloned genes within expression plasmids pI.18 
(Int_pI.18 Fwd and Rev) and phCMV1 (phCMV1 Fwd and Rev). 
Primer name Sequence NT position 
Int_pI.18 Fwd  ? ?ddd''d'ddd' ? ? 1134-1153 
Int_pI.18 Rev  ? ?'ddd'd''d''' ? ? 1430-1449 
phCMV1 Fwd  ? ?dd'ddd''' ? ? 759-778 
phCMV1 Rev  ? ?dd'ddd''dd''' ? ? 986-1003 
2.1.8 Sanger sequencing 
Sequencing was outsourced to GATC Biotech. We utilised their LIGHT run option, using ~ 
100ng of target DNA with 10 pmoles of primer. These were sent to their facility and 
sequences mailed to us or stored on their web server for download. Analysis was carried out 
using the BioEdit software (Hall 1999), whereupon sequences from forward and reverse 
reactions were checked and compiled into one gene sequence. Subsequently a BLAST was 
carried out or alignment using Clustal Omega (S F Altschul et al. 1997; Stephen F. Altschul et 
al. 1990; Boratyn et al. 2012; Camacho et al. 2009; W. Li et al. 2015; Madden et al. 1996; 
McWilliam et al. 2013; Morgulis et al. 2008; Sievers et al. 2011; States and Gish 1994; J. 
Zhang and Madden 1997; Z. Zhang et al. 2000). 
2.1.9 Polymerase chain reaction (PCR) 
PCR reactions were carried out using several enzymes or kits, depending on availability. 
Standard PCR was carried out using AccuPrime ?Pfx (Thermo Fisher Scientific). 22.5 µl of 
AccuPrime ?Pfx SuperMix was added to a microcentrifuge tube with 1 µl of DNA template 
(~200ng) and forward and reverse primers (200nM final concentration) in a total volume of 
25 µl. The microcentrifuge tube was then briefly centrifuged to consolidate the materials at 
the bottom of the tube. Reactions were then carried out according to the parameters listed 
in Table 2.3, in a Mastercycler thermal cycler (ep Gradient, Eppendorf). 
  




Table 2.3. Polymerase chain reaction parameters for ĐĐƵWƌŝŵĞ ?Pfx DNA polymerase. 
 
Step Temperature  Time period 
Initial denaturation 95°C 5 m 
35 Cycles Denaturation: 95°C 15 s 
Annealing: 55-65°C 30 s 
Extension: 68°C 60 s per KB 
Samples held at 4°C 
 
For the production of cHA plasmids Sol CHM and CS CHM, Phusion® High-Fidelity DNA 
Polymerase (New England Biolabs) was used. In this case, 4 µl of 5X Phusion Buffer, 0.4 µl of 
10mM dNTPs, 1 µl of Fwd and Rev primers each, 0.2 µl of Phusion DNA polymerase and 
~200ng of template DNA was added to a microcentrifuge tube and made up to 20 µl using 
dH2O. The microcentrifuge tube was then briefly centrifuged to consolidate the materials at 
the bottom of the tube. Reactions were then performed as shown in Table 2.4, in a 
Mastercycler ep Gradient (Eppendorf) thermal cycler. 
Table 2.4. Polymerase chain reaction parameters for Phusion® High-Fidelity DNA Polymerase. 
 
Step Temperature  Time period 
Initial denaturation 98°C 30 s 
25-35 Cycles Denaturation: 98°C 10 s 
Annealing: 45-72°C 30 s 
Extension: 72°C 30 s per KB 
Final extension 72°C 5 m 
Samples held at 4°C 
 
Gradient PCR was performed using Phusion® High-Fidelity DNA Polymerase, under the same 
parameters as listed previously, with one exception. Several microcentrifuge tubes were set-
up as previously, and the Mastercycler ep Gradient parameters altered to provide a gradient 
of annealing temperatures for each tube. 
2.1.10 DNA digestion 
DNA digestion was carried out using FastDigest restriction endonucleases obtained from 
ThemoFisher Scientific. PCR products or plasmids were incubated under various parameters 
listed in Table 2.5. KpnI, HindIII, EcoRI and BamHI were all used in diagnostic digests for the 
plasmid pI.18 as well as diagnostic digests for all cHAs produced (Chapter 3). These 
diagnostic tests were carried out to ensure the correct gene was present in the sample 




tested, whether PCR product or existing plasmid after DNA purification. For Plasmid DNA, 1 
µl of FastDigest HindIII enzyme was mixed with ~1 µg DNA, 2 µl 10X FastDigest Buffer and 
made up to 20 µl with dH2O. The reaction was incubated for 15 minutes at 37°C in a 
Mastercycler thermal cycler and then the enzyme was inactivated at 80°C for 10 m. For PCR 
products, 0.2 µg DNA was used and HindIII digestion carried out for 20 m. For KpnI 
digestion, all parameters remain the same except the digestion time which was 5 m for both 
plasmid and PCR DNA. KpnI was inactivated after digestion at 80°C for 10 m. See Table 2.5 
for a table of restriction digestion reaction conditions. 
Table 2.5. Parameters for the use of FastDigest enzymes in single digestions of Plasmid or PCR 
products. 
 
Enzyme Reaction Temperature Digestion time (m) Thermal inactivation 
KpnI 37°C 5  80°C, 5 m 
HindIII 37°C Plasmid: 15 80°C, 10 m 
PCR product: 20 
EcoRI 37°C Plasmid: 15 80°C, 5 m 
BamHI 37°C Plasmid: 5 80°C, 5 m 
 
Double digests were also performed using FastDigest enzymes, Plasmid DNA was incubated 
with 1 µl of BamHI and EcoRI each, 4 µl of 10X FastDigest Buffer, 1 µg of plasmid DNA and 
made up to 40 µl with dH2O. The mixture was incubated at 37°C for 15 m in a Mastercycler 
thermal cycler and heat inactivated at 80°C for 5 m.  
2.1.11 DNA gel electrophoresis 
DNA gel electrophoresis was carried out throughout the DNA phases of each project, in 
order to determine the size of PCR products and plasmids (digested and in various coiled 
states). In general, 1% agarose gels were used. These were produced by dissolving agarose 
powder (Fisher Scientific, cat: BP1356) in 0.5x Tris-Acetate-Ethylenediaminetetraacetic acid 
EDTA (TAE buffer). This was carried out in a 250 ml conical flask and the mixture was 
encouraged to form a solution by heating for 1 m intervals in a microwave with mixing in-
between heating steps. Once dissolved, the 1% agarose solution was left to cool, 
whereupon Ethidium Bromide was added to a final concentration of 0.1 µg/ml. In several 
experiments, SYBR safe DNA gel Stain (Thermo Fisher Scientific, cat: S33102) was used as an 
alternative, with 5 µl used for every 100 ml of agarose. Gels were cast and allowed to set 
with appropriate moulds and well inserts as to allow an adequately thin gel to be produced. 




DNA samples were loaded into wells after being mixed with 5X loading dye (QIAGEN, Cat: 
239901) at a 5:1 ratio. GeneRuler 1kb DNA Ladder Mix (Thermo Fisher Scientific, cat: 
SM0311) was used to flank sample wells and provide a molecular weight to compare to. For 
PCR products deemed suitable for DNA extraction, samples were re-run using 1% 
hůƚƌĂWƵƌĞ ?ŐĂƌŽƐĞ ?/ŶǀŝƚƌŽŐĞŶ ?ĐĂƚ P ?500-500). Gels were analysed for DNA migration using 
a transilluminator (UVItec, cat: BXT-26.MX) with G:Box Chemi XT Imaging System (Syngene) 
and gels were visualised using GeneSnap software (Syngene). 
2.1.12 DNA gel extraction 
In cases when PCR reactions did not give rise to the desired fragment exclusively, DNA 
extraction was carried out from excised fragments of agarose gel, using the QIAquick Gel 
Extraction Kit (cat: 28704). Appropriate segments were excised from agarose gels after gel 
electrophoresis, ensuring to carry over as little agarose as possible to the DNA extraction 
step. Excision was performed using a scalpel on a transilliuminator. Each excised fragment 
was inserted into a pre-weighed 1.5 ml microcentrifuge tube, and weighed. 5 volumes of PB 
buffer was then added per 100 mg of gel and tubes were incubated at 50°C for 10 m or until 
agarose was completely dissolved. 1 volume of isopropanol was then added per volume of 
gel used and the solution passed through a QIAquick column by centrifugation at 13,000 
RPM for 1 m. For larger volumes this step was repeated until all of the solution was used up. 
Flow through was discarded and 0.5ml buffer QG was added. Columns were then 
centrifuged at 13,000 RPM for 1 m. Subsequently, 0.75 ml of buffer PE was added to each 
column and they were further centrifuged at 13,000 RPM for 1 m. Flow through was 
discarded and columns centrifuged again under the same conditions.  Finally, DNA was 
eluted using 50 µl of buffer EB or dH2O (70°C) by centrifugation. Purified fragments were 
then used in further gel electrophoresis in order to confirm the correct size fragment was 
excised, or used in downstream experiments. 
2.2 Bacteria methods 
2.2.1 Antibiotic stocks, liquid and solid media 
Ampicillin (amp) sodium salt (Fisher Scientific, cat: BP1760) and kanamycin (kan) sulphate 
(Fisher Scientific, cat: BP906) were dissolved in dH2O. Each powder was weighed on a 




sensitive scale and made up with dH2O to a concentration of 100 mg/ml (amp) or 10 mg/ml 
(kan). These were sterile filtered through a 0.45 µm filter (Merk Millipore, cat: SLGP033RS). 
Amp was used at a concentration of 100 µg/ml in LB broth and 200 µg/ml in LB agar plates. 
Kan was used at a 50 µg/ml concentration in both applications. Luria Bertani (LB) agar 
(Fisher Scientific, cat: BP1425), and LB Broth (Fisher Scientific, cat: BP1426) were employed 
for solid and liquid culture of bacteria respectively. Each reagent, in powder form, was 
dissolved in dH20, adhering to ŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŐƵŝĚĞůŝŶĞƐ ? ? ?Ő ? ? ? ? ml agar and 12.5g/500 ml 
broth) in autoclavable media jars. Super Optimal Broth with Catabolite repression (SOC) 
medium was obtained from Invitrogen (cat: 15544-034). 
2.2.2 Transformation of Escherichia coli (E.coli) cells  
WůĂƐŵŝĚƐƚŽĐŬƐǁĞƌĞƉƌŽĚƵĐĞĚƵƐŝŶŐƚŚĞ, ?ɲƐƚƌĂŝŶŽĨ ?coli (Invitrogen, cat: 18265-017). 
, ?ɲ ĐĞůůƐ ǁĞƌĞ ŬĞƉƚ Ăƚ-80°C in aliquots of 25 µl. Transformation was carried out by 
ĂĚĚŝƚŝŽŶŽĨ  ? ? ? ?ŶŐŽĨƉůĂƐŵŝĚEƚŽ  ?A?ůŽĨ, ?ɲĐĞůůƐ with gentle mixing. The mixture 
was then incubated on ice for 20 minutes whereupon the cells were heat shocked for 30 
ƐĞĐŽŶĚƐ ƵƐŝŶŐ ĂŶ ĐĐƵůŽĐŬ ? ŝŐŝƚĂů ƌǇ ĂƚŚ  ?>ĂďŶĞƚ /ŶƚĞƌŶĂƚŝŽŶĂů ? ĐĂƚ P D1100-230 V). 
Tubes were then incubated on ice for 2 minutes whereupon 200 µl of SOC medium, pre-
warmed to room temperature (RT) was added. This mixture was then incubated at 37°C, 
 ? ? ? ZWD ŝŶ Ă EĞǁ ƌƵŶƐǁŝĐŬ ? ^ĐŝĞŶƚŝĨŝĐ  ? ?< /ŶĐƵďĂƚŽƌ ^ŚĂŬĞƌ ? ďĞĨŽƌĞ  ? ? ? A?ů ǁĂƐ
removed to be plated onto agar plates with a relevant antibiotic. Plates were then placed in 
an incubator (Genlab, cat: INC/75) at 37°C overnight, whereupon colonies were assessed 
and analysed.  
2.2.3 Plasmid extraction from bacterial cultures  
WůĂƐŵŝĚ ƐƚŽĐŬƐ ǁĞƌĞ ƉƌŽĚƵĐĞĚ ŝŶ , ?ɲ  ?coli and then grown up in liquid broth with 
relevant antibiotics. Plasmids were extracted using QIAprep spin miniprep kit (Qiagen, cat: 
 ? ? ? ? ? ?ŽƌY/'EWůĂƐŵŝĚDŝĚŝ<ŝƚ ?ĐĂƚ P ? ? ? ? ? ?ƵƐŝŶŐƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŝŶƐƚƌƵĐƚŝŽŶƐ. The 
QIAprep spin miniprep kit was used for the majority of plasmids, while the QIAGEN Plasmid 
Midi Kit was used for production of pCSFLW, HAT, TMPRSS2, TMPRSS4, pI.18 and cHA 
bearing plasmids pI.18-CS CHM or pI.18-Sol CHM. Bacterial transformants were picked from 
the agar plates resulting from Section 2.2.2, representing one plasmid clone per colony. One 
colony was picked and inoculated into 5-10 ml of LB broth with appropriate antibiotic (or 




200-500 ml for MIDI prep) using a pipette tip, and incubated overnight at 37°C and 225 
RPM. LB broth containing bacterial transformants was then centrifuged at 2500 RPM for 10 
minutes in a Sorvall ? Legend ? RT centrifuge in order to form a pellet of bacteria. 
^ƵďƐĞƋƵĞŶƚůǇ ? ƚŚĞ ŵĂŶƵĨĂĐƚƵƌĞƌ ?Ɛ ŝŶƐƚƌƵĐƚŝŽŶƐ ǁĞƌĞ ĨŽůůŽǁĞĚ ? Bacterial pellet was 
resuspended in buffer P1, then buffer P2 was used to lyse bacteria, and the solution was 
then neutralised using buffer N3. Solutions were then centrifuged for 10 minutes at 13,000 
RPM in a tabletop centrifuge (Thermo Fisher Scientific, cat: 10524723) whereupon the 
supernatant was decanted into QIAprep 2.0 spin columns. Columns were centrifuged for 60 
s at 13,000 RPM and flow through discarded. Buffer PB was then added; tubes centrifuged 
again for 60 s at 13,000 RPM and flow through discarded. Buffer PE was then added; tubes 
centrifuged for 60 s at 13,000 RPM and flow through discarded. Finally, tubes were 
centrifuged for a further 60 s at 13,000 RPM and DNA eluted from the QIA membrane using 
50 µl of water at 70°C or EB buffer. Eluted DNA ǁĂƐƚŚĞŶĂŶĂůǇƐĞĚƵƐŝŶŐĂEĂŶŽƌŽƉ ? ? ? ? ?
^ƉĞĐƚƌŽƉŚŽƚŽŵĞƚĞƌ ?EĂŶŽƌŽƉ ?WƌŽĚƵĐƚƐ ?dŚĞƌŵŽ&ŝƐŚĞƌ^ĐŝĞŶƚŝĨŝĐ ? ? 
2.3 PV methods 
2.3.1 PV production  
Firefly luciferase PVs were produced by transient co-transfection of HEK293T/17 cells using 
branched Polyethylenimine (PEI, Sigma, cat: 408727-100ML) in 6-ǁĞůůEƵŶĐ ?ƉůĂƚĞƐ ?&ŝƐŚĞƌ
Scientific, cat: 10119831). A DNA mix (Table 2.6) comprising of the various plasmids/genes 
required for each PV was produced depending on the number of wells of a 6-well plate 
required for transfection. To this, 100 µl of OptiMEM® was added per well, and a further 
100 µl added to a separate tube with 17.5 µl of PEI (1 mg/ml) per well. The PEI tube 
contents were then added to the DNA mix tube whereupon the contents were incubated at 
RT for 20 minutes with frequent mixing. After incubation, 6-well cell culture media was 
changed (2 ml/well), and the transfection mix was added drop wise to each well containing 
60-80% confluent HEK293T/17 cells seeded the day before (approximately 4x105 cells per 
well). 6-well plates were lightly swirled to ensure even dispersal of the transfection mix, 
plates were then incubated at 37°C, 5% CO2 for 48 h, with media being replaced 
approximately 12h after transfection to remove traces of PEI. Supernatants were harvested 
 ? ?ŚƉŽƐƚƚƌĂŶƐĨĞĐƚŝŽŶƵƐŝŶŐĂƐƚĞƌŝůĞƐǇƌŝŶŐĞĂŶĚ ? ? ? ʅŵŵŝǆĞĚĐĞůůƵůŽƐĞĞƐƚĞƌŵĞŵďƌĂŶĞ




filter (Fisher Scientific, cat: 10460031). Supernatants were kept at -80°C alongside aliquots 
for titration in micro centrifuge tubes.  
Other transfection reagents were used in this study, including, Endofectin Max and 
Endofectin Lenti (GeneCopoeia inc, cat: EFM1004-01/02 and EF001/EF002). In both of these 
cases, transĨĞĐƚŝŽŶǁĂƐĐĂƌƌŝĞĚŽƵƚĂĐĐŽƌĚŝŶŐƚŽŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŐƵŝĚĞůŝŶĞƐĂƐĨŽůůŽǁƐ ? A DNA 
mix of the relevant plasmids was prepared (E.g. Table 2.6), and diluted in 200 µl of 
OptiMEM® per well of a 6-well plate. A second tube was prepared with a further 200 µl of 
OptiMEM® and 2 µl of Endofectin for every µg of plasmid DNA. Contents of each tube were 
then mixed, incubated at RT for 25 m and then added to a 60-80% confluent HEK293T/17 
monolayer with 10ml of DMEM (In lieu of 8 ml). Supernatants were then harvested 48 h 
ƉŽƐƚ ƚƌĂŶƐĨĞĐƚŝŽŶ ĂŶĚ ĨŝůƚĞƌĞĚ ƵƐŝŶŐ Ă ƐƚĞƌŝůĞ ƐǇƌŝŶŐĞ ĂŶĚ  ? ? ? ? ʅŵ ŵŝǆĞĚ ĐĞůůƵůŽƐĞ ĞƐƚĞƌ
membrane filter to clarify cell debris. Endofectin-Max transfections were performed using 
antibiotic free medium, with cells cultured in the absence of antibiotics for the passage prior 
to transfection. Endofectin Lenti transfections were performed with standard DMEM +10% 
FBS, 1% P/S. The plasmid quantities listed in Table 2.6 represent the general optimised 
quantities for PV production for all PVs produced. PV bearing glycoproteins requiring 
different parameters are listed in the relevant chapter methods. NA bearing plasmids can be 
replaced by the addition of exogenous NA (exNA, Sigma, cat: N2876) after media 
replacement, 12h post transfection. See Figure 2.5 for a schematic representation of the PV 
production process. 
Table 2.6. DNA mix plasmid quantities.  Standard quantities of plasmids required for the production 
of HA and NA bearing PVs. NA plasmid can be substituted by addition of exogenous NA 12h post 
transfection. 
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Figure 2.5. Production of influenza PV by co-transfection of multiple expression plasmids into 
HEK293T/17 cells. Basic plasmids coding for the constituents of the desired PVs are transfected into 
HEK293T/17 cells alongside additional plasmids, if required. HEK293T/17 cells transcribe and 
translate the relevant HIV-1 core genes and influenza glycoproteins which are then packaged at the 
cell surface and bud off in an HIV-1 dependent manner. Particles are released through the NA 
glycoprotein or exNA added 12h post transfection. Figure from (Carnell et al. 2015). 
2.3.2 Pseudotype titration protocol  
Titration of firefly luciferase PV was carried out by transduction of susceptible cells 
(HEK293T/17 for the majority of influenza PV) in 96-well white plates (Thermo Fisher 
Scientific, cat: 136101). 100 µl of PV containing supernatant is added to row A for each test 
sample. One row is left empty at this stage for cell only control and one is used for 100 µl of 
VSV-G PV as a transduction control. 50 µl of DMEM (+10% FBS, 1% P/S) is added to all other 
wells on the plate, and a 1:2 serial dilution is carried out from row A to row H, with the final 
50 µl discarded. This leaves a plate with a dilution series of PV in 50 µl of DMEM, to which 
1x104 target cells in a volume of 50 µl are added. Plates are then incubated at 37°C, 5% CO2 
for 48 h. The liquid contents of each well are then removed using a Vacusip portable 
aspiration system (Integra Biosciences ltd, Surrey, United Kingdom), and 25 µl of a 50:50 mix 
of Bright-'ůŽ ? >Ƶciferase Assay System and PBS (Pan Biotech, cat: P04-36500) added per 
well. Plates are then incubated at RT for 5 m whereupon results are recorded using a 
GloMax 96 Multi detection system luminometer (Promega). Analysis was performed by 
multiplication of RLU values per well with the corresponding dilution factor, providing a 




result in RLU/ml which is used for comparison of RLU titres (Table 2.7). Care is taken at this 
stage to ensure a linear relationship is present between serial dilution and luminescence 
output. The effect of multiplication of a non-functional PV preparation can give false 
positive results due to the nature of the multiplication effect (example shown in yellow, 
Table 2.7).  
In the projects reported in this thesis, titrations were carried out with several controls, to 
which test variables were compared.  VSV-G bearing PV were used as a transduction control, 
due to their use of a ubiquitous receptor, LDLR (Finkelshtein et al. 2013).  VSV-G PV produce 
very high RLU/ml counts (>10E9) when produced using the standard protocol outlined in 
section 2.3.1.  Testing these alongside other PV allows confidence to be attributed to the 
results, as a high VSV-G titre shows that cells are correctly producing luciferase and that the 
substrate is not compromised.  Other controls used include PV bearing the HA from 
A/Vietnam/1194/2004, which is a high titre influenza PV. A negative production control was 
employed in some instances, where PV were produced using p8.91 and pCSFLW plasmids 
only, creating Delta Envelope (ȴ Env).  These PV sometimes succeed in transducing cells to 
some degree (titres 10E4-10E5 RLU/ml), despite a lack of glycoprotein, and can be used as a 
benchmark for RLU/ml titres. 
2.3.3 Pseudotype based microneutralisation assay (pMN) 
The pMN assay was the primary assay used in this project and performed in 96-well white 
plates as in the titration assay. The pMN assay is carried out using 8 and 12 channel 
multichannel pipettes and plate centrifugation carried out in an ELMI CM-6MT centrifuge 
with 6M04 rotor. The antibody source (Serum, mAb) is first transferred into the wells of row 
A at the desired starting quantity/concentration, with rows assigned for virus only, cell only 
and positive/negative neutralisation controls. Wells containing the antibody source are 
made up to 100 µl, all other wells (rows B to H) are filled with 50 µl of DMEM (+10% FBS, 1% 
P/S). Serial 1:2 dilution is then carried out with frequent mixing from row A to row H. The 
final 50 µl is discarded. This results in a 96-well plate with serial dilutions of test samples at 
known dilution or concentration; in total volumes of 50 µl. Plates are centrifuged at this 
point to ensure all samples remain in the liquid portion of each well. Subsequently, the PV 
of choice for each experiment is diluted in order to give approximately 1x106 RLU per 50 µl, 
based on previous titration results. 50 µl of this is then added to each well on the 96-well 




plate with the exception of cell-only control wells, and plates are centrifuged again to 
ensure all added virus is present in the liquid portion of each well. The plates are then 
incubated at 37°C, 5% CO2 for 1 h in order to allow antibody time to bind to the viral 
glycoproteins. The final step involves addition of 1x104 target cells per well in a volume of 50 
µl. Plates are then incubated at 37°C, 5% CO2 for 48 h. After this, the liquid contents of each 
well are then removed using a Vacusip portable aspiration system, and 25 µl of a 50:50 mix 
of Bright-'ůŽ ? >ƵĐŝĨĞƌĂƐĞ ƐƐĂǇ ^ǇƐƚĞŵ ĂŶĚ W^ are added per well. Plates are then 
incubated at RT for 5 m whereupon results are read using a GloMax 96 Multi detection 
system luminometer. See Figure 2.6 for a schematic representation of the pMN assay.  
Various controls are employed in the pMN assay.  First, PV only and cell only wells are 
assigned per 96-well plate in order to ascertain the actual input (rather than expected input) 
of PV RLU used in the assay.  The cell only wells act as a background value and 
contamination control.  PV only and cell only RLU values represent 0% and 100% 
neutralisation respectively when data is analysed  W wells with serial dilutions of serum are 
then normalised based upon these 100% and 0% neutralisation thresholds (detailed in 
section 2.3.4).  Each set of experiments will also have positive and negative serum wells 
acting as controls for the neutralisation of the PV used.  Due to the nature of the HA 
glycoprotein, the most matched antiserum standard or positive serum sample would be 
used as a positive control, based upon previous experiments.  Negative serum used is FBS 
which is used in a similar quantity to other serum test wells.  In some cases, mAbs were 
used as controls in the absence of a suitable positive serum sample. 
  
  




Table 2.7. Example data analysis of PV titration results. Raw data luminescence values (RLU) are 
multiplied up to RLU/ml (highlighted green), and RLU/ml values averaged to give an Average RLU/ml 
value. Care must be taken to ensure a linear relationship between RLU and PV dilution, as 
multiplication can lead to high RLU/ml titres which will artificially inflate Average RLU/ml titres 
(highlighted yellow). 
 
Multiplication factor H1 PV VSV-G PV Virus X 
20 5.58E+05 7.17E+08 3.05E+03 
40 2.90E+05 5.63E+08 1.10E+03 
80 1.43E+05 3.79E+08 6.29E+03 
160 6.17E+04 2.16E+08 8.80E+02 
320 3.10E+04 1.36E+08 5.43E+03 
640 2.41E+04 6.18E+07 3.39E+03 
1280 7.15E+03 3.06E+07 1.96E+03 
2560 3.62E+03 1.44E+07 3.33E+03 
    RLU/ml 1.12E+07 1.43E+10 6.11E+04 
RLU/ml 1.16E+07 2.25E+10 4.40E+04 
RLU/ml 1.14E+07 3.03E+10 5.03E+05 
RLU/ml 9.87E+06 3.46E+10 1.41E+05 
RLU/ml 9.91E+06 4.35E+10 1.74E+06 
RLU/ml 1.54E+07 3.96E+10 2.17E+06 
RLU/ml 9.16E+06 3.92E+10 2.51E+06 
RLU/ml 9.26E+06 3.69E+10 8.54E+06 
    Average RLU/ml 1.10E+07 3.26E+10 1.96E+06 
 
2.3.4 pMN analysis 
The data collected with the pMN assay was analysed using Graph Pad Prism software 
(Version 7). Non-linear regression analysis was performed, with each data point normalised 
between 100% and 0% neutralisation based on cell only and virus only controls, which 
represent 100% and 0% neutralisation respectively. These normalised values were then 
plotted alongside their corresponding dilution factor (and log10 dilution factor), which were 
used to plot a standard curve and extrapolate an IC50 (inhibitory concentration 50%) value 
for the comparison of different serum samples against the same PV. The IC50 represents the 
reciprocal dilution or concentration required for an inhibitor to reduce the PV input (1x106) 
to 50% (5x105). This 50% value is frequently used across the serological field, representing 
the linear (hill slope) section of a neutralisation curve where the serum is the variable factor. 
For data generated using serum, dilution factor was used for the analysis, and the hill slope 
of the generated curves was constrained to be <0. For mAbs/nanobodies at a known 
concentration, concentration was used for the analysis, hill slopes were then constrained to 




>0.  Correspondingly, neutralising antibody titres (IC50 or other percentile) generated 
through pMN against serum samples are given as a reciprocal dilution factor (e.g. An IC50 of 
500 requires a serum sample to be diluted 1:500 to neutralise 50% of the PV used), whereas 
neutralising antibody titres for mAbs are given in concentration (e.g. An IC50 of 500 ng/ml 




Figure 2.6. Schematic of the Pseudotype based neutralisation assay (pMN). This assay is performed 
by serial dilution of serum or mAbs in 96-well white plates followed by addition of a known quantity 
of PV based on previous titration results. Approximately 1x104 HEK293T/17 cells are then added and 
plates incubated for 48 h at 37°C, 5% CO2. Data is collected after 48 h depending on the reporter 
used, in the case of firefly luciferase, cells are lysed and luciferase substrate is added in the form of 
Bright-Glo ? and results collected using a GloMax 96 luminometer. Figure from (Carnell et al. 2015). 




2.3.5 Pseudotype based ELLA 
PV based ELLA was performed largely according to standard methods produced and detailed 
by the CONSISE group (Eichelberger et al. 2016; Gao et al. 2016). PV containing supernatants 
were serially diluted in 120 µl of sample diluent from a starting well of 240 µl PV 
supernatant, in clear 96-well plates (Sigma, cat: M9410-1CS). 50 µl of each dilution point 
was then transferred to 50 µl of sample diluent in a 96-well maxisorp plate (Thermo Fisher 
Scientific, cat: 439454) previously coated in fetuin (Sigma, cat: F3385), in duplicate. These 
plates were then incubated for 16-18 h in a humidified incubator at 37°C, 5% CO2.  
Subsequently, plates were washed 6 times with wash buffer, then 100 µl of PNA-HRPO 
(Sigma, cat: L7759) diluted (1:500 or 1:1000) in conjugate buffer was added per well. Plates 
were incubated at RT in the dark for 2 h whereupon plates were washed 3 times with wash 
buffer to remove traces of PNA-HRPO. 100 µl of OPD substrate (Sigma, cat: P8287) dissolved 
in citrate buffer (Sigma, cat: P4922) was then added and plates were incubated at RT in the 
dark for 10 minutes. Reactions were stopped by the addition of 100 µl 1N H2SO4 and plates 
were read using a Tecan Sunrise (Jencon) ELISA plate reader at 492nm for 0.1sec. 
Background results were subtracted from sample wells and plotted using PRISM GraphPad. 
For inhibition assays, 24 µl of serum (in 240 µl) was diluted across a 96-well clear plate. 50 µl 
of these dilutions were then transferred to a 96-well maxisorp plate, previously coated in 
fetuin, in duplicate. A set amount of virus, as calculated from the titration ELLA, yielding a 
desired OD492 per well, was then added and plates left to incubate overnight. The remaining 
steps are identical to the titration ELLA. Exogenous neuraminidase (exNA) was used as a 
fetuin digestion control for ELLA titrations.  Antisera or positive serum samples suitable for 
the PV strain used were employed as positive or negative controls in the ELLA inhibition 
assay. 
2.4 Cell work 
2.4.1 Cell lines 
Multiple cell lines were used in this project for various experiments. In general, HEK293T/17 
cells were used for the production of PV as well as a target cell for transduction in titration 
and pMN assays. MDCK I, MDCK II, rat intestinal epithelial 1495 (RIE 1495) cells were used 
as target cells for titration and pMN using H17 bearing PV. Human embryo kidney cells 




(HEK293T/17) were obtained from Dr Davide Corti, Institute for Research in Biomedicine, 
Switzerland. MDCK cells used originate from two sources. MDCK I cells were obtained from 
Prof Sarah Gilbert, University of Oxford. MDCK II and rat intestinal epithelial cells (RIE 1495) 
were obtained from Dr Martin Schwemmle, Institute of Virology, University of Freiberg, 
Germany. All cell lines were cultured in DMEM (Pan Biotech, cat: P04-04510) with 10% heat 
inactivated FBS (Pan Biotech, P40-37500HI) and 1% penicillin/streptomycin (Pan Biotech, 
cat: P06-07100). 
2.4.2 Cell subculture 
Cells were subcultured 2-3 times per week depending on project requirements. Cells were 
diluted in differing volumes dependent on the rate of growth of each cell line. HEK293T/17 
Cells were subcultured 1:4 on Mondays and Wednesdays and 1:8 on Fridays in 10 cm2 
NuŶĐ ?dishes (Sigma, cat: 150318). Cell monolayers were washed once with 1 ml Trypsin-
EDTA (Pan Biotech, cat: P10-040100) and then incubated with 2 ml Trypsin-EDTA for 5 
minutes, allowing the cells to detach. Cells were then resuspended with 6 ml DMEM (+10% 
FBS, 1% P/S), giving a total volume of 8 ml. Resuspension was performed vigorously in order 
to ensure the majority of cells were dispersed and not clumped. For the purposes of future 
cell culture, 1 or 2 ml of the resuspended cells were added to fresh 10cm2 dishes containing 
8 ml of DMEM in order to give 1:4 or 1:8 dilutions of cells for subsequent work. For 
pseudotype virus production, 200 µl of cell suspension was used per well of a 6-well plate 
(approx 4x105cells).  For other cell lines, two washes were performed using PBS in lieu of 
Trypsin-EDTA. 
2.4.3 Freezing/thawing of cell lines  
In order to maintain stocks of low passage cells, cells were frozen and stored at -80°C upon 
acquisition from each stated source. After initial cell culture and several passages in the 
laboratory, confluent cell monolayers were washed and trypsin was added as in previous 
cell culture methods. Detached cells were then resuspended, centrifuged (ELMI CM-6MT 
centrifuge with 6M Rotor, Spectra Services) at 300 rpm for 5 minutes in 15 ml falcon tubes 
(Greiner Bio-One, cat: 188271) using a 15 ml tube attachment. Media was then decanted, 
and cell pellets resuspended in FBS with 5% DMSO (VWR International, cat: 282164K). 1 ml 
of this cell/FBS/DMSO mix was then aliquoted per 1.5ml cryotube (Corning, cat: 430915) 




and placed inside a Mr Frosty (Fisher Scientific, cat: 5100-0001) in order to be brought to -
80°C at 1°C/minute, minimising cell death during the freezing process. Multiple aliquots of 
low passage cells were produced for each cell line obtained, around 1x106 cells were frozen 
per 1 ml. When currently in-use cells had reached a passage number of over 30, aliquots 
were removed from the -80°C freezer, rapidly thawed by hand and liquids were transferred 
to a 10cm2 dish or T75 flask containing 10 or 15 ml of DMEM +10% FBS 1% P/S. Media was 
replaced after overnight incubation at 37°C, 5% CO2 in order to remove traces of DMSO. 
Cells were subcultured at least two times after this step before being used in PV production 
or pMN assays. 
2.4.4 Justification for use of non standard Bright-Glo quantities 
A preliminary test was carried out using the Bright-Glo ? reagent, in order to maximise its 
use in the projects detailed in this thesis. The Promega Bright-Glo ? manual suggests that 
addition of 50 µl of Bright-Glo ? directly into the wells of 96-well plates post 48 h incubation. 
However, due to the difference in DMEM volumes for titration (100 µl final) and pMN (150 
µl final), addition of 50 µl of Bright-glo ? leads to a difference in concentration of the 
luciferase substrate and cell lysis agent between assays. This discrepancy in volumes of 
media could lead to anomalous results; therefore this preliminary test was carried out in 
order to evaluate the removal of DMEM from 96-well plates prior to addition of a mix of 
pre-diluted Bright-Glo ?. 
Two PV bearing the influenza HA from A/gyrfalcon/Washington/41088-6/2014 (H5, 
henceforth referred to as Gyr) with WT or human codon optimised (Opt) sequences were 
tested alongside VSV-G PV and cell only controls. Three 96-well titrations were carried out, 
with Gyr (WT) and Gyr (Opt) titrated in quadruplicate, alongside VSV-G PV and cell only 
being titrated once each per plate. Each plate was titrated according to the standard 
method described in section 2.3.2 with 100 µl of PV containing supernatant diluted 1:2 
down a 96-well plate. All three plates were incubated for the standard 48 h at 37°C 5% CO2 
in a humidified incubator, whereupon the contents of each well were removed using a 
Vacusip. 50 µl of a 50:50 mix of PBS and Bright-Glo ? was added to the wells of plate 1 (T1), 
25 µl of the same mix to plate 2 (T2) and a 50 µl of a 25:75 mix of PBS and Bright-Glo ? was 
added to the third plate (T3). After a 5 minute incubation period, plates were read for 
luminescence using a Glomax 96 plate reader and results analysed using Microsoft Excel and 




Prism Graph Pad. Initial RLU/ml results showed titres in the same range, with a slightly 
reduced titre recorded for T3 PV which was performed with the lower concentration of 
Bright-Glo ? (25:75), see Figure 2.7. A Wilcoxon paired, nonparametric T test was carried out 
between the grouped results from T1, T2 and T3. Results for Gyr (WT) showed effective 
pairing between all three groups (P=<0.0001), however differences in the median results 
were only seen between different concentrations of Bright-Glo. T1 and T2 results were not 
significantly different (P=0.0584), whereas comparing T1/T2 with T3 showed a significant 
difference in median values (P=0.0078). Similarly, for Gyr (Opt), pairing was effective 
between T1, T2 and T3 (P=<0.0001) and median values were only significantly different 
between T1/T2 and T3 results (P=0.0078). T1 and T2 results were not significantly different 
(P=0.9453). Due to these results, it was decided to carry out the projects in this thesis by 
removing media from 96-well plates post incubation and then incubating cells with a 50:50 



























T 1  5 0 :5 0  B G :P B S  (T = 5 0  u l)
T 2  5 0 :5 0  B G :P B S  (T = 2 5  u l)
T 3  2 5 :7 5  B G :P B S  (T = 5 0  u l)
E ffe c t  o f B r ig h t-G lo  c o n c e n tra tio n
o n   R L U /m l  t it re s
 
Figure 2.7. Effect of Bright-Glo ? concentration on RLU/ml titres. Reduction in quantity of Bright-
Glo ? (T1 to T2) had no significant effect on RLU/ml titres, whereas reduction in concentration (T1/T2 
to T3) resulted in reduced RLU/ml outputs. All experiments carried out in quadruplicate with PV 
bearing three different glycoptoteins (A/gyrfalcon/Washington/41088-6/2014, WT and opt, and 
VSV-G. 




Chapter 3 : Development and utilisation of cHA bearing PV to 
dissect head and stalk mediated antibody responses from 
human serum. 
3.1 Introduction 
3.1.1 Universal vaccines 
As described in chapter 1, universal vaccines represent a major avenue for the future of 
influenza vaccine research. The ability to induce a broadly protective immune response, 
covering multiple subtypes and persisting for multiple seasons of influenza virus disease is a 
worthy goal to aim for. Not only would this kind of vaccine reduce costs for administration 
of vaccines on a yearly basis or through reduced morbidity and mortality, the staggering 
costs for yearly update of influenza vaccines across the globe could be reduced and better 
employed.  
Various methods have been employed in order to design and test such vaccines, which 
primarily aim at elicitation of antibodies to the conserved regions of the influenza virus, 
such as the stalk of the HA trimer or M2. Due to the constraints involved with the functional 
parts of the HA glycoprotein and its ability to change conformation to allow membrane 
fusion, this target is less amenable to antigenic drift and therefore likely less able evade a 
targeted stalk immune response. 
One of the most exciting developments in the universal vaccine section of influenza virus 
research is the progress being made on utilisation chimeric/hybrid cHA based vaccines, 
reviewed by Kramer and Palese over recent years (Krammer 2016; Krammer and Palese 
2013, 2014, 2015). These vaccines employ cHA, originally developed by Pica and colleagues 
(Hai et al. 2012; Krammer et al. 2013) and developed by this group since 2012 multiple 
studies have shown ƚŚŝƐĂƉƉƌŽĂĐŚ ?ƐĂďŝůŝƚǇƚŽŝŶĚƵĐĞďƌŽĂĚůǇŶĞƵƚƌĂůŝƐŝŶŐĂŶƚŝďŽĚŝĞƐŝŶŵŝĐĞ
models, covered in section 1.16 and 1.18. Vaccine immunogenicity for these trials have been 
tested by pMN assay as well as neutralisation of recombinant cHA bearing influenza viruses 
by plaque assay (Hai et al. 2012) and ELISA (Krammer et al. 2013). 





vaccines allowing the host to produce an immune response against the conserved stalk 
region in the absence of the immunodominant globular head. This approach has been 
followed by other groups with varying levels of success (Mallajosyula et al. 2014; Steel et al. 
2010; Valkenburg et al. 2016), covered in section 1.16. Immunogenicity data for these 
projects were tested by HI, ELISA, neutralisation of live virus (Steel et al. 2010) as well as 
pMN, competition ELISA (Mallajosyula et al. 2014; Valkenburg et al. 2016) and 
microneutralisation assay (Valkenburg et al. 2016). 
3.1.2 Stalk antibody detection 
One major obstacle impeding universal vaccine efforts is the inability of gold standard and 
globally trusted assays to efficiently detect the antibodies being generated by these 
vaccines. The HI assay, described in section 1.19 is unable to detect stalk binding antibodies 
as they do not impedĞ ƚŚĞ ǀŝƌƵƐ ? ĂďŝůŝƚǇ ƚŽ ďŝŶĚ ƚŽ ƚŚĞ ƐŝĂůŝĐ ĂĐŝĚ ƌĞĐĞƉƚŽƌ ĂŶĚ ƚŚĞƌĞĨŽƌĞ
agglutinate RBCs. This has lead to a variety of approaches for the detection and 
characterisation of antibody responses elicited from universal vaccines. Among the methods 
described in section 1.19, ELISA remains the most popular as this assay is flexible and it is 
possible to use cHA as a substrate, allowing the detection of stalk directed antibodies with 
this well established system (Nachbagauer, Kinzler, et al. 2016). Other methods used include 
production of recombinant viruses for use in traditional neutralisation assays (Mallajosyula 
et al. 2014; Steel et al. 2010) as well as several studies employing reporter-based 
pseudotype systems such as pMN (Hai et al. 2012; Valkenburg et al. 2016). The benefits of 
pMN in the ability to detect functional antibodies which neutralise the action of the HA give 
this assay an advantage which is not apparent in the literature, with this assay still being 
used in conjunction with gold standard ELISA and MN. The post attachment assay, allowing 
neutralising antibodies to bind to HA after attachment of the HA to its receptor under cold 
conditions has been used previously, but is not regularly employed for the evaluation of 
universal vaccine immunogenicity (Edwards and Dimmock 2001; Hsueh-Ling et al. 2010). 
3.1.3 2009 pandemic and stalk antibodies 
Multiple studies have demonstrated or re-confirmed an increase in cross-reactive immune 
responses as a result of pH1N1 infection (Mahallawi et al. 2013; Medina et al. 2010; 




Wrammert et al. 2011). Subsequent work has attributed this partly to similarities with the 
1918 pandemic virus (Medina et al. 2010) and overall unique origin, it has been shown that 
sequential immunization with pH1N1 leads to increased cross-reactive neutralising antibody 
titres when compared to sequential immunization with a drift variant from the original 
vaccine (Krammer et al. 2012). This data enables us to consider the 2009 pandemic to test 
our cHA pMN system, as natural infection should boost heterosubtypic immunity. The effect 
of the 2009 pandemic is discussed in further detail in section 1.11.2. 
3.1.4 Project aims 
The primary goal of this project was to determine the extent of cross-reactive, stalk directed 
antibodies elicited by the 2009 influenza pandemic strain, through assay of human sera pre 
and post 2009. Various parameters render this task difficult, such as the nature of human 
infection and pre-existing immunity to H1 influenza viruses. Similarly, with the number of 
serum samples collected, it is difficult to determine the proportion of patients that had 
actually encountered the pandemic strain. The linked secondary goal of this project was to 
produce cHA expression plasmids and to employ them in a PV system in order to build up a 
library of group 1 influenza stalks to which antibodies could be tested. The production of 
cHA expression plasmids with group 2 (H3) and Influenza B stalks were secondary objectives 
of this project. While the cHA pMN system has been tested previously in pilot projects, this 
represents the broadest project undertaken to date using this system. 
3.2 Methods 
3.2.1 PCR and production of cHA expression plasmids 
cHA plasmids were constructed by long distance PCR using oligonucleotide primers spanning 
two different HAs within their respective expression plasmids pI.18, as shown in Figure 3.1. 
DNA fragments were amplified from the expression plasmid bearing the HA stalk and HA 
head of choice using primers listed in Tables 3.1 to 3.3. These PCR fragments were then 
fused into one plasmid via the In-Fusion or Gibson Assembly methods (Gibson et al. 2009; B. 
Zhu et al. 2007). The first fragment consisted of the pI.18 sequence and HA stalk sequences, 
ǁŝƚŚ ĂŶ ŽǀĞƌůĂƉ ŽĨ ĂƌŽƵŶĚ  ? ? ŶƵĐůĞŽƚŝĚĞƐ ŽĨ ƚŚĞ ƚĂƌŐĞƚ, ŚĞĂĚ ƌĞŐŝŽŶ Ăƚ ƚŚĞ  ? ? ĂŶĚ  ? 
termini. The second fragment consisted of the HA head region of choice, with overlaps of 




ƚŚĞ,ƐƚĂůŬŽĨĐŚŽŝĐĞĂƚƚŚĞ  ? ?ĂŶĚ  ? ?ƚĞƌŵŝŶŝ ? These two fragments were then incubated 
together with In-Fusion or Gibson assembly kits, in order to yield the pI.18 expression 
plasmid bearing a cHA composed of the head region from one HA (H11) and the stalk from 
another (H1, H3, and Flub). Figure 3.1 shows a schematic of the production process for 
these cHA expression plasmids. 
 
 
Figure 3.1. cHA expression plasmids were produced using either Gibson Assembly or In-Fusion 
cloning kits. PCR fragments were produced from plasmids bearing the HA stalk and HA head of 
interest with complementary overlap regions, leading to a cHA expression plasmid with the head 
and stalk region from two different plasmids, after assembly.  
 
  




3.2.2 Cloning methods for the production of cHA plasmids 
In-Fusion® HD Cloning system (Clonetech, cat: 639645) was used for the generation of cHA 
plasmids (B. Zhu et al. 2007). cHAs with stalks from A/Solomon Islands/3/2006 (Sol CHM) 
and 2009pdm consensus sequence (A/Texas/50/2009 or CS CHM) were produced. Original 
primers were designed to produce a further cHA bearing the stalk from A/Brisbane/59/2007 
(Bris CHM) but this was not used in downstream applications. Briefly, Linearised plasmid 
(pI.18) containing the stalk from A/Texas/05/2009 or A/Solomon Islands/3/2006 and H11 
head overlaps was incubated in a 1:2 ratio with H11 head PCR fragments, themselves 
containing ŽǀĞƌůĂƉƉŝŶŐƐĞĐƚŝŽŶƐŽŶ ? ?ĂŶĚ ? ?ĞŶĚƐĐŽŵƉůŝŵĞŶƚĂƌǇǁŝƚŚƚŚĞ/Texas/05/2009 
or A/Solomon Islands/3/2006 stalks. This equated to 100 ng of linearised plasmid and 200 
ng of PCR head fragment. To each reaction, 1 µl of In-Fusion enzyme was added after 
addition of 2 µl 5X In-Fusion reaction buffer, making up the final volume to 10 µl with dH20. 
Each reaction was incubated for 15 minutes at 37°C, followed by 15 minutes at 50°C, then 
placed on ice. The reaction volume was then mixed with 30 µl of TE buffer (pH 8), and then 
tested via gel electrophoresis or transformed into competent E. coli. Gibson Assembly® 
Master Mix (New England Biolabs, cat: E611S) was used to produce G2 (G2 CHM) and Flu B 
(Flu B CHM) cHA plasmids (Gibson et al. 2009). Briefly, linearised plasmid (pI.18) containing 
the stalk from B/Brisbane/60/2008 or A/Udorn/307/1972 with H10 head overlaps was 
incubated in a 1:2 ratio with H10 head PCR fragments, containing overlapping ƐĞĐƚŝŽŶƐŽŶ ? ?
ĂŶĚ  ? ?ĞŶĚƐĐŽŵƉůŝŵĞŶƚĂƌǇǁŝƚŚ ?ƌŝƐďĂŶĞ ? ? ? ? ? ? ? ?Žƌ ?hĚŽƌŶ ? ? ? ? ? ? ? ? ?ƐƚĂůŬƐĞĐƚŝŽŶƐ ? 
This equated to 100 ng of linearised plasmid and 200 ng of PCR head fragment. To this, 10 µl 
of Gibson Assembly Master Mix (2x) was added, and dH20 used to make the reaction up to 
20 µl. Samples were then incubated at 50°C for 15 minutes and then stored on ice until used 
in gel electrophoresis or for transformation of competent E. coli. 
  




Table 3.1. Primers for the generation of PCR fragments used in the production of cHA expression 
plasmids Bris CHM, Sol CHM and CS CHM. Forward and Reverse primers bearing the name of the 
cHA and fragment type (in = head fragment, out = linearised vector fragment) are listed alongside 
their annealing temperatures (°C). 
Primer ID Sequence Annealing 
temperature °C 
H11_Bris_in_fwd: CACAACGGCAAGCTGTGCAGCATCGACGGAAAAG  64.7 
H11_Bris_in_rev: CTGACACTTGGCGTCGCAAGACTCGATATTCAGGTCGC 64.3 
H1_Bris_out_fwd:  CGACGCCAAGTGTCAGACC 58.1 
H1_Bris_out_rev:  CAGCTTGCCGTTGTGGCT 59.1 
H11_CS_in_fwd:  CACAACGGCAAGCTGTGCAGCATCGACGGAAAAG 64.7 
H11_CS_in_rev:   CTGACAGGTGGTGTTGCAAGACTCGATATTCAGGTCGC 63.1 
H1_CS_out_fwd:  GCAACACCACCTGTCAGACC 57.9 
H1_CS_out_rev: CAGCTTGCCGTTGTGCTT 56.5 
H1_CS_fwd: TCTAGAGTCAAAATGAAGGCTATCCTGGTCGT 58.4 
H1_CS_rev:   TCTAGAAATTTAAATACAGATCCGGCACTGC 55.3 
H11_sol_out_fwd CACAACGGCAAGCTGTGCAGCATCGACGGAAAAG 64.7 
H11_sol_out_rev TGACACTTGGCGTCGCAAGACTCGATATTCAGGTCGC 64.4 
H1_sol_in_fwd TGCGACGCCAAGTGTCAGACC 61.3 
H1_sol_in_rev  GCACAGCTTGCCGTTGTGGC 62.1 
 
Table 3.2. Primers for the generation of PCR fragments used in the production of cHA expression 
plasmids for G2 CHM. Forward and Reverse primers bearing the name of the cHA and fragment type 
(in = head fragment, out = linearised vector fragment) are listed alongside their annealing 
temperatures (°C). 
Primer ID Sequence Annealing 
temperature °C 
H10_In_Fwd  ? ?d''''dd'd''''d ? ?  58.4 
H10_in_Rev  ? ?'d'dd'd''d'dd'dd' ? ? 58.1 
H3_out_Rev  ? ?'ddddddd'ddddd'dd''' ? ? 58.5 
H3_out_Fwd  ? ?dd''d'dddd'd'dd ? ? 58.5 
 
  




Table 3.3. Primers for the generation of PCR fragments used in the production of cHA expression 
plasmids for FluB CHM. Forward and Reverse primers bearing the name of the cHA and fragment 
type (in = head fragment, out = linearised vector fragment) are listed alongside their annealing 
temperatures (°C). 
Primer ID Sequence Annealing 
temperature °C 
H10_in_fwd CTCAAAGGAACAGAATGCATGAAAGGAAGATCA 56.9 
H10_in_rev CGTATTTTTCGTGGAGGCAGCTGTTGTC 59 
B_out_fwd ATTGACAACAGCTGCCTCCACGAAAAATACG 59.3 
B_out_rev TGATCTTCCTTTCATGCATTCTGTTCCTTTGAG 56.9 
3.2.3 Serum information 
 ƉĂŶĞů ŽĨ ƐĞƌĂ ? ĚĞƐŝŐŶĂƚĞĚ  ‘:ĞŶŶĞƌ ^ĞƌĂ ? ? ǁĂƐ ŬŝŶĚůǇ ƉƌŽǀŝĚĞĚ ďǇ WƌŽĨ ^ĂƌĂŚ 'ŝůďĞƌƚ ?
University of Oxford. This panel consisted of sera taken from clinical trials involving vaccines 
designed at the Jenner Institute, University of Oxford. Clinical trials were carried out using 
NP based vaccines, therefore no detected HA response should be attributed to the effect of 
the vaccine. For the purpose of this study, the serum samples can be considered from the 
population of Oxford between 29/07/2008 and 26/10/2016. A total of 179 samples were 
obtained from patients just prior to and in the years following the 2009 influenza pandemic, 
with 13 samples from 2008, 7 from 2009, 27 from 2010, 13 from 2011 and 118 from 2012-
2016. For the purpose of this study, samples were arranged according to the date on which 
samples were taken and then assigned a number from 1-179 in order to make results easier 
to analyse. Serum panel information is displayed in appendix X1. These sera were tested 
using the three virus chimeric pMN system consisting of parental 
A/duck/Memphis/546/1974 (H11), A/California/7/2009 (H1) and the CS CHM composed of 
the head from the parental H11 strain and stalk from parental H1 strain.  
 
ƐĞĐŽŶĚƉĂŶĞůŽĨƐĞƌĂ ?ĚĞƐŝŐŶĂƚĞĚ ‘^ƉŽƌƚƐ^ĐŝĞŶĐĞ^ĞƌĂ ?ǁĂƐĂůƐŽƵƐĞĚŝŶƚŚŝƐƉƌŽũĞĐƚ ? This 
panel consisted of 60 pairs of sera originating from a set of athletes in Scotland.  These sera 
were tested via pMN on A/Brisbane/59/2007 (H1), A/Vietnam/1194/2004 (H5) 
A/Udorn/307/1972 (H3) and A/Shanghai/2/2013 (H7), representing a human seasonal (H1, 
H3) as well as pandemic potential avian subtype (H5, H7) per influenza group. This would 
allow for measurement of pan-group cross-reactive immune responses between the four 
subtypes tested as published previously but with the addition of human seasonal strains 




(Molesti et al. 2014). Serum samples were paired, with a 12 week interval between them 
per patient. No action or effect was being measured for the 12 week period; samples were 
taken as part of an unrelated study on the effects of chronic exercise. Antibody standards 
were used as controls for all pMN assays. These were produced by hyperimmune 
stimulation, involving the vaccination of sheep multiple times with a HA protein vaccine. 
This was carried out by the NIBSC. 
3.3 Results and discussion 
3.3.1 Production of cHA expression plasmids 
First, primers listed in tables 3.1-3.3 were used to produce the two components required for 
the production of cHA expression plasmids. Linear pI.18 DNA including the H1 stalk overlap 
of choice (A/Texas/05/2009 (H1), A/Brisbane/59/2007 (H1) and A/Solomon Islands/3/2006 
(H1)) was produced by PCR, yielding a fragment ~5 kb in length. However the expected 5 kb 
product was accompanied by various nonspecific bands and smears. A shorter fragment 
bearing the H11 head and short overlaps for each specific H1 stalk were also produced, 
yielding a clean band at ~500 bp in length. See Figure 3.2 and 3.3 for the results from 
duplicate PCR and gel electrophoresis of the fragments generated as described above. 
 
It was decided that gel extraction, rather than PCR optimisation was the most efficacious 
and cost-effective method to obtain the desired PCR fragment in pure form, due to the size 
of the desired fragment and lack of flexibility in primer design. Gel extraction was 
performed (Section 2.1.12) after excision of the bands containing the putative constructs 
designed in this project: linear H11 head and H1 stalk bearing fragments designed for in-
fusion or Gibson assembly. Figure 3.4 shows gel electrophoresis of the purified fragments 
excised from the gels shown in Figures 3.2 and 3.3. 
 






Figure 3.2. Initial attempt at PCR of pI.18 linear vector with H1 stalk overlaps, as well as H11 head 
DNA fragments with complementary H1 stalk overlaps. Strong bands at the expected 5.3kb mark for 
pI.18 + H1 stalks and 700bp band for H11 heads are present. Several nonspecific bands present after 




Figure 3.3. Repeat of the Initial attempt at PCR of pI.18 linear vector with H1 stalk overlaps, as well 
as H11 head DNA fragments with complementary H1 stalk overlaps. 
 
 





Figure 3.4. Gel electrophoresis of gel extracted PCR products. Left hand side of the figure shows the 
production of a linear DNA fragment consisting of the pI.18 expression plasmid sequence flanked by 
H1 stalk sequences. The right side of the graph shows the remaining part of the chimera, linear DNA 
fragments consisting of the H11 head flanked by H1 stalk sequences. 
  
The first attempt at the production of cHAs via in-fusion was unsuccessful, yielding no band 
or smear for the Sol CHM when tested directly by gel electrophoresis. This first Sol CHM 
attempt was run alongside further PCR reactions of H11 heads with CS, Brisbane and Sol 
overlaps, as well as pI.18 CS and Sol stalks with H11 overlaps (Figure 3.5). 
Due to the possibility that cHA plasmids were present in the previous sample, but not 
detectable by gel-electrophoresis, In-Fusion was then attempted again and the reaction mix 
was then immediately transformed into competent E. coli (section 2.2.2). Colonies were 
successfully grown overnight in the presence of amp. Four colonies from both CS CHM and 
Sol CHM plates were picked and grown in LB broth overnight as per section 2.2.2. Of these 
four clones, three were selected based on the optimal optical density of bacterial growth, 
plasmids were extracted as per Section 2.1.11 and gel electrophoresis was performed on 
plasmids resulting from each colony, alongside parental phCMV-H11 (Figure 3.6). Typical 
plasmid conformation was observed for each clone, at varying strengths, indicating the 
presence of dsDNA plasmids in various coiled and uncoiled states for both cHA plasmids. 





Figure 3.5. Gel electrophoresis of H11 heads with CS, Bris and Sol overlaps, alongside pI.18-CS and 
pI.18-Sol linearised plasmids with H11 head overlaps. Dark lanes (CS CHM, Sol CHM) show the 




Figure 3.6. Gel electrophoresis of plasmids pI.18 bearing Sol CHM and CS CHM genes, alongside 
phCMV-H11. Three colonies of bacterial transformants were grown overnight in LB broth and 
plasmids were extracted. Clones 2, 3 and 4 for Sol CHM and 1, 2 and 4 for CS CHM were run in this 
gel. Clones were selected based upon the optical density of LB broth after overnight culture. 
 
ĂĐŚ Đ, ƉůĂƐŵŝĚ ǁĂƐ ƚŚĞŶ ƵƐĞĚ ŝŶ WZ ƵƐŝŶŐ ƚŚĞ ŽƌŝŐŝŶĂů  ? ? ĂŶĚ  ? ? ƉůĂƐŵŝĚƐ ŝŶ ŽƌĚĞƌ ƚŽ
obtain a full length HA fragment. Results show the presence of a strong band at ~1.7 kb, the 




expected length of the cHA gene for both cHA plasmids (Figure 3.7A). Restriction digestion 
was also performed; plasmids were linearised using KpnI, cutting once at a site within the 
MCS which should still be present within the cHA plasmids MCS. Results show the presence 
of one large band at above 5 kb, the expected size for this plasmid being ~6kb (Figure 3.7B). 
A double digestion was also carried out, with BamHI and EcoRI, two sites flanking the MCS 
region containing the cHA gene. This yielded two fragments as expected; a ~1.7 kb band 
composed of the cHA gene, and a ~4 kb band composed of the pI.18 plasmid (Figure 3.7C). 
 
Figure 3.7. Gel Electrophoresis of PCR and restriction digestion of cHA plasmids Sol CHM and CS 
CHM.  ?WZŽĨ^Žů,DĂŶĚ^,DƉůĂƐŵŝĚƐƵƐŝŶŐ ? ?ĂŶĚ ? ?terminal primers yields a band at ~1.7 
kb, consisting of the cHA gene. B) KpnI digestion of Sol CHM and CS CHM plasmids yields one band at 
>5 kb consisting of the linearised pI.18 plasmid containing the cHA genes. C) Double digestion of Sol 
CHM and CS CHM using BamHI and EcoRI yields two bands at ~1.7 kb and ~4 kb, consisting of the 
cHA genes and linearised pI.18 plasmid respectively.  
 
Sol CHM and CS CHM clones were then sequenced using pI.18 internal primers, yielding 
sequences which were analysed using BioEdit to ensure the expected sequence and 
orientation was present in both cHA plasmids, which was the case. Large stocks of each 
plasmid were then produced using the QIAGEN Plasmid Midi kit (cat: 12125), yielding stocks 
sufficient for the completion of the project (200 µl at 1-2 µg/µl each). Generation of two 
further cHA plasmids was attempted during this project. The first was a group 2 (G2) cHA 
with A/chicken/Germany/N/1949 (H10) head and A/Udorn/307/1972 (H3) stalk. The second 




was a Flu B cHA with A/chicken/Germany/N/1949 (H10) head and B/Brisbane/60/2008 stalk. 
These were produced in a similar fashion to the previous Sol CHM and CS CHM cHA 
plasmids, with a few differences. These chimeras were produced by Gibson assembly (New 
England BioLabs, cat: E2611S). Fragments were first generated by PCR, expected fragments 
were gel extracted as with previous cHAs and run on 1% agarose gels alongside the original 
PCR products (Figure 3.8). Gibson assembly was then carried out as described previously, 1 
µl of the reaction mix was used to transform competent E. coli and plasmids were sent off 
for sanger sequencing alongside being employed for the production of PV. While the 
production of plasmids bearing G2 and Flu B cHAs was successful, it was not possible to 




Figure 3.8. Gel electrophoresis of PCR and Gel extracted fragments for Flu B CHM and G2 CHM 
alongside phCMV1-H10 plasmid. From left to right: 10kb ladder, PCR of H10 head with 
B/Brisbane/60/2008 overlaps before and after extraction (x). B/Brisbane/60/2008 stalk with H10 
head overlaps in pI.18 before and after extraction. H10 head with A/Udorn/307/1972 stalk overlaps, 
before and after extraction. A/Udorn/307/1972 stalk with H10 head overlaps in phCMV1 before and 
after extraction. H10 plasmid in phCMV1. 10kb ladder. 
3.3.2 Production of cHA bearing PV 
A cHA bearing the H11 head and A/South Carolina/1/1918 stalk has previously been 
produced by a PhD student in the Viral Pseudotype Unit, Dr Francesca Ferrara. This was 
used in preliminary tests which gave rise to this project. However, this cHA PV was difficult 
to produce, and only low titre preparations resulted when transducing HEK293T/17 cells 




(Figure 3.9). Production was attempted with co-transfection of pCAGGS-HAT in 6-well 
format, which was found to be the optimal protease for production of this chimera (PhD 
Thesis, Francesca Ferrara). Due to the success in the production of further chimeras, this 
plasmid was not used further in this project, and efforts were focused on establishing the CS 
CHM for use with the Jenner Sera. 
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Figure 3.9. Production of cHA bearing stalk from 1918 pandemic influenza. cHA bearing PV with 
A/South Carolina/1/1918 (H1) stalk and A/duck/Memphis/546/1974 (H11) head), co-transfected 
with pCAGGS-HAT. Production was attempted using a range of concentrations of pCAGGS-HAT 
plasmid from 50 to 450 ng per transfected well (6-well format). 
3.3.3 Production of pandemic 2009 H1 PVs 
Due to the cHA system benefiting from the ability to test the cHA PV alongside its parental 
subtype strains, it was a requirement for this project to produce a working PV bearing the 
H1 from the 2009 pandemic. Early efforts to produce PV bearing this 2009 pandemic HA 
were unsuccessful, employing the A/Texas/05/2009 codon optimised gene (kind gift from 
Prof Sarah Gilbert, University of Oxford) cloned into plasmid pI.18. A further plasmid 
expressing the influenza M2 protein from A/Hong Kong/156/97 (H5N1), cloned into 
pcDNA3.1, was transfected in a final attempt to increase titres of A/Texas/05/2009 PV, after 
M2 was successfully used by other research groups to the same ends (Figure 3.10) (McKay 
et al. 2006; Wei Wang, Castelán-Vega, et al. 2010). Initial results were successful and a linear 
relationship was observed between quantity of M2 expression plasmid added to the 




transfection mix and RLU titre (Figure 3.10). However this experiment could not be repeated 
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Figure 3.10. Effect of co-transfection of M2 expression plasmid on the RLU titres of PV bearing the 
A/Texas/05/2009 (H1) glycoprotein. Production was carried out in HEK293T/17 cells with the co-
transfection of 100, 200 and 300 ng of M2 expression plasmid. The results from this experiment 
could not be repeated. 
 
Further attempts at the production of pandemic 2009 HA bearing PV resulted in the 
commercial synthesis of the WT A/California/7/2009 (H1) (CA/09) gene cloned into plasmid 
pI.18 by Genscript (Piscataway, New jersey, USA). PVs were then produced in the presence 
of the previous proteases HAT and TMPRSS4; with results yielding useable titres of virus 
within the 10E8 RLU/ml range (Figures 3.11 and 3.12). Due to the success in production of 
CA/09 PV above 10E8 RLU/ml with both TMPRSS4 and HAT, no further optimisation was 
carried out and further stocks were produced with co-transfection of 150 ng/well of 
pCAGGS-HAT in 6-well format. However these titres were not significantly different from 
production with 50 ng (P=0.306), 250 ng (P=0.166), 300 ng (P=0.365) or 750 ng (p=0.821), 
but significantly different from 100 ng (P=0.157).  
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Figure 3.11. RLU/ml titres for the optimisation of A/California/7/2009 (H1) bearing PV with the co-
transfection of 50-750ng of pCAGGS-HAT per well. Highest RLU/ml titres were obtained using 150 ng 
HAT, however this was not significantly different from 50 (P=0.306), 250 (P=0.166), 300 (P=0.365) or 
750 (p=0.821), but significantly different from 100 (P=0.157). 
 
For production of CA/09 PV in the presence of TMPRSS4, the highest RLU/ml titres were 
obtained with 100 ng of pCMV-TMPRSS4, giving an average titre of 1.69E8, compared to 
9.12E7 and 2.75E7 for 150 and 250 ng respectively. Differences between 100 and 150 
(P=0.0011), 100 and 250 (P=0.0050) as well as 150 and 250 (P=0.225) were all significant.  
CA/09 PV produced with 110ng of pCMV-TMPRSS4 was significantly greater than PV 
produced with 50 ng (P=0.0255), 100 ng (P=0.0007), 250 ng (P=0.0026) and 750 ng 
(P=0.0030) of pCAGGS-HAT. 
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Figure 3.12. RLU/ml titres for the optimisation of A/California/7/2009 (H1) bearing PV with the co-
transfection of 100-250ng of pCMV-TMPRSS4 per well. The highest RLU/ml titre was obtained with 
co-transfection of 100 ng pCMV-TMPRSS4. 
 
Employment of a newly available transfection reagent (Endofectin Max ©) did lead to a 
further rise in RLU/ml titres, despite this also not being significantly greater than those 
generated using PEI (P=0.836), see Figure 3.13. PVs transfected using this reagent were 
incubated in a larger volume of DMEM (10 ml in lieu of 8 ml) without antibiotics, and no 
medium change was required the day after transfection. These two factors must be 
considered alongside the transfection reagent to evaluate any further increases in titres 
when comparing reagents. It is likely that a larger quantity of virus has been produced with 
Endofectin Max to allow similar titres with a 25% increase in volume of PV containing 
supernatant. The exact parameters used are listed in section 2.4.1. 
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Figure 3.13. RLU/ml titres for various stocks of PV bearing the H1 from A/California/7/2009. Data 
comparison between production with polyethilynimine and Endofectin Max. There is no significant 
difference between PEI and Endofectin Max RLU/ml values (p=0.863). 
3.3.4 Production of cHA PV 
Optimisation of the process for the production of cHA bearing PV was carried out in 6-well 
format using a range of protease expression plasmids, notably pCAGGS-HAT and pCMV-
TMPRSS4. For the Sol CHM, optimal results were obtained when co-transfecting 
HEK293T/17 cells with 200 ng of pCAGGS-HAT alongside the lentiviral and HA plasmids 
(Figure 3.14), yielding an RLU titre of over 10E8 RLU/ml. Co-transfection of 100 ng or 250 ng 
pCAGGS-HAT yielded the second highest results with titres just under 10E8 RLU/ml. pCMV-
TMPRSS4 had little effect when co-transfected under the same conditions, titres remained 
below 10E7 RLU/ml, higher than the ȴƉƌŽƚĞĂƐĞĐŽŶƚƌŽů  ?10E5 RLU/ml) but lower than the 
optimal condition of 200 ng pCAGGS-HAT. See Figures 3.14 and 3.15 for bar charts of 
RLU/ml titres for Sol CHM PVs produced in the presence of different quantities of pCAGGS-
HAT and pCMV-TMPRSS4.  
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Figure 3.14. Production of Sol CHM PVs with co-transfection of pCAGGS-HAT from 100-450 ng per 
well (6-well format).  Production ȴƉƌŽƚĞĂƐĞƌĞƐƵůƚƐƐŚŽǁŶŝŶďůĂĐŬ ? ? ? ? 100, 200 and 250 parameters 
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Figure 3.15. Production of Sol CHM PVs with co-transfection of pCMV-TMPRSS4 from 100-400 ng per 
well (6-well format).  Production ȴƉƌŽƚĞĂƐĞƌĞƐƵůƚƐshown in black (0). Experiment performed in 
duplicate for 100, 250 and 400 parameters. 100-400 ng of pCMV-TMPRSS4 resulted in similar titres 
in the 106 RLU/ml range. 
  




For the CS CHM cHA, more varied results were obtained when producing PV bearing this 
glycoprotein with different quantities of the protease expression plasmids pCAGGS-HAT and 
pCMV-TMPRSS4. Addition of 100-450 ng of pCAGGS-HAT to the transfection mix in 6-well 
format increased titres of CS CHM several logs higher than the ȴ protease control (0). The 
highest RLU titre is seen with co-transfection of 100 ng pCAGGS-HAT, however there was no 
significant difference between 100 and 200 (p=0.45), 100 and 250 (p=0.43) or 200 and 250 
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Figure 3.16. Production of CS CHM PVs with co-transfection of pCAGGS-HAT from 100-450 ng per 
well (6-well format).  Production ȴƉƌŽƚĞĂƐĞƌĞƐƵůƚƐƐŚŽǁŶŝŶďůĂĐŬ ? ? ? ? 100, 200 and 250 ng 
parameters performed in duplicate. Highest luciferase titres (RLU/ml) are observed with the addition 
of 100ng pCAGGS-HAT, giving a titre of over 107 RLU/ml. 
 
CS CHM bearing PV produced in the presence of pCMV-TMPRSS4 had low RLU/ml titres, 
with averages around one log higher than the ȴ Protease control. The highest RLU/ml value 
was obtained with co-transfection of 400 ng of pCMV-TMPRSS4 (7E7 RLU/ml). However, as 
with transfection with pCAGGS-HAT, there was no significant difference between 100 and 
250 (p=0.06) 100 and 400 (p=0.63) or 250 and 400 (p=0.43) RLU titres. See Figure 3.17. 
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Figure 3.17. Production of CS CHM PVs with co-transfection of pCMV-TMPRSS4 from 100-400 ng per 
well (6-well format).  Production ȴƉƌŽƚĞĂƐĞƌĞƐƵůƚƐƐŚŽǁŶŝŶďůĂĐŬ ? ? ? ? Experiment performed in 
duplicate for 100, 250 and 400 parameters. Highest luciferase titres (RLU/ml) are observed with 
addition of 400 ng pCAGGS-TMPRSS4, followed by 100 ng and 250ng. 
 
Optimal conditions for the production of PV were decided as the lowest concentration of 
protease encoding plasmid required to obtain the highest RLU/ml titre. For Sol CHM this 
was 200 ng and for CS CHM 100 of pCAGGs-HAT per well in 6-well format. These parameters 
were employed with other standard plasmid quantities (500 ng p8.91, 750 ng pCSFLW, 500 
ng pI.18-HA per well) in order to produce stocks of each cHA PV. Titres for stocks produced 
after optimisations are displayed in Figure 3.18. 





























Figure 3.18. Production of Sol CHM and CS CHM bearing PV. RLU/ ml titres for Sol CHM (200 
pCAGGS-HAT per well) and CS CHM (100 pCAGGS-HAT per well) produced in bulk after the protease 
plasmid optimisation process. Sol CHM titres average above 108 RLU/ml while CS CHM titres average 
between 107 and 108 RLU/ml. 
3.3.5 Group 2 and Influenza B cHAs   
Attempts to produce PVs bearing cHAs with group 2 and influenza B stalks were 
unsuccessful. Proteases HAT, TMPRSS2 and TMPRSS4 were tested in an optimisation grid 
with a range of 50-500ng per well co-transfected alongside 500 ng of p8.91, 750ng pCSFLW 
and 500ng cHA, as per standard method (section 2.4.1). No effect was seen with any of the 
proteases as RLU values resembled ȴƉƌŽƚĞĂƐĞvalues when each preparation was titrated 
on HEK293T/17 cells.  
3.3.6 pMN of Jenner Sera 
The Jenner Sera were assayed in duplicate against the three viruses of the chimeric CS CHM 
system: Parental H11 PV (A/duck/Memphis/546/1974), Parental H1 PV 
(A/California/7/2009) and the CS CHM. By utilising the cHA alongside the parental strains, 
this allowed the CS CHM neutralising antibody titres to be interpreted in the context of the 
same serum neutralising antibody titres against the parental strains  W allowing dissection of 
the head-only and stalk-only responses seen. Care was taken to reduce variability in this 
project which involved 179 unique sera, requiring a large quantity of PV stocks and cells to 




be produced and pooled in order to ensure the sera could be compared with no variation in 
PV or cell input. Neutralising antibody titres (IC50) for these experiments are shown in 
appendix X1. Overall, neutralising antibody titres were higher in the period after the 2009 
pandemic than before it, despite a low sample size pre 2009 (n=20). Titres for H11 increased 
from 12 to 199, CA/09 from 3596 to 5068 and CS CHM from 376 to 1380. See Figure 3.19.  
Neutralising antibody titres were bracketed in different ways due to the way in which 
samples were taken each yearly period. First, neutralising antibody titres were bracketed 
according to year (Figure 3.20) in order to include all the data collected and provide an 
overview for the trend in neutralising antibodies against the cHA system PVs between 2008 
and 2016. For PV bearing H11, low neutralising antibody titres were recorded for patients in 
2008 and 2009. 2010 saw a sharp increase in neutralising antibody titres, with one patient 
recording an IC50 of 1883 against this HA subtype. 2011, 2012 and 2013-2016 (2013+) show 
an overall increase in neutralising antibody titres against H11 with several patients 
displaying neutralising antibody titres over 500. For PV bearing the pH1 CA/09 HA, pre 2009 
pandemic results were high when compared to H11, with the average IC50 reading at 3596. 
This is most likely due to the nature of H1 infection; conserved epitopes within the pH1 HA 
are likely to have been encountered in human populations previously, despite the exotic 
swine nature of this particular strain (Xu et al. 2010). This may explain the relatively high IC50 
values recorded from sera obtained before the existence of this strain in human populations 
when considering the sensitivity of pMN over traditional assays (Temperton et al. 2007). 
However, 2009 sera neutralising antibody titres remained similar to that pre-2009, with just 
two patients showing increased neutralising antibody titres (7388 and 9274), raising the 
average IC50 for 2009 to 4068. Subsequent years showed a similar trend, with average IC50 
remaining around 3-4000 but increasing to 5000+ after 2012: 2010 (3878), 2011 (3395), 
2012 (5018) and 2013-2016 (5858). While these averages remain similar, it is apparent in 
Figure 3.20 that some patients have elevated neutralising antibody titres against the 
pandemic strain in each bracket. For the CS CHM itself, neutralising antibody titres are low 
pre 2009 and for 2009 itself, with average neutralising antibody titres at 410 for 2008 and 
278 for 2009. Average IC50 values rise to an average of 1410 for 2010 and remain higher than 
pre 2010 at 1224 for 2010, 1430 for 2012 and 1386 for 2013-2016. Figure 3.20 shows this 
data alongside a distinct increase in average and quartile IC50 results for the sera against CS 
CHM. 




Second, values were bracketed for the influenza season (September to April) between years, 
excluding values taken between these times (May to August), shown in Figure 3.21. This 
data shows a very different profile to the year-bracketed data, with an increase in 
neutralising antibody titres against H11, CA/09 and CS CHM observed for the 2009-2010 
influenza season, the first season for pH1N1. Neutralising antibody titres against H11 are 
very low for the 2008-2009 season (n=19) and rise sharply in the 2009-2010 (n=9) season 
due to one patient with an IC50 of 1883. Neutralising antibody titres then remain in the 0-
500 range with patients in 2010-2011, 2011-2012 and 2014-2015 showing titres higher than 
500. For CA/09, neutralising antibody titres remain similar between seasons, with IC50 values 
averaging around 3-5000. There are occasional high data points such as in 2012-2013 
(23,954) and 2013-2014 (15,535) seasons which skew the data, and may represent serum 
being taken from a patient shortly after exposure to a pH1N1 strain after it had replaced 
previous H1N1s as the dominant seasonal strain. Average neutralising antibody titres seem 
to increase in the 2013-2014 and 2014-2015 seasons with average IC50 values of 6892 and 
5711 respectively. For CS CHM, the 2008-2009 season shows the lowest neutralising 
antibody titres as with H11 and CA/09 PV. The 2009-2010 season sees titres increase as a 
ƌĞƐƵůƚŽĨŽŶĞƉĂƚŝĞŶƚ ?Ɛ /50 of 5420. Subsequent seasons show average IC50 values remain 
well above the 393 (mean) of the 2008-2009 seasons, averaging at 1209, 1506, 1455, 1328, 
1264 and 1318 for seasons 2009-2010 to 2014-2015. Neutralising antibody titres then drop 
for the final season in which serum samples were taken in this serum panel, with an average 
IC50 of 750. However, with only two patients in this group, this is most likely not an accurate 
representation of neutralising antibody titres for this season. See Figure 3.21 for graphic 
representation of influenza season bracketed neutralising antibody titres described in this 
paragraph. 





Figure 3.19. Box plots for pMN neutralising antibody titres (IC50) generated by Jenner Sera against A/duck/Memphis/546/1974 (H11), A/California/7/2009 
(H1) and CS CHM bearing PV. Neutralising antibody titres for sera are bracketed pre and post pH1N1 pandemic. Elevated antibody titres are observed 
against all three PVs after the 2009 pandemic. Cross-reactivity is seen through pre 2009 sera neutralising A/California/7/2009. Mean antibody titres are 
increased due to a small subset of patients with increased titres. 





Figure 3.20. Box plots for pMN neutralising antibody titres (IC50) generated by Jenner Sera against A/duck/Memphis/546/1974 (H11), A/California/7/2009 
(H1) and CS CHM bearing PV. Neutralising antibody titres bracketed by year of serum collection. Pre 2009 neutralising antibody titres are low for all three 
PV except for CA/09 PV. Neutralisation of all three PV increases post 2009 when considering average IC50, this is driven by a small group of patients having 
raised neutralising antibody titres, displayed as whiskers. NB: 20 samples between 2008 and 2009.  
 





Figure 3.21. Box plots for pMN neutralising antibody titres (IC50) generated by Jenner Sera against A/duck/Memphis/546/1974 (H11), 
A/California/7/2009(H1) and CS CHM bearing PV. Neutralising antibody titres are bracketed by influenza season (September-April) for sera collected 
between 2008 and 2016. Mean neutralising antibody titres are similar for all seasons for H11 PV, with several high titres observed in the 2009 pandemic 
season. Mean titres against CA/09 fluctuate, with a slight increase seen in the 2013-2014 and 2014-2015 seasons. Antibody titres against CS CHM increase 
after the 2008-2009 season with a small dip observed after the 2011-2012 season. Sera with high titres are observed against all three PV, shown by distinct 
whiskers rising above the 75% quartiles. NB: only 2 patients fall within the 2015-2016 season.  




Finally, neutralising antibody titres were bracketed by age to observe the extent to which 
immunity is dictated by age and previous exposure amongst the group of Jenner Institute 
patients (Figure 3.22). One of the aims of this project was to use the cHA system via PV to 
detect increases in stalk-directed antibodies elicited by natural infection with the pH1N1 
pandemic (Wrammert et al. 2011). However, due to the serum set being spread over 
multiple years and the lack of data regarding the infection history of each patient, it is 
difficult to distinguish whether high responders against the chimera have stalk directed 
antibodies as a result of pH1N1 or previous strains. Nevertheless, when bracketing 
neutralising antibody titres by age group, CA/09 titres match the infection data for pH1N1, 
with young adults being one of the hardest hit groups (Karageorgopoulos et al. 2011; 
Shrestha et al. 2011). Despite this, the 40-50 and 50+ age groups show an increased ability 
to neutralise CS CHM as well as the heterologous H11 PV, which is consistent with other 
studies showing an increase in broadly neutralising antibodies in the elderly after repeated 
exposure to influenza viruses throughout their lifetime (Nachbagauer et al. 2016). One 
drawback of this bracketing is the spread of ages within the panel patients, with 67 patients 
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Figure 3.22. Average neutralising antibody titres (IC50) bracketed by age group between 2008 and 
2016 against PV bearing A/duck/Memphis/546/1974 (H11), A/California/7/2009 (H1) and CS CHM 
glycoproteins. Neutralising antibody titres to H11 are highest in the 40 and 50+ age groups whereas 
for CA/09 the 20 and 40 age groups show the highest titres. The highest titres for CS CHM are seen 
in 40 and 50+ age groups.  




3.3.7 Sports Science sera 
Aside from the cHA system, it is also possible to test for heterosubtypic immunity by testing 
the same sera against a range of PV bearing HAs of different subtypes or strains. It was 
decided that utilising this alternative approach with a separate set of sera (Sports Science 
Sera) could serve as a useful comparison between currently available and novel systems. 
This serum set was used as this approach requires considerable quantities of serum in order 
for the same sample to be assayed using multiple PV bearing different HAs.  The samples 
originate from a group of athletes studied in a chronic exercise study, taken from patients in 
their morning resting states at baseline (0 weeks, V1) and after a 12 week interval (V2). 
The Sports Science Sera were tested on a wide range of influenza A PV (H1, H5, H3, H7) in 
order to assess heterosubtypic responses per patient against a wide range of unrelated virus 
HAs. This experiment was carried out foremost to evaluate the level of heterosubtypic 
responses obtainable from the testing of different influenza viruses using the same serum 
sample. Data generated in this way shows a snapshot of the immune repertoire of the 
patient at the time the sample was taken, which can be employed in our PV system to 
determine whether exposure to H1 or H3 seasonal strains have boosted H5 or H7 group 
specific immunity, or cross group immunity. 
Predictably, neutralising antibody titres generated by assay of serum samples on the above 
listed PV using pMN generated high values for human seasonal subtypes (H1, H3) and lower 
values for the exotic avian subtypes of pandemic potential (H5, H7). Mean IC50 values for 
sera against H1 were 7407 (median 4014), while the H5 IC50 mean was 647 (median 385). 
For group 2 influenza PV, the mean IC50 for H3 and H7 were 4384 and 557 respectively 
(median 3095 and 400 respectively). This data is shown in Figure 3.23. 
  






Figure 3.23. Neutralising antibody titre (IC50) for the 60 pairs of Sports Science Sera assayed against 
A/Brisbane/59/2007 (H1), A/Vietnam/1194/2004 (H5), A/Udorn/307/1972 (H3) and 
A/Shanghai/2/2013. Median and mean IC50 values are displayed in bar graph and tabular format. 
 
Due to the lack of definitive thresholds for positive or negative results in the pMN assay, it is 
difficult to determine the level of cross-reactivity between subtypes, and especially whether 
these cross-reactive responses would result in immunity or reduced morbidity in case of 
challenge. These problems can only be addressed by challenge experiments, in a suitable 
model, which will be required for the further development of this assay and its more 
widespread use. The resources, expertise and ethical requirements for such an experiment 
were not available during the length of this studentship and therefore objectives were 
focused on the interpretation of data obtained and comparisons between these generated 
datasets. Within the data summarized in Table 3.4, 10 patients with high neutralising 
antibody titres against H1 showed correspondingly high IC50 values against H5. 8 patients 
with high IC50 against H3 showed high IC50 against H7 (Table 4). Within this subset, a further 
two patients (serum ID: 9 and 41) neutralised H1, H5, H3 and H7 PV. 
  




Table 3.4. Sera that strongly neutralised group 1 (H1, H5) or group 2 (H3, H7) influenza PV tested. 
Sera 9 and 41 (bold) showed high neutralising antibody titres against all PV tested 
 
Group: Serum ID 
1 5 7 8 9 15 23 35 41 45 49 
2 3  -  - 9 12 26 28 41 57 58 
 
This method for the detection of heterosubtypic immunity is laborious and costly in terms of 
reagents and materials. Due to the nature of serum and its (lack of) availability, this method 
is perhaps not suitable for analysis of vaccine immunogenicity in terms of broadly 
neutralising antibodies. This is especially true when mouse models are used, as these 
unfortunately do not yield high volumes of serum. Furthermore, due to the fact that each 
PV used will represent just one strain and one subtype of influenza virus, vast amounts of 
serum will be required to use a system such as this and obtain comprehensive results taking 
into account drift between currently circulating strains of the same subtype. 
3.3.8 ELLA data 
Six serum samples were selected from the Jenner Sera which displayed a range of 
neutralising antibody titres against H1 CA/09 in order to test these samples against the 
matched strain NA using ELLA. These were tested using various parameters investigated 
further in chapter 5. H11N1 and N1 bearing PVs were tested using serum samples 20, 31 
and 23 which were all low positives against H1 (CA/09) HA PV via pMN, having average 
neutralising antibody titres of 1115, 1492 and 2033 respectively. High positives, determined 
in the same fashion, were samples 34, 91 and 59. These displayed neutralising antibody 
titres against CA/09 HA in pMN of 3868, 3769 and 6219 respectively. Negative controls 
included influenza anti-A/California/7/2009 and anti-B/Brisbane/60/2008 HA serum (NIBSC). 
exNA from Clostridium perfringens was used as a digestion control to determine the 
maximum digestion possible per well (data not shown). Results correlated strongly with IC50 
values generated against H1 (CA/09) PV, with HP and LP samples acting as low and high 
positives against N1 as well as the original H1. LP samples 20, 31 and 23 gave IC50 values of 
0, 30 and 14 with a  OD90% input, with the OD2.0 input, IC50 values were 0, 341 and 150. 
For HP samples, 34, 91 and 59 IC50 values were 91, 153 and 209 respectively at OD90%, and 
629, 1288 and 1613 for OD2.0. Negative controls all gave values of zero except B/Brisbane 
antiserum which had an IC50 of 4 at OD2.0. Despite this, negative samples are clearly 




grouped at the negative end of the spectrum of results. However, the curves generated are 
slightly elevated when using an input of OD2.0, inhibition starting between 20-40% at 
starting dilution compared to below 5% with an OD90% input. See Figure 3.24 for inhibition 
curves generated by ELLA using these Jenner Sera samples. Correlation between neutralising 
antibody titres against the CA/09 HA (pMN) and the CA/09 NA (ELLA) was very strong, pMN 
and ELLA (OD90%) correlated with a Pearsons r of 0.95 (P=0.0031) and with ELLA (OD2.0) 
with a Pearsons r of 0.92 (P=0.0089). Both ELLA parameters tested using the same sera also 










Figure 3.24. ELLA inhibition curves generated using Jenner Institute sera against H11N1 bearing PV (N1 A/California/7/2009). High positive (34, 91 and 59) 
and low positive (20, 31 and 23) sera based upon pMN IC50 values against A/California/7/2009 HA PV were tested against the matched N1. Serum sample 59 
showed the strongest inhibition of N1, followed by 91 and 34, all three high positives. The low positive sera neutralised the least, with 31 and 23 
neutralising weakly and serum 20 not at all. Negative controls include anti-A/California/7/2009 and anti-B/Brisbane/60/2008 HA serum (NIBSC). This 
experiment was carried out in duplicate with an input virus of OD492 90% or 2.0.  






Figure 3.25. Correlation of neutralising antibody titres against the HA and NA of A/California/7/2009. pMN IC50 values generated against the HA of CA/09 
are compared with ELLA IC50 values against the NA of CA/09. ELLA (OD90%) neutralising antibody titres and pMN neutralising antibody titres correlate 
strongly (Pearsons r= 0.95). ELLA (OD2.0) neutralising antibody titres and pMN neutralising antibody titres also correlate strongly (Pearsons r=0.92). ELLA 
neutralising antibody titres for OD90% and OD2.0 inputs show an almost perfect correlation, Pearsons r=0.99). 
 




3.4 Discussion and conclusions 
This project has been successful in that novel cHAs have been produced, optimised and 
tested against a large serum panel. While PV luciferase titres are not optimal for the CS 
CHM, they are still useable, further efforts can be made to improve titres using new 
transfection reagents as they become available. While the Gibson/In-Fusion assembly 
methods are laborious, they are excellent tools for the creation of cHA expression plasmids 
at relatively low cost (Gibson et al. 2009; B. Zhu et al. 2007). Unexpectedly high neutralising 
antibody titres were recorded against the CA/09 PV in the year prior to its existence, despite 
the exotic swine nature of this HA (Figure 3.21). While this is partly explained due to shared 
epitopes as mentioned previously (Xu et al. 2010), it renders efforts to interpret the cHA 
data more difficult. Interpretation of the cHA pMN system works by comparison of the CS 
CHM with each parental PV, H11 and CA/09. The premise is that H11 responses should only 
be present in the form of anti-stalk antibodies due to conserved epitopes within the group 1 
influenza stalk  W and not the exotic H11 head which is dissimilar to that of CA/09. Alongside 
this, the CA/09 chimera gives us an overall idea of the potency of antibodies in the serum at 
neutralising CA/09 at the globular head and stalk regions. As for the CS CHM, which is 
composed of the H11 head and CA/09 stalk, this PV should only be neutralised by stalk 
directed antibodies which have neutralised CA/09 or H11, but should be unaffected by 
antibodies targeting the HA head of CA/09, thus allowing dissection of the head response 
and focus on those stalk-reactive antibodies that are relevant to universal vaccine design. 
This has been achieved as the sera has less of an effect on the CS CHM than the parental 
CA/09 PV, but correlation is still observed in that high responders against CS CHM are likely 
to have high neutralising antibody titres against CA/09 and the H11 parental strain, both 
having a conserved group 1 stalk (Figure 3.19). 
In regards to the Sports Science sera, a larger quantity of reagents was required to perform 
the assays against multiple different subtypes. However, the data generated did give an 
excellent overview on the immune repertoire of each patient at the point in time that the 
serum was collected. It was possible to determine some cross-reactive responses in patients 
when assaying the same sera against different subtypes within the same group of influenza 
A (Table 3.4), however, great care must be taken in the choice of strains used as this method 
remains intensive in the quantity of serum used.  




Unfortunately it was not possible to troubleshoot the lack of success in the production of 
group 2 or influenza B PV. The problems are most likely due to incompatibility issues 
between the H10 (group 2) head and H3 (group2) or influenza B stalks used. Sanger 
sequencing showed that each gene was as designed and theoretically should have formed a 
polyprotein with distinct head and stalk regions post cleavage. However, for reasons which 
were not further investigated in this project, these two cHA expression plasmids did not give 
rise to working PV. This could be due to the stability of the protein, expression of the gene, 
toxicity issues with the cells and the pI.18-HA or phCMV-HA constructs, or lack of 
compatibility with the three proteases tested as well as those presently expressed in 
HEK293T/17 cells. While attempts to produce these cHAs failed, other research groups have 
successfully produced and tested similar systems (Ermler et al. 2017). Further time and 
investment is required to assess and overcome the problems which lead to these negative 
results, for the sake of this project it was decided that the CS CHM and its matched CA/09 
parental strain would be the most suitable for pMN testing of the Jenner Sera, and to thus 
proceed with it. 
The use of ELLA in conjunction with pMN using the chimera system gave rise to a further 
subset of data (Figure 3.24), possibly proving that certain patients had or had not been 
infected with the pH1N1 strain. By testing high positive and low positive samples 
(determined by pMN) using ELLA, we were able to show that the same strength of antibody 
response was present against the matched NA of this virus. This is very useful as there are 
currently no thresholds in pMN for positive or negative samples, especially as the sensitivity 
of pMN can often lead to strong neutralisation from human sera when regarding H1 PV, as 
seen with CA/09 neutralising antibody titres in sera collected prior to 2009 (Figure 3.19). In 
the ELLA results, low positive samples with HA neutralising antibody titres at or below 2000 
tested low or negative in ELLA, whereas the high positives with titres above 3000 all tested 
positive (Figure 3.24). This was even more apparent when using a viral input of 2.0 OD, with 
increased values for high positive samples. Furthermore, correlation between pMN 
neutralising antibody titres and ELLA antibody tires was excellent (Figure 3.25), further proof 
that this relationship between NA and HA antibody titres is present as would be expected 
after infection with pH1N1. 
  




3.5 Further work 
Within the specific aims of this project, ideally the CS CHM system should be tested on a 
further set of sera, ideally from a larger group of patients pre and post the 2009 pandemic 
with accompanied metadata detailing infection status in regards to the 2009 strain. One of 
the major limitations of this project was the availability of sera pre 2009 as well as the 
majority of sera sourced in the 2012-2016 period. Further work should also focus on solving 
the issues surrounding the group 2 and Flu B chimeras, and after efforts have been made to 
produce working PV, more recent strains of H3 as well as Victoria and Yamagata influenza B 
stalks should be incorporated into this system.  
  




Chapter 4 : Correlating SRH, HI and pMN using influenza B HA 
bearing PV 
 
4.1  Introduction 
4.1.1 Influenza B Virus classification and disease 
Influenza B viruses comprise two co-circulating, antigenically distinct lineages that diverged 
ĨƌŽŵ ƚŚĞŝƌ ƉƌŽŐĞŶŝƚŽƌ ? ƐƚƌĂŝŶ  ?,ŽŶŐ <ŽŶŐ ? ? ? ? ? ? ? ? ŝŶƚŽ ƚŚĞ  ‘zĂŵĂŐĂƚĂ ůŝŬĞ ?
 ? ?zĂŵĂŐĂƚĂ ? ? ? ? ? ? ? ?ƚǇƉĞ ?ĂŶĚ ‘sŝĐƚŽƌŝĂůŝŬĞ ? ? ?sŝĐƚŽƌŝĂ  ? ? ? ? ? ?ƚǇƉĞ ?ůŝŶĞĂŐĞƐ(Rota et al. 
1990). This human virus causes a significant proportion (20-30%) of global morbidity 
associated with influenza virus disease, due to its global distribution and unpredictable 
switches in the predominating lineage circulating (Ambrose and Levin 2012; Glezen et al. 
2013; Mccullers et al. 2004). The WHO vaccine recommendations include an up to date 
strain from both lineages for quadrivalent vaccines but only one for trivalent ones. Should 
the circulating lineage not match the predicted lineage there is an inevitable drop in 
coverage against influenza B linked disease (Ambrose and Levin 2012; Belshe 2010; 
Heikkinen et al. 2014; WHO 2016). In the United States, multiple quadrivalent vaccines have 
been approved and are in use (Weir and Gruber 2016). 
4.1.2 Assays for influenza and the B type 
Single radial immuno-diffusion (SRID) has been one of the mainstays for the identification 
and characterisation of inactivated influenza vaccines, correlating with immunogenicity and 
clinical benefit/protection (Cate et al. 1983; Hobson et al. 1972; La Montagne et al. 1983; M. 
S. Williams 1993; M. S. Williams et al. 1980; T. G. Wise et al. 1977; Wood et al. 1977; P. F. 
Wright et al. 1983). HI has been used for many decades as the tool used for detection of 
influenza antibodies (section 1.19) (Hirst 1941). These assays, in combination with ELISA 
(Lambré and Kasturi 1979) and single radial haemolysis (Schild et al. 1975) form the gold 
standard assays for detection of influenza virus antibodies, and are generally applicable to 
the B type. However, more recent work has highlighted the shortcomings of the traditional 
assays, focusing on the development of novel assays utilising various different technologies 




(Bodle et al. 2013; Estmer Nilsson et al. 2010; Hashem et al. 2013; Khurana et al. 2014; Kuck 
et al. 2014; Pierce et al. 2011; Schmeisser et al. 2014; Temperton et al. 2007; Trombetta et 
al. 2014; Wen et al. 2015). 
In this chapter, determining the correlation of the gold standard assays of HI and SRH with 
the recently Flu-B adapted pMN assay is the goal, as HI detects primarily RBS proximal 
antibodies while SRH detects IgG1, IgG3 and IgM class antibodies which are compatible with 
the complement cascade. pMN detects HA neutralising antibodies. As with SRH, HI has been 
correlated with protection against influenza, with titres at or above 40 linked to 50% or 
greater protection from infection in adults (Al-Khayatt et al. 1984; Cox 2013; Hobson et al. 
1972; Potter and Oxford 1979). Linking either of these assays with pMN, despite the 
detection of different types of antibody, would allow more confidence to be attributed to 
the results generated using this assay, despite it actually detecting neutralisation of the 
function of the influenza HA glycoprotein. 
Ether treatment has been employed for influenza B viruses, prior to HI experiments, raising 
the efficacy of the HI test to that of the complement fixation (CF) test (Kendal and Cate 
1983; Monto and Maassab 1981; Pyhälä et al. 1985). This technique was developed due to 
the lack of reactivity of certain strains of influenza with RBCs, as well as the B type. 
Alongside the adaptation of SRID to influenza B resulting in SRH, ether treatment was found 
to increase sensitivity but reduces specificity of HI during assay of serum samples against 
influenza B (Chakraverty 1980; Julkunen et al. 1985; Kendal and Cate 1983; Monto and 
Maassab 1981; Oxford et al. 1982; Schild et al. 1975; Turner et al. 1982). 
4.1.3 mAbs and camelid derived antibodies 
mAbs are increasingly being used in influenza research, whether for development of 
standards to complement or validate assays or more directly to evaluate HA epitopes 
targeted through vaccination or as a therapy, as seen in the semi-recent Ebola outbreak 
(Davey et al. 2016; X. Qiu et al. 2014). The mAbs employed in this chapter were developed 
as an antibody-based alternative for influenza B identity (Yamagata or Victoria lineages) and 
potency assays (Verma et al. 2017). 
Nanobodies are single domain antibodies derived from camelids which lack light chains and 
are able to bind to one single epitope. These have been developed and used in a wide range 




of experiments ranging from use as crystallography chaperones, diagnostic tools and 
therapeutics (Muyldermans 2013).  
4.1.4 Project aims 
Correlation data between assays is important for in depth interpretation of immunogenicity 
data, especially when correlation is determined with an assay that has been used for in vivo 
or challenge studies, establishing a correlate of protection. By inter-comparison of assays 
utilising different approaches, the scientific community can make more informed decisions 
on the future direction of vaccine design and testing. To date, no experiment of this sort has 
been performed using influenza B, with efforts focusing more on the predominant A type. 
As a major contributor to morbidity and mortality, it is essential to interrogate the 
correlations and relationships between data produced for influenza B. This is especially 
important as this type is lacking a definitive reservoir and circulates yearly as part of two 
lineages. In this project, influenza B PVs will be interrogated using a defined set of mAbs and 
a panel of sera, to put this resource to use in the correlation of pMN, SRH and HI. 
4.2 Methods 
4.2.1 Plasmids 
Expression plasmid phCMV1 bearing the HA gene for B/Hong Kong/8/1973, B/Yamagata/16/1988 
and B/Florida/4/2006 were obtained from Dr Davide Corti, Institute for Research in Biomedicine, 
Bellinzona, Switzerland. B/Victoria/60/2008, B/Brisbane/60/2008 and B/Bangladesh/3333/2007 
HA genes were sub cloned into plasmid pI.18 at the Viral Pseudotype Unit, University of Kent by 
Dr Francesca Ferrara.  
Plasmids p8.91 and pCSFLW are described in section 2.1.2 and 2.1.3 respectively. Protease 
encoding plasmids used are detailed below in Table 1, alongside other information regarding the 
strains of influenza B used in this project (Accession #, Lineage, optimal protease for production). 
These optimal values for co-transfection of proteases were derived from previous work, and 
scaled down (50%) to 6-well format from 10cm2 dish format (Ferrara 2015). 
  




Table 4.1. Influenza B strains, accession numbers, lineage, protease type and quantity required for 
production in 6-well format are displayed. 
Strain Accession # Lineage Protease ng per 6-well 
B/Hong Kong/8/1973 K00425 Pre-split HAT 125 
B/Victoria/2/1987 FJ766840 Victoria HAT 125 
B/Brisbane/60/2008 KX058884 Victoria TMPRSS4 125 
B/Yamagata/16/1988 CY018765 Yamagata HAT 125 
B/Florida/4/2006 EU515992 Yamagata HAT 125 
B/Bangladesh/3333/2007 CY115255 Yamagata HAT 250 
4.2.2 Serum samples 
One serum set was used per lineage of influenza B, consisting of samples taken pre and post 
seasonal vaccination. Paired low and high responders (according to HI results) were chosen 
by Dr Claudia Trombetta, University of Siena, Italy. In total, 41 pairs of sera were assayed 
against B/Brisbane/60/2009 and 43 pairs against B/Florida/04/2006. Due to anonymity laws 
in Italy regarding the collection and use of human sera, no further data is available regarding 
these samples. 
4.2.3 HI assay 
This experiment was carried out by Dr Claudia Trombetta, University of Siena, Italy. The 
influenza viruses used in the HI were B/Brisbane/06/2008 (15/146) and B/Florida/04/2006 
(08/138) obtained from the NIBSC, United Kingdom. Serum samples were pre-treated with 
receptor destroying enzyme (RDE) from Vibrio cholerae (Sigma Aldrich) at 1:6 ratio for 18 h 
at 37°C in a water bath and then heat-inactivated for 1 hour at 56°C in a water bath with 8% 
sodium citrate at a 1:5 ratio. Turkey erythrocytes (Emozoo S.N.C, Invorio, Italy) were 
centrifuged twice, washed with a saline solution (0.9%) and adjusted to a final dilution of 
0.35%. RDE-treated serum samples were diluted two fold with saline solution (0.9%) in a 96-
well plate, starting from an initial dilution of 1:10. 25 µl of influenza virus was added to each 
well and the mixture was incubated at room temperature for 1 h. At the end of the 
incubation, erythrocytes were added and the plates were evaluated for the inhibition of 
agglutination after 1 h at R.T. 




The neutralising antibody titre was expressed as the reciprocal of the highest serum dilution 
showing complete inhibition of agglutination. Since the starting dilution was 1:10, the lower 
limit of detectable neutralising antibody titre was 10. When the titre was below the 
detectable threshold, the results were conventionally expressed as 5 for calculation 
purposes, half the lowest detection threshold. Geometric mean titers were calculated from 
experimental repeats. 
4.2.4 SRH assay 
This experiment was carried out by Dr Claudia Trombetta, University of Siena, Italy. The 
influenza viruses B/Brisbane/06/2008 (15/146) and B/Florida/04/2006 (08/138) were 
obtained from the NIBSC. Serum samples were heat-inactivated at 56°C for 30 min in a 
water bath. Turkey erythrocytes (Emozoo S.N.C.) were centrifuged twice and washed with 
phosphate buffered saline (PBS). Diluted virus was added to the erythrocyte suspension at a 
concentration of 2000 haemagglutination units (HAU) per ml. The erythrocyte - virus 
suspension was incubated at 4°C for 20 minutes and subsequently, a solution of 2,5 mM 
Chromium Chloride (CrCl3) was added to the suspension and it was incubated at R.T for 10 
minutes. The suspension was then carefully mixed once and then centrifuged. A stock 
solution, consisting of 1.5% agarose in PBS containing 0.1% sodium azide and 0.5% low 
gelling agarose was prepared. This agarose stock solution was maintained at 45°C in a water 
bath. The final suspension of erythrocytes, virus and guinea pig complement was vigorously 
shaken and evenly spread onto each plate. Plates were incubated at room temperature for 
30 minutes and then stored at 4°C for 30 - 90 minutes. Holes were introduced into each 
plate with a calibrated punch and 6 µl of each serum sample was dispensed into each hole. 
The plates were stored in a humid box and incubated at 4°C for 16  W 18 hours in the dark. 
Subsequently, plates were incubated in a water bath at 37°C for 90 minutes; diameters of 
the areas of haemolysis were then read in mm with a calibrating viewer (Schild et al. 1975). 
4.2.5 mAbs, nanobodies and controls 
mAbs were obtained from Dr Jerry Weir, Food and Drug Administration (FDA), U.S.A. These 
were produced by immunization of BALB/c mice with mammalian-derived VLP containing 
the HA glycoprotein of a relevant influenza B strain. When antibody titres for HA VLP ELISA 
were above 1:50,000, respective spleen cells were fused with a myeloma cell line. 




Hybridomas were then titrated, selected and expanded for further testing, whereupon the 
clones in the following table were derived (Table 4.2). mAb specificity was determined by 
ELISA (Verma et al. 2017). A panel of nanobodies was obtained from the NIBSC as part of a 
joint project to determine their ability to neutralise PV bearing HAs from various influenza 
strains, including influenza B PV. These were produced in-house by the NIBSC team led by Dr 
Simon Hufton, Dr Walter Ramage and Dr Tiziano Gaiotto. Specificity of nanobodies was 
determined by yeast display and binding, these specificities are listed in Table 4.3. 
Anti-B/Brisbane/60/2008 HA serum (11/136) was obtained from the NIBSC and employed 
against all strains of influenza B as a serum positive control. This antiserum had previously 
been tested in our laboratory by Dr Francesca Ferrara, showing that it was capable of 
neutralising all available strains of influenza B (table 4.1) to varying degrees, with the 
highest potency against the matched B/Brisbane/60/2008 strain.  
Table 4.2. mAbs obtained from Dr Jerry Weir, FDA, U.S.A. Five total mAbs, two specific for each 
lineage of influenza B and one binding to an epitope conserved between both lineages (cross). 
 
mAb 2F11 3E8 1H4 8E12 5A1 
Target lineage Cross Yamagata Yamagata Victoria Victoria 
 
Table 4.3. Panel of llama derived nanobodies obtained from the NIBSC. 14 different nanobodies with 
specificity to epitopes which are shared between influenza B lineages (Cross) or confined to one 








4.2.6 Statistical analysis 
The final neutralising antibody titres for each serum sample were averaged between replicates 
and these averages were compared between assays. This resulted in a table of results which 
could be compared. This comparison was carried out in Prism Graph pad where a two tailed 
Pearson ?s correlation was performed on pairs of data sets which were plotted against each 
other. A line of best fit was used in order to show the general trend of correlation between data 
sets. Analysis was performed between pre vaccination (V1), post vaccination (V2) and V1 to V2 
fold change data sets. pMN data consisted of both IC50 and IC90 values, and further analysis was 
carried out on transformed (log10) V2 data.  
4.3 Results 
4.3.1 Production of influenza B PV 
Prior to starting this project, large stocks of influenza B PV were produced in order to reduce 
batch to batch variation between repeated experiments. Titres were more variable for 
strains in the Victoria lineage; many attempts were made to produce high titre preparations 
which could span the length of each project. Later attempts succeeded in producing high 
titre B/Brisbane/60/2008 with titres exceeding 1x109 RLU/ml, thus sufficient for the length 
of the project. Yamagata lineage preparations were less variable, and all production 
attempts yielded virus with titres exceeding 1x108 RLU/ml. Viral titres for influenza B PV 
produced during the duration of this project are shown in Figure 4.1, with VSV-G positive 
transduction control as an example of maximum titres achievable. 
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Figure 4.1. Titres (in RLU/ml) for all influenza B HA bearing PV produced prior to the start of this 
project. VSV-G titres titrated alongside influenza B PV displayed as a maximal transduction/luciferase 
production signal for comparison. 
4.3.2 Lineage specific and cross-reacting mAbs neutralise influenza B PV 
Lineage specific mAbs functioned as expected against all PV except B/Brisbane/60/2008 
which was not susceptible (Figure 4.3). This PV was unaffected by either the Victoria specific 
mAbs, or the 2F11 cross-lineage mAb. This is also despite the anti-B/Brisbane/60/2008 HA 
serum (NIBSC) having the greatest effect on its matched PV strain (IC50 >256,000), Figure 
4.5. The 2F11 mAb neutralised Yamagata lineage strains the strongest (IC50: 2-4 ng/ml), 
followed by the pre lineage strain B/Hong Kong/8/1973 (IC50: 8 ng/ml) and finally the 
Victoria strain B/Victoria/2/1987 (IC50: 160). The Yamagata specific mAbs 3E8 and 1H4 only 
had an effect on Yamagata PVs, neutralising B/Bangladesh the strongest (IC50: 3 and 4 ng/ml 
respectively), followed by B/Florida (IC50: 21 and 3 ng/ml) and B/Yamagata (IC50: 34 and 6 
ng/ml). Victoria specific mAbs 8E12 and 5A1 neutralised B/Hong Kong the strongest (IC50: 2 
and 4 ng/ml respectively) followed by B/Victoria (IC50: 47 and 22). See Table 4.4 for list of 
IC50 values for each mAb. 





Table 4.4. IC50 values in ng/ml for the neutralisation of 6 strains of influenza B HA-PV by mAbs. 
Yamagata and Victoria lineages highlighted in pink and blue respectively. With the exception of 
B/Brisbane, the cross lineage mAb 2F11 acts as expected, neutralising all influenza B PV. Yamagata 
specific mAbs neutralise PV bearing HAs from Yamagata lineage strains while Victoria specific mAbs 
neutralise PV bearing HAs from Victoria lineage strains. The pre-lineage split strain B/Hong Kong is 




The data for the Victoria lineage viruses show reduced antibody potency, with IC50 values up 
to 20 times higher. Also, Victoria epitope targeting mAbs neutralise B/Victoria and the Hong 




Figure 4.2. pMN neutralisation curves for FDA mAbs 2F11, 3E8, 1H4, 8E12 and 5A1 against PV 
bearing the HA glycoprotein from the influenza B pre-lineage split strain, B/Hong Kong/8/1973. This 
PV is neutralised in a Victoria like manner, knocked down strongly by Victoria specific mAbs 5A1, 
8E12 and cross-lineage mAb 2F11 but not Yamagata specific mAbs 3E8 or 1H4. 
 





Figure 4.3. pMN neutralisation curves for FDA mAbs 2F11, 3E8, 1H4, 8E12 and 5A1 against PV 
bearing HA glycoproteins from Victoria lineage strains B/Victoria/2/1987 and B/Brisbane/60/2008. 
Victoria lineage PV are not neutralised by Yamagata specific mAbs 3E8 or 1H4. A/Victoria/2/1987 PV 
acts as expected, being neutralised by Victoria lineage specific mAbs 5A1, 8E12 and cross-lineage 
mAb 2F11. B/Brisbane/60/2008 PV are not neutralised by any of the mAbs tested, including Victoria 
lineage and cross-lineage mAbs. 
 
Anti B/Brisbane/60/2008 polyclonal sheep serum was used as an anti-influenza B control in 
all of these experiments and for all strains of influenza B PV due to its polyclonal nature and 
therefore ability to cross-react. This antiserum neutralises the matched strain 
B/Brisbane/60/2008 and the other Victoria lineage strain B/Victoria/2/1987 the highest 
(Figure 4.5), 100% neutralisation is seen from the starting dilution point of 1:200 up to the 
penultimate point 1:128,000. 
4.3.3 Llama derived antibody neutralisation of Victoria and Yamagata 
lineages. 
Varying results were seen when the NIBSC panel of llama derived antibodies (subsequently 
referred to as nanobodies) was tested on the type strains of the Victoria and Yamagata 
lineages. Nanobodies targeting the conserved epitopes shared between both lineages did 
neutralise them (samples 60, 63, 66, 67, 71, 72, and 74). However, B/Victoria specific 
nanobody 61 neutralised both lineage strains whereas Yamagata specific nanobodies were 
unable to neutralise either PV. Figure 4.6 shows the IC50 values for nanobodies assayed 
against B/Victoria and B/Yamagata PV, as well as specificity determined by yeast epitope 
display at the NIBSC. 





Figure 4.4. pMN neutralisation curves for FDA mAbs 2F11, 3E8, 1H4, 8E12 and 5A1 against PV bearing HA glycoproteins from Yamagata lineage strains 
B/Yamagata/16/1988, B/Florida/4/2006 and B/Bangladesh/3333/2007. Strong neutralisation is observed by Yamagata specific mAbs 3E8 and 1H4, and by 
cross-lineage 2F11. No neutralisation is observed for Victoria specific mAbs 8E12 and 5A1.
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Figure 4.5. Anti-B/Brisbane/60/2008 HA serum (11/136) neutralises matched and related strains 
B/Brisbane/60/2008 and B/Victoria/2/1987 the strongest, but also neutralises Yamagata lineage 
strains and the B/Hong Kong/7/1973 precursor to a lesser extent. 
4.3.4 Correlation of SRH, HI, pMN 
Completion of pMN, SRH and HI on B/Florida/04/2006 and B/Brisbane/60/2008 
experiments yielded neutralising antibody titres for all three assays which could then be 
compared and contrasted. Endpoint titres for high responders (V2) are displayed in Figure 
4.7. The titre profiles of each serum set are very similar between the two viruses, when 
considering each virus has its own unique set of sera. HI values range from 5 to 1280 for 
both B/Brisbane/60/2008 and B/Florida/04/2006, with arithmetic means at 156 and 270 
respectively. SRH values range from 37 to 106 and 38 to 99 mm2 for B/Brisbane/60/2008 
and B/Florida/04/2006 respectively. Arithmetic means were 58 and 57 mm2. pMN (IC50) 
values ranged from 4594 to 209,395 for B/Brisbane/60/2008 and 3349 to 31,954 for 
B/Florida/04/2006. Arithmetic mean pMN titre means were 41,613 and 11,740 respectively. 
 





Figure 4.6. pMN assay carried out using a panel of llama derived nanobodies on original lineage 
specific influenza B strain PV, B/Victoria/2/1987 and B/Yamagata/16/1988. Neutralisation curves for 
a subset of samples, and IC50 values in ng/ml for all nanobodies tested. Nanobody information is 
shown in table 4.3.  
  






Figure 4.7. HI, SRH and pMN endpoint titres (IC50) for high responders (V2, based on previous HI 
assay) against B/Brisbane/60/2008 and B/Florida/04/2006. Titres displayed show similar profiles for 
each strain tested, with a broader range of pMN IC50 values for B/Brisbane/60/2008. 
 
4.3.5 Correlation of data: B/Brisbane/60/2008 IC50 
Correlation was evaluated between all three assays: pMN, SRH and HI. Three different sets 
of values for each assay were correlated, V1 data (pre-vaccination low responders), V2 data 
(post-vaccination high responders) and fold change between V1 and V2. For 
B/Brisbane/60/2008, no correlation was observed between pMN and the other assays, with 
WĞĂƌƐŽŶ ?ƐƌǀĂůƵĞƐranging from -0.07 to -0.08 (P = 0.13 to 0.9). SRH and HI correlated when 
fold changes were compared (r= 0.224, P=0.1539), and much more so after the removal of 
two outliers (r= 0.60, P= >0.0001). V1 results weakly correlated (r=0.32, P=0.0375) for SRH 
and HI, and more so for V2 results (r=0.39, P=0.0123). See Figures 4.8, 4.9 and 4.10 for 
correlation graphs and data.  
4.3.6 Correlation of data: B/Brisbane IC90 and transformed data 
Upon transformation of the V2 data to a logarithmic (log10) scale, correlation is still not 
seen between pMN and SRH or HI, with weak correlation between the latter two (r=0.35, 
P=0.0189). pMN IC90 data correlated weakly with HI and SRH (r= 0.37 and 0.45, P= 0.00188 
and 0.0026 respectively). The correlation seen was reduced by transformation of IC90 data 
and comparison on a log scale (r= 0.23 and 0.32, P= 0.132 and 0.0372 respectively). See 
Figures 4.11, 4.12 and 4.13. 




4.3.7 Correlation of data: B/Florida IC50 
In the same fashion as the B/Brisbane results, V1, V2 and fold change (V1  WV2) data sets 
were correlated between pMN, SRH and HI. In contrast to the results for B/Brisbane, pMN 
data correlated well with SRH and HI. For the fold change data, pMN correlated with HI and 
SRH (r= 0.66 and 0.56, P= <0.0001). SRH and HI correlated strongly (r= 072, P= <0.0001), see 
Figure 4.16. V1 data predictably showed very little, if any, correlation, with r values from -
0.07 to 0.33 across the three assays, see Figure 4.14. For V2 data, pMN correlated well with 
SRH (r=0.46, P=0.0023), HI (r=0.61, P= >0.0001). V2 SRH and HI correlated strongly (r=0.79, 
P=<0.0001), see Figures 4.15 and 4.16. 
4.3.8 Correlation of data: B/Florida IC90 and transformed data 
Transformation to a log10 scale caused a slight reduction in the significance attributed to 
the correlation between pMN and SRH or HI (r= 0.57 or 0.30, P= 0.0002 or 0.0555), but 
correlation remained strong between all three assays. IC90 data correlated very well 
between pMN and SRH or HI (r= 0.85 and 0.65, P= <0.0001) and this was maintained when 
data was transformed to the log10 scale (r= 0.78 and 0.62, P= <0.0001). See Figures 4.17, 
4.18 and 4.19. 
  





Figure 4.8. Correlation of SRH, HI and pMN (IC50 ?ŵĞĂŶs ?ǀĂůƵĞƐĂƐƐĂǇĞĚĂŐĂŝŶƐƚ ?ƌŝƐďĂŶĞ ? ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐƉĞƌĨŽƌŵĞĚƵƐŝŶŐ
prism Graph Pad. No correlation was observed between IC50 neutralising antibody titres and SRH or HI (Pearsons r = -0.23 and -0.19 respectively). Weak 
correlation was observed between SRH and HI for these V1 sera (Pearsons r = 0.32).





Figure 4.9. Correlation of SRH, HI and pMN (IC50 ?ŵĞĂŶs ?ǀĂůƵĞƐĂƐƐĂǇĞĚĂŐĂŝŶƐƚ ?ƌŝƐďĂŶĞ ? ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐƉerformed using 
prism Graph Pad. No correlation was observed between IC50 neutralising antibody titres and SRH or HI (Pearsons r = 0.009 and -0.152 respectively). SRH and 
HI values correlated (Pearsons r = 0.38).





Figure 4.10. Correlation of SRH, HI and pMN (IC50 ?s ?ƚŽs ?ĨŽůĚĐŚĂŶŐĞǀĂůƵĞƐĂƐƐĂǇĞĚĂŐĂŝŶƐƚ ?ƌŝƐďĂŶĞ ? ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐ
performed using prism Graph Pad. No correlation was observed between IC50 neutralising antibody titres and HI or SRH (Pearsons r = -0.07 and -0.08 
respectively). Weak correlation was observed between SRH and HI (Pearsons r = 0.22), which was improved after removal of outlying HI value (Pearsons r = 
0.60).





Figure 4.11. Correlation of transformed (log10) SRH, HI and pMN (IC50 ?ŵĞĂŶs ?ǀĂůƵĞƐĂƐƐĂǇĞĚĂŐĂŝŶƐƚ ?ƌŝƐďĂŶĞ ? ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚ
analysis performed using prism Graph Pad. Weak correlation is observed between log SRH and HI values (Pearsons r =0.36). No correlation is observed 
between log IC50 neutralising antibody titres and log HI or SRH values (Pearsons r = -0.196 and 0.007 respectively)





Figure 4.12. Correlation of transformed (log10) data for pMN (IC90) with HI and SRH using mean 
V2 values for sera assayed against B/Brisbane/60/2008 PV. Pearson ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐ
performed using prism Graph Pad. Weak correlation is observed between log IC90 neutralising 
antibody titres and log HI or SRH values (Pearsons r = 0.23 and 0.32 respectively). 
 
 
Figure 4.13. Correlation of pMN (IC90) with HI and SRH using mean V2 values for sera assayed 
ĂŐĂŝŶƐƚ ?ƌŝƐďĂŶĞ ? ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐ ƉĞƌĨŽƌŵĞĚƵƐŝŶŐƉƌŝƐŵ'ƌĂƉŚ Pad. 
Weak correlation is observed between IC90 neutralising antibody titres and HI (Pearsons r = 
0.36). IC90 values correlate well with SRH values (Pearsons r =0.45). 





Figure 4.14. Correlation of SRH, HI and pMN (IC50 ?ŵĞĂŶs ?ǀĂůƵĞƐĂƐƐĂǇĞĚĂŐĂŝŶƐƚ ?&ůŽƌŝĚĂ ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐƉĞƌĨŽƌŵĞĚƵƐŝŶŐ
prism Graph Pad. No correlation is seen between IC50 neutralising antibody titres and SRH (Pearsons r=0.06), or between SRH and HI (Pearsons r= -0.06). 
Weak correlation is observed between IC50 values and HI (Pearsons r = 0.33) 
  





Figure 4.15. Correlation of SRH, HI and pMN (IC50) ŵĞĂŶs ?ǀĂůƵĞƐĂƐƐĂǇĞĚĂŐĂŝŶƐƚ ?&ůŽƌŝĚĂ ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐƉĞƌĨŽƌŵĞĚƵƐŝŶŐ
prism Graph Pad. Weak correlation is observed between IC50 neutralising antibody titres and SRH (Pearsons r= 0.46). Strong correlation is observed 
between IC50 antibody titres and HI (Pearsons r=0.61), as well as between SRH and HI (Pearsons r =0.79) for the V2 data tested. 
  





Figure 4.16. Correlation of SRH, HI and pMN (IC50) V1 to V2 fold change values assayed against B/Florida/4/2006 PV. WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐ
performed using prism Graph Pad. Strong correlation is seen between fold change in pMN and HI values between V1 and V2 neutralising antibody titres 
(IC50), Pearsons r = 0.65. pMN and SRH V1/V2 fold changes correlate well, Pearsons r = 0.55, and strong correlation is observed for V1/V2 fold change for 
antibody titres of SRH and HI (Pearsons r= 0.72).





Figure 4.17. Correlation of transformed (log10) SRH, HI and pMN (IC50) mean V2 values assayed against B/FloƌŝĚĂ ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐ
performed using prism Graph Pad. Strong correlation is observed between log SRH and HI (Pearsons r = 0.62. log pMN and log HI correlate well (Pearsons r= 
0.56) and weak correlation is seen between log pMN and log SRH (Pearsons r= 0.30).





Figure 4.18. Correlation of transformed (log10) data for pMN (IC90) with SRH and HI mean V2 values, 
ĂƐƐĂǇĞĚĂŐĂŝŶƐƚ ?&ůŽƌŝĚĂ ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶ ůǇƐŝƐƉĞƌĨŽƌŵĞĚƵƐŝŶŐƉƌŝƐŵ'ƌĂƉŚ 
Pad. Strong correlation is observed between log IC90 neutralising antibody titres and log HI or SRH 
values, with Pearsons r values of 0.77 and 0.62 respectively. 
 
Figure 4.19. Correlation between pMN (IC90) with SRH and HI mean V2 values, assayed against 
B/FloƌŝĚĂ ? ? ? ? ? ? ?Ws ?WĞĂƌƐŽŶ ?ƐƚǁŽƚĂŝůĞĚĂŶĂůǇƐŝƐƉĞƌĨŽƌŵĞĚƵƐŝŶŐƉƌŝƐŵ'ƌĂƉŚ Pad. Strong 
correlation is observed between IC90 neutralising antibody titres and HI or SRH, with Pearsons r 
values of 0.85 and 0.64 respectively. 





Neutralisation of influenza B bearing PV with influenza B specific mAbs was consistent, with 
the exception of B/Brisbane/60/2008 results. Victoria lineage specific mAbs neutralised the 
type B/Victoria/2/1987 PV while Yamagata lineage specific mAbs neutralised Yamagata 
lineage strains (Figures 4.3 and 4.4). The cross-lineage specific mAb 2F11 neutralised both 
lineages as well as the pre-lineage split strain B/Hong Kong/8/1973. Similar results were 
obtained for the nanobodies tested on influenza B PV, with the majority of data matching 
specificities determined by yeast epitope display by project collaborators at the NIBSC 
(Figure 4.6). However, this project is still ongoing with further work required before 
conclusions can be drawn about their efficacy in comparison with the mAbs tested in this 
project. Discordant correlation was seen between Victoria and Yamagata lineages, with the 
former correlating well between pMN, SRH and HI and the latter only correlating between 
SRH and HI. 
4.4.1 Neutralisation by influenza B mAbs 
While the majority of influenza B mAbs generated by the FDA neutralised the expected 
strains in the pMN assay, neutralisation was not seen for B/Brisbane/60/2008 by Victoria 
specific mAbs, in contrast to data in the originally published article (Verma et al. 2017). 
One possible explanation for this is N-linked glycosylation masking epitopes on the HA 
surface. The presence or absence of a glycosylated residue would drastically alter results 
when neutralising with a mAb which targets one specific epitope. In this project, a WT 
B/Brisbane/60/2008 gene was used to produce PV for use in pMN, while B/Victoria/2/1987 
was human codon optimised. HI and SRH conducted by Dr Claudia Trombetta made use of 
inactivated antigen produced in bacteria whereas Verma and colleagues used a combination 
of ELISA using inactivated antigen and PV assays. For the latter assay, it is very likely that the 
B/Brisbane/60/2008 gene used was human codon optimised, as this research group 
employs this practice regularly (Personal communication with Dr. Jerry Weir, FDA). There is 
research to suggest differences in N-linked glycosylation between WT and human codon 
optimised genes in the HIV-1 glycoprotein gp120, with optimised sequences showing a 
reduction in glycosylation frequency (Ebrahimi and West 2014). Studies on egg-adaptation 
of influenza B viruses have characterised mutations within the 190 helix loop of the RBD 
which lead to significant change in antigenicity of the HA (Robertson et al. 1985; Shaw et al. 




2001), due to the loss of an N-linked glycosylation site (Saito et al. 2004). Despite the lack of 
neutralisation shown against B/Brisbane/60/2008 by the Victoria specific mAbs, polyclonal 
hyperimmune antisera produced against the same HA subtype was the most effective at 
neutralising ŝƚ ?&ŝŐƵƌĞ ? ? ? ? ?ƐƵŐŐĞƐƚŝŶŐƚŚĂƚƚŚĞ,ŝƚƐĞůĨŝƐĂŶƚŐĞŶŝĐĂůůǇ ‘ĐŽƌƌĞĐƚ ?ĂŶĚƚŚĂƚƚŚĞ
problem lies in the specific epitopes targeted by 8E12 and 5A1. These mAbs were reported 
to bind to the amino acid residues 241 and 203 respectively which are within or close to the 
190 helix which spans from residue 195 to 235 (Ni et al. 2013; Verma et al. 2017). 
The fact that mAbs specific for the Victoria lineage also neutralised the pre-lineage split 
strain (Figure 4.2) is not surprising, as fewer structural differences have been reported 
between these than between the pre lineage strain and the Yamagata lineage. The positions 
of escape mutations generated against the Victoria lineage specific mAbs 8E12 and 5A1 
presented in their characterisation were P241Q and K203R respectively (Verma et al. 2017). 
These are present within the 190 helix (RBD) of Victoria strains which is very similar in amino 
acid composition to the 190 helix of the pre lineage split strain B/Hong Kong/8/1973 (Ni et 
al. 2013).  
4.4.2 Correlation between SRH and HI 
Overall, SRH and HI correlated the strongest across both lineages, except for in V1 samples 
which were predictably very low due to the lower sensitivity of these assays (Figure 4.8 and 
4.14). As most of the V1 samples are negative in terms of HI and SRH data, they are 
clustered around the respective titres of 5 and 4 mm2, which lead to a lack of correlation 
when analysed. Fold change and V2 samples correlated for both Victoria and Yamagata 
lineages (Figures 4.8-4.13 and 4.15-4.19), indicating that increases in antibody are being 
detected in a similar fashion between these two assays. 
4.4.3 Correlation between pMN and SRH 
pMN correlated well with SRH for the Yamagata lineage strain B/Florida (Figure 4.15-4.19), 
correlation was observed for all analyses apart from V1 samples (Figure 4.14), which could 
be attributed to the same reasons for the lack of correlation in this set of samples between 
SRH and HI. As many of these samples would be classed as negative in SRH, the data is 
skewed towards the 4mm2 SRH data, while pMN is detecting a much larger breadth of 
responses from each so-called negative sample. This suggests that pMN would be a better 




assay for evaluation of low-response samples, as its sensitivity offers an advantage over 
SRH. For B/Brisbane however, the only correlation observed was between IC90 values 
(transformed and raw data). ĞƐƉŝƚĞƚŚŝƐ ?WĞĂƌƐŽŶ ?ƐƌǁĂƐƐƚŝůůďĞůŽǁ ? ? ?ŝŶĞĂĐŚĐĂƐĞ ? This is 
most likely due to the same problem as discussed in section 4.4.1 regarding the source of 
HA antigen used in each assay. 
4.4.4 Correlation between pMN and HI 
As with pMN and SRH, good correlation is seen for the Yamagata strain (Figures 4.15-4.19) 
but not the Victoria strain (Figures 4.8-4.12), once again, B/Brisbane/60/2008 is only poorly 
correlating when analysis is performed using IC90 values (Figure 4.13). B/Brisbane/60/2008 
IC50 neutralising antibody titres are not correlating with SRH or HI when using either fold 
change or V2 serum data, transformed or raw. 
4.5 Conclusions 
The results discussed in this section, while discordant in regards to B/Brisbane/60/2008 PV, 
still represent the first comprehensive study correlating HI, SRH and pMN assays on this less 
well studied influenza type. Future work should focus on the Victoria lineage serum samples 
which should either be assayed against a codon optimised B/Brisbane/60/2008 PV, or all 
experiments regarding this lineage should be performed on a different strain within the 
same lineage, in order to evaluate whether the problem lies in the B/Brisbane/60/2008 
protein itself or within the whole of the Victoria lineage. Ideally this project would be carried 
out on the lineage type strains B/Victoria/2/1987, B/Yamagata/16/1988 and the pre-lineage 
strain B/Hong Kong/8/1973. 
  




Chapter 5 : Development and use of ELLA for detection of 




ELLA is a safe and reproducible system for the detection of sialidase activity (or its 
inhibition) in a 96-well format (Couzens et al. 2014; Lambré et al. 1991; Westgeest et al. 
2015). This assay has taken over from the traditional thiobarbituric acid (TBA) assay 
(Sandbulte et al. 2009; Warren 1959), and is used regularly to detect NA activity or for 
follow-on experiments such as inhibition assays (Cate et al. 2010; Couzens et al. 2014).  
Using this assay, antiviral compounds in addition to antibodies (monoclonal, polyclonal or 
serum based) can be tested against different subtypes and strains of NA in the context of its 
intrinsic activity rather than simple binding as would be measured by ELISA. This allows 
investigators to evaluate any increases in NA inhibiting antibodies as a result of vaccination, 
whether these are protective and the extent to which the evolution of the protein escapes 
antibody based enzyme inhibition (Hassantoufighi et al. 2010; Kilbourne 1976). This assay 
employs the lectin from the species Arachis hypogaea (peanut), conjugated to horseradish 
peroxidase (PNA-HRPO). This lectin binds to galactose, which is exposed after sialidase 
activity on the carbohydrate fetuin. Fetuin is therefore used to coat 96-well plates in the 
ELLA assay, with PNA-HRPO used to quantify NA activity through detection of digested 
fetuin (Figure 5.1). 
 





Figure 5.1. A schematic for the enzyme-linked lectin assay (ELLA). PV samples are diluted 1:2 across a 
96-well clear plate (A), before being transferred to a maxisorp plate coated in fetuin (B). After 
incubation (C), PNA-HRPO is added and plates incubated, before OPD substrate is added and plates 
read at an optical density of 492nm (D). Typical results of an ELLA titration are shown in panel D.  
 
Alternative assays are available and utilised in other studies, such as MUNANA, named after 
the chemical substrate used:  ? ?-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (Potier 
et al. 1979), and a chemiluminescence assay, originally devised by (Buxton et al. 2000) and 
compared to MUNANA by (Wetherall et al. 2003). 
ELLA is being increasingly used and developed further towards the goal of validating it to 
measure antibody responses elicited by vaccination (Changsom et al. 2016; EMA 2010; Fritz 
et al. 2012; Sandbulte et al. 2016). There are however issues surrounding the instability of 
NA in commercial vaccines, with reported variances in NA activity post vaccine production 
(Kendal et al. 1980; Trombetta et al. 2014). Irrespective of these issues, the elicitation of NA 
antibodies through vaccination and the detection of such antibodies is of growing interest to 
the influenza community (Wohlbold and Krammer 2014). 
  




Further issues have been reported in the form of HA stalk-directed antibodies, which have 
been shown to interfere with the activity of NA in the ELLA assay for 2009pdm H1N1 
(Rajendran et al. 2017). Despite this interference, it seems that NA antibody responses 
match those against HA, with immunity against a primary infection being boosted through 
original antigenic sin after infection by subsequent strains (Rajendran et al. 2017). The data 
presented in this study showed that N1 titres tended to be low in the groups studied, in 
comparison to N2 or influenza B NA titres, which was postulated to be due to lower 
antigenicity of the N1. 
5.1.2 CONSISE study 
The CONSISE group, described in chapter 1, published a position piece aimed at 
standardisation of ELLA across different laboratories worldwide, by comparing data 
generated using the same reagents (Couzens et al. 2014; Eichelberger et al. 2016). N1 and 
N2 antigens were used to measure antibodies targeting these proteins from a panel of 12 
sera in three different assays and in 23 different laboratories worldwide. These serum 
samples (8 of the original 12) and their attributes are shown in Table 5.1. Each serum 
sample was tested against reassortant H6N1 and H6N2 influenza viruses (inactivated virus), 
providing neutralising antibody titres against each NA. These were compared between labs, 
showing differences in titres between labs remained below 4-fold (n=15/23 and 16/23 for 
H6N1 and H6N2 respectively). The study identified the crucial factors involved in ELLA such 
as background signal and viral input, of which it was decided to evaluate the latter with PVs 
as a source of NA instead of the traditional use of WT virus. 
5.1.3 Study aims 
The aim of this project was to establish and make use of the ELLA system with available 
reagents, making use of and measuring NA activity of PVs. Until now, the Viral Pseudotype 
Unit had only incorporated NA into PVs in order to measure its activity (or lack of) through 
the increase or decrease in PV production titre in comparison with exogenous NA or no 
source of NA at all. Essentially, NA had only previously been tested through its ability to 
allow influenza PV to bud from the producer cell surface. The ultimate desired goal of this 
project was to be able to measure immune responses inhibiting the action of NA. After 
producing stocks of NA PVs and titrating them using ELLA, efforts were made to produce 




high titre, reproducible stocks to employ in inhibition assays. It was also decided to fully 
evaluate this assay by challenging the standard operating conditions used when utilising WT 
virus, including the concentrations of materials (PNA-HRPO) and input quantities (PV). The 
traditional pMN assay benefits from the ability to produce HA only PV, enabling neutralising 
or inhibiting compounds to be measured against only one protein. Addition of NA to the PVs 
allows steric hindrance of HA binding by NA-antibody complexes, preventing certainty that a 
detected inhibition response is due to HA directed antibodies. Similarly, the goal of this 
project was to evaluate whether production of NA only PVs was possible in order to 
measure clean inhibition titres against this enzyme in the absence of HA and its ability to 
interfere via steric hindrance. 
Table 5.1. Panel of sera obtained from the CONSISE group via the NIBSC. A total of 8 samples were 
tested in this project. High positive samples S1 and S2 derive from purified human IVIG and 
Transgenic bovine plasma (vaccinated with TIV 2012/2013). Sample S3 is pooled human sera and 
samples S4-S8 individual human sera vaccinated post 2009/2010. 
 
Sample I D Description 
S1 Human purified IVIG, chosen from HP HI neutralising antibody titres in 2013  
(Source: Baxter Biomedical Research) 
S2 Transgenic bovine plasma (TIV 2012/2013) 
(Source: Sanford Research) 
S3 Pooled human sera 
(Source: Lonza Pharma & Biotech) 
S4-S8 Human sera, post 2009/2010 Influenza vaccination 
(Source: Accelovance, Contract Research Organisation) 
5.2 Methods 
The ELLA protocol detailed in this chapter was initially derived from Couzens et al. 2014, 
several variations in the parameters used in this protocol were used in order to examine the 
system using PVs as a source of NA. PNA-HRPO was used at both 1:500 and 1:1000 dilutions 
during the galactose-binding step. In the inhibition assay (Section 5.2.5), PV input and 
dilution was varied in order to give ranges from OD2.0 to OD3.5, the latter being equivalent 
to 90% of the maximal signal obtained in the ELLA NA titration (Section 5.2.4).  
  




5.2.1 Alignment of NAs 
Amino acid sequences for A/Brisbane/59/2007 (Accession: AHG96686.1) and 
A/California/7/2009 (Accession: ACQ63272.1) NA genes were aligned using the PROMALS3D 
online tool, accessible at http://prodata.swmed.edu/promals3d/promals3d.php (Pei et al. 
2008). 
5.2.2 Production of HA/NA bearing VLPs 
In parallel to PVs produced bearing HA/NA or NA only detailed in section 5.2.3, VLPs were 
produced, essentially composed of PVs bearing HA/NA or NA glycoproteins but lacking the 
lentiviral reporter, core or both. A schematic diagram for the types of PV or VLP used in this 




Figure 5.2. Different NA bearing particles produced and tested during this chapter. PVs bearing 
HA/NA or NA only were produced alongside the same particles lacking the lentiviral reporter or 
lacking both the lentiviral reporter and core (designated VLPs).  
 
5.2.3 Production of HA/NA and NA only PV 
HA/NA and NA only PV were produced by PEI mediated co-transfection of HEK293T/17 cells, 
as described in chapter 2. However, various different plasmid inputs and combinations were 
tested during the optimisation of ELLA using PV, which are detailed in each respective 




results data section. Further deviances from the previously described method include 
harvesting of PV 72 h post transfection in lieu of 48h. 
5.2.4 ELLA (Titration) 
The standard ELLA protocols used in this chapter are detailed in chapter 2, deriving from the 
CONSISE protocol described by (Couzens et al. 2014). Titrations were originally carried out 
with a starting volume of 24 µl of sample diluted in a total of 240 µl sample diluent (1:20 
starting dilution after transfer to maxisorp plate). Due to the lower activity observed from 
PV preparations in comparison with available CONSISE concentrated inactivated virus 
samples, it was decided to use 120-240 µl of PV in the first well, giving a starting dilution of 
1:2 when transferred to fetuin coated maxisorp plates. 
5.2.5 ELLA (Inhibition assay) 
Serum inputs remained the same as previously described in chapter 2; at 24 µl in 240 µl 
(1:10 start). exNA (sources from Sigma and Roche) were originally tested from 1:240 (1 µl) 
and 1:48 (5 µl) starting dilutions, eventually 1:240 was deemed suitable for control purposes 
due to the very high activity seen from these commercial bacterial preparations. 
5.3 Results 
5.3.1 Initial testing & controls 
Initially, ELLA was performed with a set of standard reagents, kindly provided by CONSISE 
through the NIBSC as part of a collaborative study which was carried out as part of efforts to 
standardise ELLA across laboratories worldwide (Eichelberger et al. 2016). These reagents 
included inactivated reverse genetics (RG) influenza viruses bearing the H6 HA and either 
N1: A/Brisbane/59/2007 (H1N1) and A/California/7/2009 (H1N1) or N2: 
A/Uruguay/716/2007 (H3N2), while internal genes were derived from A/Puerto Rico/8/38 
(H1N1). A set of serum samples was also included, detailed in the cited article and Table 5.1. 
In parallel to testing of the CONSISE virus samples, two sources of bacterial exNA were 
employed as controls in the initial tests, from Sigma (Clostridium perfrigens, cat: N2876) and 
Roche (Vibrio cholerae, cat: 000000011080725001). These exNAs of bacterial origin (both 
genes and method of production) were highly potent in terms of NA activity (Figure 5.3). 
The first titration of these exNAs was carried out at 1:48 (5 µl, 0.05 Units) and 1:240 (1 µl, 




0.01 Units) starting dilutions, Figure 5.3. High absorbance values were observed along the 
length of the dilution series, with the only drop in attributed to the Clostridium perfringens 
origin exNA after dilution past 1:10,000. The other dilution series tested in this experiment 
remained at OD492 values of between 3 and 4 with no decrease in absorbance detected 
despite increasing serial dilutions.  
 
Figure 5.3. exNA was tested for use as a positive control in the ELLA assay. Two exNAs from different 
sources were tested. exNA Roche from Vibrio cholerae and exNA Sigma from Clostridium 
perfringens. Digestion of the fetuin coated plates, exposing galactose which could then be detected 
by PNA-HRPO is variable but consistently high across the diution series, with 1:48 and 1:240 starting 
dilutions. Only one test sample was titrated to the point where reduced digestion was seen with 
increased dilution of the sample (exNA Sigma 1:240). 
 
CONSISE reverse genetics viruses H6N1 and H6N2 displayed high titres (OD492 >3.0) even 
when diluted past 1:1000, in the same range as exNA (see Figure 5.4). These results 
provided a benchmark to which PV NA titres could be compared to in subsequent 
experiments. It was decided to produce of a panel of PVs by transfecting expression 
plasmids coding for different combinations of HA/NA subtype glycoproteins, in order 
broaden the likelihood for positive results, and to detect NA activity where possible which 
could then be built upon.  
5.3.2 Use of VLPs as a source of NA 
Initial experiments did not utilise lentiviral packaging or vector plasmids, only HA or NA 
genes were transfected, as they had previously been shown to bud independently of other 
proteins (B. J. Chen et al. 2007) ?ƵĞƚŽ,ĂŶĚE ?ƐĂďŝůŝƚǇƚŽĨŽƌŵƉĂƌƚŝĐůĞƐŝŶĚĞƉĞŶĚĞŶƚůǇ ?
it was first decided to use these VLPs bearing only the N1 of A/Puerto Rico/8/1934 or the N2 




of A/Udorn/307/1972, both of which were from characterised and widely used laboratory 
strains of influenza (Figure 5.5). In parallel, VLPs bearing H11 (A/duck/Memphis/546/1974) 
in combination with the N1 from A/California/7/2009 or N2 of A/Texas/50/2012 were also 
produced (H11N1, H11N2), which were acquired for this project by commercial gene 
synthesis from Genscript (USA). This was also repeated with H5 from A/Vietnam/1194/2004 
(H5N1, H5N2). Finally, H1N1 (A/California/7/2012) and H3N2 (A/Texas/50/2012) matched 
HA/NA VLPs were produced and titrated by ELLA. For ELLA titration data for all of the above 
NA bearing VLPs, see Figures 5.3-5.6. High absorbance values were observed for all 
reassortant RG viruses, with high values seen past the 1:100 dilution point (Figure 5.4). Poor 
or no NA activity was detected from N1 (PR8) and N2 (Udorn) VLPs tested, with results at 
1:10 dilution yielding absorbance values of just over 1 for VLPs bearing N2 Udorn produced 
using 1.5 µg of NA plasmid (Figure 5.5). For the A/California/7/2009 N1 however, high 
absorbance values were measured, providing an OD492 readout near 4.0, while other 
glycoprotein combinations of H11N2, H5N1, H5N2 or the matched H1N1/H3N2 showed 
lower NA activity (<3.0). Figure 5.6 shows this data, including exogenous NA control.  
 
Figure 5.4. ELLA titration data for the CONSISE viruses (H6N1 A/Brisbane/57/2007 and 
A/California/7/2009, H6N2 A/Uruguay/716/2007) and three different PV (H5N1and H11N1 A/Puerto 
Rico/8/1934 and H5N2 A/Udorn/307/1972. High titres above OD492 of 3.0 are observed for all three 
viruses, while VLPs bearing N1 from A/Puerto Rico/8/1934 (PR8) or A/Udorn/307/1972 (Udorn) 
show no activity. 
 





Figure 5.5. ELLA titration data for VLPs bearing N1 from A/Puerto Rico/8/1934 (PR8) and N2 from 
A/Udorn/307/1972 (Udorn) glycoproteins. Production inputs of NA plasmids listed, from 0.25 µg to 
1.5 µg. Low NA activity is observed for the starting dilutions of N2 Udorn produced with 1.0 or 1.5 µg 
of NA plasmid. 
 
Figure 5.6. ELLA titration data for various different NA bearing VLPs. NAs from A/California/7/2009 
(N1), A/Texas/50/2012 (N2) in combination with different HAs (H11, H5, H1 and H3). High NA activity 
is observed for the H11N1 VLP, followed by weaker activity for H5N1, H11N2 and H1N1. 
 
In parallel with the previously described experiment, an attempt was made to produce N1 
and N2 bearing VLPs with the same H3 from A/Texas/50/2012, producing each VLP in 6-well 
format with differing quantities of NA plasmid (Figure 5.7 A). This was carried out with 
addition of 0.1 µg, 0.25 µg, 0,5 µg, 1 µg, 1.5 µg and 3 µg of N1 plasmid. A further experiment 
was carried out with the H3 from A/Texas/50/2012 and 500ng of matched N2 per well, this 
time supplementing the transfection mix with pCMV-TMPRSS4 protease. However, these 
experiments were unsuccessful and no NA activity was observed for any of the different 
preparations when compared to positive results or exNA (Figure 5.7 B). 






Figure 5.7. ELLA of VLPs bearing H3 (A/Texas/50/2012) and either N1 (A/California/7/2009) or N2 
(A/Texas/50/2012). A) H3N1 VLPs produced with between 0.1 and 3.0 µg of NA per well. B) H3N2 
VLPs produced with 0.5 µg of NA and between 0.2 and 0.45 µg of pCMV-TMPRSS4 per well. No NA 
activity is observed for any of the above listed VLPs. 
  




5.3.3 Detection of N1 activity, addition of lentiviral core/reporters 
Following these results, it was decided to then test whether the addition of plasmid p8.91 to 
the transfection mix would influence subsequent NA activity from our produced PVs, 
thinking that this could ameliorate the budding of particles bearing the glycoproteins whose 
action were being measured. The N1 (A/California/7/2009) or N2 (A/Texas/50/2012) 
expression plasmids were transfected into HEK293T/17 cells, supplementing the lowest and 
highest test wells with plasmid p8.91 in order to assess its influence on the budding of 
particles and subsequent NA activity. As shown by the data in Figure 5.8 A, the addition of 
higher quantities of NA plasmid and addition of p8.91 increases N1 titres. This was not 
reproduced with N2 (A/Texas/50/2012), however, the lack of any detected NA activity 
suggests a different problem in this instance (Figure 5.8 B).  
From this point forwards, p8.91 and pCSFLW were always used to produce HA/NA PV, rather 
than HA/NA bearing VLPs. This was decided in order to not only reduce the amount of 
variables in this experiment, but by the strong suggestion from this data that the presence 
of p8.91 and pCSFLW in the production process enables higher NA titres from resulting PV 
containing supernatants. 
5.3.4 Production of PVs with high NA activity 
Upon use of p8.91 and pCSFLW plasmids in the production process, higher NA titres were 
observed, as seen in Figure 5.9 where N1 and N2 PV were produced with both lentiviral 
plasmids. As observed in previous experiments, increasing NA plasmid quantity lead to 
increased activity from the same input of PV containing supernatant, with 1 µg of NA 
plasmid per 6-well well giving the highest absorbance values and therefore highest NA 
activity (Figure 5.9). We repeated these results with H1 in addition to N1, observing a similar 
trend in the data, with the exception that lower NA quantities produced detectable NA 
activity when expressed on the surface of PV alongside H1 (Figure 5.10). N2 
(A/Texas/50/2012) activity was still not detected in this experiment, titres being below an 
OD492 of 1.0 (Figures 5.9 and 5.10). 
  





Figure 5.8. ELLA of VLPs bearing N1 (A/California/7/2009) or N2 (A/Texas/50/2012). A) Increasing the quantity of NA plasmid (shown in µg) leads to an 
increase in NA activity, with 3.0 µg yielding the highest activity in this experiment for VLPs. Addition of 0.5 µg of plasmid p8.91 (HIV-1 packaging plasmid) 
leads to an increase in NA activity alongside increased quantities of NA plasmid. VLPs produced with 0.10 µg of NA and 0.5 µg of p8.91 show increased 
activity compared to 0.25 µg NA with no p8.91 plasmid. Addition of 3.0 µg of NA plasmid alongside 0.5 µg p8.91 plasmid lead to the highest NA activity 
detected to date in these experiments. B) No NA activity is detected for N2 bearing VLPs, shown alongside exogenous NA control.






Figure 5.9. ELLA of lentiviral PVs bearing N1 (A/California/7/2009) and N2 (A/Texas/50/2012) 
glycoproteins, produced with p8.91 and pCSFLW lentiviral core and reporter plasmids. Increasing 
input of NA plasmid in the production stage leads to increased activity in ELLA. Poor or no NA activity 
detected for N2 PVs. 
 
 
Figure 5.10. ELLA of lentiviral PVs bearing H1 and N1 (A/California/7/2009) glycoproteins, produced 
with p8.91 and pCSFLW lentiviral core and reporter plasmids. Increasing input of NA plasmid in the 
production stage leads to increased activity in ELLA. Addition of H1 to PVs increases NA activity of 
PVs produced with lower quantities of NA plasmid. 




5.3.5 Addition of exotic HA (H11) to NA bearing PVs 
Having successfully produced matched H1N1 PV with NA activity was a significant step, as 
the same PV could thus be used to detect NA and HA mediated antibody responses through 
ELLA and pMN respectively, using the same batch of PV. One of the benefits of the pMN 
assay is the ability to produce PVs with only HA on the surface, releasing particles with 
ĞǆŽŐĞŶŽƵƐ E ĂŶĚ ĞŶĂďůŝŶŐ Ă  ‘ĐůĞĂŶ ? ƌĞĂĚŝŶŐ ŽĨ ĂŶƚŝďŽĚǇ ĂĐƚŝǀŝƚǇ ĂŐĂŝŶƐƚ , ? In a similar 
fashion, the rational in this case was to produce an analogous system for ELLA in the 
production of NA only PVs as described in Prevato et al. 2015. However, it was decided to 
additionally attempt the production of HA/NA PVs with a mismatched, exotic HA, that from 
H11 (A/Shear Water/Western Australia/2576/1979 (H11N9)) alongside the tested NAs in 
order to determine the effect on NA inhibiting antibody titres. Due to the avian nature of 
H11, as with the H6 used in RG virus production, few neutralising antibodies should be 
present in human serum samples due to the presence of different head epitopes humans 
have not encountered, though this is still an assumption. This would allow for a more even 
platform for comparison between H11NX PVs and H6NX RG viruses in ELLA. At the time 
these experiments were carried out, no H6 expressing plasmid was available in our 
laboratory. H11 was chosen due to its previous use in cHA experiments as a non-reactive 
glycoprotein, as well as its overall lack of reactivity with previously used human serum 
samples (chapter 3). 
5.3.6 PV bearing exotic H11 and NA 
The final attempts at producing high titre NA activity PV preparations were carried out 
through the use of H11 plasmid in conjunction with p8.91, pCSFLW and the NA plasmid of 
choice (Figure 5.11). This yielded PVs bearing both N1 (A/California/7/2009) and N2 
(A/Texas/50/2012) in sufficient quantities to perform multiple titrations and progress to the 
inhibition phase of this ELLA project.  Having these PVs with high NA activity also allowed us 
to test the concentration of PNA-HRPO required to reach the digestion ceiling for this assay, 
a variable within the two studies which we based this project upon (Eichelberger et al. 2016; 
Prevato et al. 2015). It was suggested in the CONSISE protocol that each batch of PNA-HRPO 
should be titrated with a known NA source in order to determine the optimal concentration 
to detect full digestion of the fetuin coat, saving on costs associated with this expensive 
reagent and increasing the number of assays which could be performed per batch. 




Therefore it was decided to test the same PV preparations with 1:500 and 1:1000 dilutions 
of PNA-HRPO. H11N1, H11N2 and N1 only PV all produced with p8.91 and pCSFLW and 
harvested 72 h post transfection were titrated (1:1000 PNA-HRPO) in duplicate (Figure 
5.11). Subsequently, the same titration was carried out using 1:500 and 1:1000 PNA-HRPO 
dilutions in parallel (Figure 5.12). As shown by this data, there is a clear increase in the 
detection of NA activity when using more concentrated (1:500) PNA-HRPO and this is more 
evident for the lower titre PVs N1 (only) and H11N2 at lower dilution points of PV. The exNA 
control was the least affected by the change in PNA-HRPO dilution, with values only 
marginally lower when halving the PNA-HRPO concentration. 
 
Figure 5.11. ELLA of lentiviral PVs bearing only N1 (A/California/7/2009) or H11 
(A/duck/Memphis/546/1974) and N1 or N2 (A/Texas/50/2012) glycoproteins. 3 µg of NA plasmid per 
well alongside standard quantities of HA, p8.91 and pCSFLW. H11N1 NA activity is higher than N1 
only activity while both show high NA activity at early dilution points. H11N2 activity is low in 
comparison with N1 and H11N1 PVs. 
 






Figure 5.12. ELLA Titration of N1, H11N1 (A/California/7/2009) and H11N2 (A/Texas/50/2012) with 1:500 and 1:1000 dilution of PNA-HRPO. exNA controls 
shown in grey. Increases in PNA-HRPO concentration lead to increased NA titres detected for N1, H11N1, H11N2 and exNA sources of NA tested. The largest 
increase was seen with N1 PV, increasing from OD492 of 2.0 to 3.2. Increased titres were more apparent at higher concentrations of NA source, suggesting 
that 1:1000 dilution of PNA-HRPO is not sufficient to detect all available galactose with theses sources of NA. 
  




Eichelberger et al. 2016 detailed that an absorbance value ranging between 1.7 to 4, in the 
linear phase of the titration curve, should not give rise to any differences in geometric mean 
antibody titres (GMT) when used as an input for inhibition ELLA (Eichelberger et al. 2016). 
This suggests that even low titre PVs produced in the previously detailed experiments could 
be used in inhibition ELLA and give comparable antibody titres to the same experiment 
carried out with a higher PV input. The article from which the ELLA protocol used was 
obtained, utilised an OD492 input of 2, within the 1.7-4 range (Prevato et al. 2015). In order 
to test these arguments in conjunction with the PV system in ELLA, it was decided to 
perform inhibition assays with the same panel of sera, using different viral inputs as well 
different PNA-HRPO dilutions. 
5.3.7  Inhibition ELLA with CONSISE sera 
After the successful production of H11N1 and N1 preparations with NA activity titres at an 
OD492 >3, it was decided to employ the set of CONSISE sera shown in Table 5.1. To begin 
with, inhibition assays were carried out using a viral input of 90% of the maximal titre 
obtained, as described by (Couzens et al. 2014). Due to the constraints of the 12 row by 8 
column plates used for ELLA, we opted to assay 8 sera in duplicate across the plate, using 6 
post vaccination human sera (2009/2010 TIV), purified human IVIG from patients 
immunized against H1N1 strain A/Brisbane/59/2007 (2009/2010 TIV) and finally transgenic 
(humanised IG) bovine plasma immunized with the 2012/2013 vaccine strain (including 
A/California/7/2009 (H1N1)). The latter sample, vaccinated with strain A/California/7/2009 
acts as a positive control in this experiment. 
These sera were assayed against both H11N1 and N1, providing inhibitory IC50 results. 
Increased inhibition titres were observed for N1 only pseudotypes (Figure 5.14). As 
expected, S2, the transgenic bovine plasma immunized with the matched CA/09 virus 
showed the highest titres against H11N1 or N1. The second highest titres were observed for 
S1, the purified human IVIG from 2009/2010 TIV vaccinated patients. The NA of the strain 
used in this vaccine (A/Brisbane/59/2007) is dissimilar to Eurasian swine CA/09 NA, with 88 
amino acid changes or insertions/deletions (Figure 5.13). 





Figure 5.13. Amino acid alignment of the NA gene from A/Brisbane/59/2007 (Accession: 
AHG96686.1) and A/California/7/2009 (Accession: ACQ63272.1). Predicted consensus secondary 
ƐƚƌƵĐƚƵƌĞĚĞŶŽƚĞĚďǇĐŚĂŝŶƐŽĨ “Ś ?ĨŽƌĂůƉŚĂŚĞůŝĐĞƐĂŶĚ “Ğ ?ĨŽƌďĞƚĂƐŚĞĞƚƐ ? 2D and 3D alignment 
generated using amino acid sequences in the PROMALS3D tool. (Pei et al. 2008)  
5.3.8 Inhibition of N1 by CONSISE sera 
The human serum samples (S3-S8) inhibited the N1 to varying degrees and higher titres may 
indicate previous infection with a virus bearing a similar N1 or better reaction/presence of 
antibodies to the 2009/2010 vaccine strain. Data in Figure 5.14 shows two sets of repeats 
for each experiment, Figure 5.15 shows datasets merged and corresponding differences in 
IC50 values which are small. Inhibitory titres against N1 were higher compared to those 




against H11N1, despite the same input of serum and PV. IC50 values increased 5 to 35 fold 
ǁŚĞŶƵƐŝŶŐƚŚĞ ‘ĐůĞĂŶ ?EŽŶůǇWs ?&ŝŐƵƌĞ ? ? ?4 & 5.15).  
 
Upon testing the same panel of sera on H11N2 PV, higher IC50 values were seen, as well as a 
different neutralising profile for samples S3-S8. S1 and S2 behaved as against the CA/09 NA, 
S1 showed an IC50 of 2627, 3-fold higher than against H11N1. S2 was again the strongest 
inhibitor, with IC50 of above 5120 and 100% neutralisation throughout the dilution series. 
Samples S3-S8 showed different inhibitory profiles against H11N2 than H11N1. Samples S3 
and S4 showed higher titres against H11N2 (IC50: 286 & 385) in comparison to H11N1 (IC50: 
83 & 68). S5 was more inhibitory than the previous two samples against H11N2 (IC50: 407) 
and H11N1 (IC50: 287) while S6 and S7 were weak inhibitors of both H11N1 and H11N2 (IC50: 
109 & 117 for H11N2 and 5 & 101 for H11N1). Interestingly, sample S8 very strongly 
inhibited H11N2 (IC50: 1130) but not H11N1 (IC50: 9), see Figure 5.16 for H11N2 CONSISE 
sera ELLA data.  
 





Figure 5.14. ELLA Inhibition curves for CONSISE serum samples S1-S8 assayed against H11N1 and N1 PV using ELLA. The top and bottom graphs on the left 
are replicates for H11N1 PV whereas the top and bottom graphs on the right are replicates for N1 PV. IC50 values for each serum sample are shown adjacent 
to the key. Replicates show near identical inhibition curves and antibody titres (IC50). Replicate values are merged together to produce Figure 5.15.





Figure 5.15. ELLA inhibition curves for CONSISE serum samples S1-S8 assayed against H11N1 and N1 PV, including error bars and average IC50 values. Fold 
increase in IC50 values from H11N1 to N1 shown in the column titled FI*. Inhibition profiles are similar between H11N1 and N1 PV, with sera S2 and S1 
showing the strongest inhibition and sera S6 and S6 the weakest inhibition. Changing from H11N1 to N1 only PV leads to an increase of 1-36 fold difference 
in antibody titre (IC50). 
 
  





Figure 5.16. ELLA inhibition curves for CONSISE serum samples S1-S8 assayed against H11N2 PV, 
including error bars and average IC50 values. Sera S2 followed by S1 and S8 show the highest levels of 
inhibition of N2 activity, followed by S5, S4, S3, S7 and S6 in descending order. 
5.3.9 Evaluation of PNA-HRPO and Viral input factors on antibody titres 
In order to test the difference in results obtained from using different concentrations of 
PNA-HRPO, it was decided to perform a set of experiments comparing 1:500 and 1:1000 
dilutions. As previously mentioned, it was suggested that each NA source should be titrated 
with differing dilutions of PNA-HRPO, in order to determine the digestion ceiling for each 
virus and adapt the dilution for subsequent experiments, saving on reagents where possible. 
The aims for this part of the project were to test its effect on the generation of inhibitory 
IC50 data and whether any changes occurred as a result of the PNA-HRPO dilution variable. 
This test was also duplicated while using two different PV inputs, 90% of the maximal 
titration and an input of OD2.0, as calculated from the titration results listed previously. This 
variable, as mentioned earlier, was stated to not influence inhibitory titres between OD492 
inputs of 1.7-4 (Eichelberger et al. 2016), and experiments in the published literature report 
varying inputs (Prevato et al. 2015).  
We decided to test these variables with H11N1 PVs and one high (HP) and one low (LP) 
positive serum sample, as determined by previous pMN experiments (chapter 3), run in 
duplicate. All the data for these experiments are displayed in Figures 5.17 and 5.18 with 
inhibition curves alongside IC50 values. All data points represent mean values of two data 
points with variation depicted through whiskers. Changing the dilution of PNA-HRPO had a 
strong effect on IC50 values recorded, whether inputs were OD90% or OD2.0. OD90% input 




IC50 values increased when dilution was increased from 1:500 to 1:1000. The HP sample 
increased from 908 to 1511 and the LP sample from 1 to 2. With a 2.0 input the HP sample 
increased from 8125 to 9524 and the LP from 55 to 228. To compare 90% and 2.0 inputs 
(Figure 5.17), IC50 values increased noticeably when moving from 90% to 2.0 inputs, the HP 
sample increased from 1511 to 9524, LP from 2 to 110 when using 1:1000. For 1:500 PNA-
HRPO, the HP sample IC50 increased from 908 to 8125, and the LP from 1 to 41. 
5.3.10 Jenner sera ELLA 
After evaluating the ELLA system and deciding to use 1:500 PNA-HRPO as well as an OD492 of 
90% where possible, it was decided to field test this assay on relevant serum samples in 
order to produce some useful and interesting data, as opposed to assaying samples which 
have been previously tested and published. We selected six serum samples from the Jenner 
Sera panel, obtained from Prof. Sarah Gilbert, Jenner Institute Laboratories, University of 
Oxford, which are detailed in more depth in chapter 3 (and appendix X1). This section of this 
chapter represents a preliminary study on these serum samples. The decision was made to 
continue the OD90% vs. 2.0 experiments using these serum samples to determine the effect 
this variable has on negative controls which ǁĞƌĞŶ ?ƚ ŝŶĐŽƌƉŽƌĂƚĞĚ ŝŶƚŽ ŽƵƌ ƉƌĞǀŝŽƵƐ
experiments. H11N1 PVs were tested using serum samples 20, 31 and 23 which were all low 
positives against H1 (A/California/7/2009) HA PV (Figure 5.19). High positives, determined in 
the same fashion, were 34, 59 and 60. Negative controls anti-A/California/7/2009 HA serum 
as well as anti-B/Brisbane/60/2008 HA serum (NIBSC). exNA was used as a 
digestion/positive control as seen previously. 
Results correlated well with IC50 values generated against H1 (CA/09) PV as seen in chapter 
3 (Figure 3.25), with HP and LP samples acting as low and high positives against N1 as well as 
the original H1. LP samples 20, 23 and 31 gave IC50 values of 0, 30 and 14 with a 90% OD 
input. With the OD input of 2.0, IC50s were 0, 341 and 150. For HP samples, 34, 59, and 60 
IC50 values were 91, 209 and 153 respectively at OD90%, and 629, 1613 and 1288 for OD2.0. 
Negative controls all resulted in values of zero except B/Brisbane antiserum which had an 
IC50 of 4 at OD2.0. Despite this, negative samples are clearly grouped at the negative end of 
the spectrum of results. However, the curves generated are elevated when using an input of 
OD2.0, inhibition starting between 20-40% at the starting dilution compared to below 5% 
with an OD input of 90%. 




A further set of serum samples were assayed against H11N2 (A/Texas/50/2012), originating 
from the sports science sera project collected in the United Kingdom (chapter 3, serum IDs 
in appendix X2), see Figure 5.20. Five serum samples (3 HP and 2 LP), as determined through 
pMN carried out against A/Udorn/307/1972 in Chapter 3 were tested against H11N2 PV in 
ELLA. Three HP samples were 9 0V (IC50 8170), 21 12V (IC50 11279) and 39 0V (IC50 12763), 
and two low positive samples were 33 12V (no IC50) and 50 12V (IC50 957). Controls used 
include the same negative controls as used previously, with added antiserum generated 
against inactivated H3N2 (A/Udorn/307/1972) virus, despite this virus being very different 
to the PV strain utilised (A/Texas/50/2012). Due to the low titre/activity of H11N2 
preparations, they were used without dilution, which generated an OD of 2.2 per well (50 
µl). This was not optimal based on previous results comparing higher ODs to 2.0. Serum 
sample 50 had a matched IC50 with the Anti H3N2 control at 33. 39 generated an IC50 of 89 
and other samples were more positive, 9, 21 and 33, giving IC50 values of 137, 103 and 225 
respectively.  Negative control antisera for A/California/7/2009 and B/Brisbane/60/2008 
were once again elevated, as seen in Figure 5.19 with H11N2 and a 2.0 viral input. 
  





Figure 5.17. Analysis of multiple variables in ELLA. Two graphs comparing H11N1 PV input on neutralisation of PVs by high positive (red) and low positive 
(blue) serum samples. The left graph compares neutralisation with 1:500 or 1:1000 PNA-HRPO and an OD90% input. The right graph compares the same 
with an OD2.0 input. Similar neutralisation profiles are seen for the same serum samples in ELLA performed with 1:500 or 1:500 PNA-HRPO concentration, 
with a drop in NA activity signal observed for 1:1000 PNA-HRPO data points.





Figure 5.18. Analysis of multiple variables in ELLA. Two graphs comparing the dilution of PNA-HRPO on neutralisation of H11N1 by high positive (red) and 
low positive (blue) serum samples. The left graph compares HP and LP samples with OD90% and OD2.0 inputs at 1:1000 PNA-HRPO. The right graph 
compares the same variables at 1:500 PNA-HRPO. Neutralisation of N1 activity is reduced when changing from 1:500 PNA-HRPO to 1:1000 as well as when 
using a higher viral input (OD90% rather than OD2.0). Different neutralisation profiles are seen for HP samples when reducing viral input from OD90% to 
OD2.0.






Figure 5.19. ELLA inhibition assay testing serum samples from the Jenner institute, University of Oxford on H11N1 PV. Six sera were tested against H11N1, 
representing three high positive (S245, S236 and S221) and three low positive samples (S004, S214 and S086) based upon results against 
A/California/7/2009 HA PV. Similar results are obtained against the N1, showing distinct positive and negative samples against H1 as against N1. 
Negative controls include anti-A/California/7/2009 and anti-B/Brisbane/60/2008 HA serum (NIBSC). Experiment carried out in duplicate with an input virus 
of OD492 90% or 2.0.  
 





Figure 5.20. ELLA inhibition assay testing Sports Science Serum samples obtained from Dr. Glen 
Davison, University of Kent on H11N2 PV with an OD492 2.2 input. Negative controls include anti-
A/California/7/2009 and anti-B/Brisbane/60/2008 HA serum (NIBSC). A PV positive control from 
H3N2 positive antiserum against A/Udorn/307/1972 is also included (Anti H3N2). 
5.4  Discussion and conclusions 
In general, this project has been successful in A) setting up the ELLA assay with PV and B) 
employing it in a project involving available sera. The CONSISE protocol was employed and 
after initial unsuccessful attempts, PVs with high titre NA activity were produced, enough so 
to perform various experiments interrogating the other parameters of the assay (Viral input 
& PNA-HRPO concentration). The ability to produce these high NA titre PVs at relatively little 
expense and effort is very useful in terms of the future for generation of inhibition data 
against influenza NAs. Interestingly, it seems that the ability to induce budding from the cell 
surface is one of the largest factors influencing the titre of the NA PV, as production with the 
addition of HIV-1 core genes and HA increases titres (Figure 5.8). The latter point is most 
likely due to the HA ability to induce membrane curvature with NA (B. J. Chen et al. 2007). 
The increases in NA titres when using lentiviral vector and packaging plasmids are most 
likely due to an increase in particles exiting the cell, taking influenza glycoproteins present 
on the cell membrane, with them. The combination of HA and lentiviral plasmids lead to the 
highest NA titres recorded and enabled subsequent ELLA inhibition assays with a single 
batch of PV. The addition of lentiviral plasmids most likely increased titres by increasing the 
number of PV coming off the surface of the HEK293T/17 producer cells, taking with them 
the NA glycoproteins present on the cell membrane. The ability of gag and HIV core proteins 
to induce budding has been reviewed in extensive detail (Sundquist and Kräusslich 2012). 




When using exNA throughout the experiments in this chapter, the typical data was variable, 
with many data spikes or troughs, as opposed to a typical 100% cut-off line that we would 
have expected from fully digested fetuin (Figure 5.3). This may be due to the concentrated 
nature of this reagent in combination with inadequate or insufficient mixing during the 
dilution steps. Another explanation would be possible discrepancies in the coating of wells 
in the maxisorp plates, leading to slight differences in the amount of galactose exposed 
upon full digestion of the fetuin. This would explain how NA activity seems to drop after 
three dilution points, but then rises back up after 6 dilution points. PVs tended to present 
differently, with much smoother titration curves observed.  
The data generated using H11N1 and N1 only PV was interesting, due to the fact that H11 
should have no or little influence on the inhibition of the NA enzyme. A large increase (1 to 
36 fold increase) in antibody titres was seen from H11N1 to N1 PV, suggesting that the 
presence of HA is having a dampening effect on available antibodies (Figure 5.15). One 
possible explanation is steric hindrance caused by the presence of the HA, which may mask 
certain sites on the NA as seen in other published articles (Rajendran et al. 2017). This 
ƉŚĞŶŽŵĞŶŽŶ ŝƐŵĂƚĐŚĞĚ ŝŶ ƚŚĞ ƌĞƐƵůƚƐǁĞ ƐĞĞ ŝŶ ƚŚĞ ƉDEĂƐƐĂǇ ?ǁŝƚŚ  ‘ĐůĞĂŶ ?, ŽŶůǇWs
easier to neutralise than HA/NA PV using the same serum. It is possible that the presence of 
HA allows binding of PV to the fetuin coated walls of the 96-well plates, possibly 
immobilizing PVs and preventing access to other PVs to the substrate. 
H11N1 tests against the CONSISE serum samples showed the use of ELLA in detection of 
cross-neutralising responses against NA. Serum sample S1, consisting of pooled human 
serum vaccinated with the 2009/2010 TIV neutralised N2 higher than N1, which is expected 
due to the relationship between PV strains and vaccine strains. The A/California/7/2009 N1 
originated from Eurasian swine in this triple reassortant virus, the A/Texas/50/2012 strain 
represents a drift mutant from the 2009/2010 vaccine strains, therefore sharing a greater 
similarity. Nevertheless, the decreased viral input for H11N2 of OD2.2 compared to the 
OD90% (>3.0) for H11N1 is another possible explanation for the increased antibody titre of 
S2 against H11N2 in comparison to H11N1 (Figure 5.16).  
These data reinforce previous concerns about input of virus and use of differing 
concentrations of reagents. We have shown that using lower viral inputs leads to an 
inflation of IC50 values; including those for negative controls which are a cause for concern 




when data is generated using these lower inputs (Figures 5.17 and 5.18). We have also 
shown that use of N1 only vs. H11N1 PVs leads to an inflation of IC50, most likely due to HA 
directed antibodies hindering the ability of NA. This previous point could be interrogated by 
the use of NA only antisera or a panel of mAbs, which could be tested on H11N1 and N1 PV. 
This highlights the problem posed by the use of human sera in serology, each sample is from 
an individual with an unknown number of exposures to various subtypes of influenza virus, 
the interplay between HA and NA mediated antibodies lead to discrepancies in results. 
These discrepancies would be better explained with the aid of such a study. 
Poor NA titres were observed for N2 bearing PV produced during this project, representing a 
problem which must be solved in order to make full use of this assay (Figure 5.12). Issues 
leading to these low titres may involve the optimal conditions required for this enzyme to 
function in the assay. Quantities of NA present on the surface of PV may also be involved, 
through the lower expression of NA proteins in HEK293T/17 cells. However there is no 
evidence for this and WT viruses (H1N1, H3N2 and influenza B) have been reported to have 
no statistically significant differences in the content of NA (Tanimoto et al. 2005). 
The results presented in this chapter are encouraging in the respect that over a short time 
period, PV based ELLA has very rapidly been employed using relevant subtypes of NA, and 
these have been used in inhibition assays. ELLA is a useful tool, as future circulating or 
vaccine strains could be produced at short notice and useful data generated. This project 
saw two previous vaccine strain NAs synthesized (A/California/7/2009 and 
A/Texas/50/2012), alongside their matched HAs, providing the ability to produce H1N1, H1 
or N1 PVs. While these strains are no longer matched to current vaccine or circulating 
strains, they are still relevant as the majority of sera obtained will have been exposed to the 
H1N1 pandemic, or the H3N2 seasonal strain. By keeping a PV library with current strains 
and updating it, we can perform archeo-serology and scan backwards through circulating 
ƐƚƌĂŝŶƐƵƐŝŶŐƚŚĞƐĂŵĞƐĞƌƵŵƐĂŵƉůĞƚŽĞƐƚŝŵĂƚĞĂƉĞƌƐŽŶ ?ƐŝŶĨĞĐƚŝŽŶŚŝƐƚŽƌǇ ? 
  




Chapter 6 : Development and use of H17 and H17N10 PV 
6.1 H17N10 and H18N11 
The bat derived influenza viruses H17N10 and H18N11 were discovered recently in fruit bats 
using consensus-degenerate RT-PCR in Guatemala and Peru respectively (Tong et al. 2012, 
2013). Both viruses contain eight gene segments in the standard IAV conformation. A 
marked sequence divergence in the genetic material of both of these viruses is seen when 
compared to other IAV subtypes. However, this chapter will focus on H17N10 due to the 
availability of H17 and N10 genes. 
6.1.1 H17N10 genes and proteins  
The H17 HA can be placed within group 1 of Influenza A (Tong et al. 2012). Studies have 
shown that it is not capable of agglutinating red blood cells in a standard HI assay and it has 
ďĞĞŶƐƵŐŐĞƐƚĞĚƚŚĂƚ “ŚĂĞŵĂŐŐůƵƚŝŶŝŶ-ůŝŬĞ ? ? ?,> ? ? ?ďĞĂŵŽƌĞĨŝƚƚŝŶŐĚĞƐŝŐŶĂƚŝŽŶ(Ma et al. 
2015). Trypsin-like and TMPRSS2 mediated cleavage has been demonstrated for H17, and as 
with other IAVs, it is required for proteolytic activation and fusion competence (M. 
Hoffmann et al. 2016; Maruyama et al. 2016). However, the dynamics surrounding 
activation and fusion mediated by H17 are under question due to its instability at 37°C (50% 
ƵŶĨŽůĚĞĚ ? ? ĂďŝůŝƚǇ ƚŽ ƚƌŝŐŐĞƌ Ăƚ ŚŝŐŚ Ɖ,  ? ? ? ? ? ? ĂŶĚ ŝƚ ?Ɛ ŚŝŐŚ ƚƌǇƉƐŝŶ ƐƵƐĐĞƉƚŝďŝůŝƚǇ(Sun et al. 
2013). The H17 trimer does not bind to traditional (2,6 or 2,3) linked sialic acid as its 
receptor, as do other IAVs - according to surface plasmon resonance (SPR), MDCK cell 
binding and glycan microarray assays (Sun et al. 2013). Either the binding of this 
glycoprotein cannot be detected by currently available assays or it utilises a different 
receptor entirely.  Interestingly, the fusion peptide of H17 is highly conserved when 
compared to other IAV strains, especially those in group 1. Figure 6.1 shows an amino acid 
alignment carried out using the web tool Clustal Omega (Sievers et al. 2011). Here the C-
terminal region of the HA protein shows high conservation in the fusion peptide (starting 
residues highlighted by a red box) alongside recent H1 (group 1) and H3 (group 2) vaccine 
strains (A/California/7/2009 and A/Texas/50/2012).  
 





Figure 6.1. HA C-terminal amino acid sequence alignment of influenza A strains A/little yellow 
shouldered bat/Guatemala/060/2010 (H17), A/Texas/50/2012 (H3) and A/California/5/2009 
(H1pdm). Starting residues of the fusion peptide highlighted by a red box. Alignment carried out 
using Clustal Omega.  
 
The internal genes (PB1, PB2, PA, NP, M, and NS) sequences are related to Influenza A and B 
according to phylogenetic analysis, but do not cluster within either group. The polymerase 
complex has been shown to be functional via genome mini reporter assay, and all other 
genes have been shown to function in vitro when HA and NA genes are used from surrogate 
non-bat influenza A viruses. These replicative synthetic viruses produced with the H17 
internal genes also infected mice with high disease severity (Tefsen et al. 2014; Tong et al. 
2012; B. Zhou et al. 2014). The NA gene is more greatly diverged, and sits outside either A or 
B types (Tong et al. 2012), possibly originating from an extinct or as-yet unknown type (Q. Li 
et al. 2012). No sialidase activity has been detected from this enzyme which shares overall 
structural features with other NAs, but displays differences in crucial conserved amino acids 
attributed to the function of previously described NAs  W sialic acid binding and enzymatic 
cleavage (Colman et al. 1983; García-Sastre 2012; Q. Li et al. 2012; X Zhu et al. 2012). 
Despite this, N10 has a typical canonical NA fold as well as calcium binding site, and shares 
overall structure when superimposed onto other NAs. The putative active site has a wider 
binding site pocket with an open pseudo-active site which has unfavourable electrostatic 
potential, making it a poor candidate for sialic acid binding and cleavage (Q. Li et al. 2012; X 
Zhu et al. 2012; Xueyong Zhu et al. 2013). 
6.1.2 Culture of H17N10 influenza virus 
Initial attempts at culture or rescue of WT H17N10 virus failed (Tong et al. 2012, 2013). 
However, other groups have since succeeded in producing H17 bearing particles 
pseudotyped with H17 and N10 glycoproteins (M. Hoffmann et al. 2016; Maruyama et al. 
2016). In both the previously cited articles, a rhabdoviral (VSV) system was used to 




characterise H17 and N10. Hoffmann et al. managed to show infection of the bat derived 
cell lines EidNi/41, HypNi/1.1, EpoNi/22.1, but not traditional IAV or other cell lines (MDCK, 
HEK293T, and Vero). Maruyama et al. 2016 published similar results, successfully infecting 
bat derived cell lines (IndFSPT1, YubFKT1, and SuBK12-08), and interestingly, managed to 
infect the MDCK cell line used. A more recent study succeeded in using a VSV system to 
infect a variety of human or other mammalian derived cells including MDCK II and RIE 1495, 
also succeeding in producing competent H17N10 and H18N11 which were propagated in the 
same cell lines in the presence of trypsin (Moreira et al. 2016). The fact that some research 
groups have had success with MDCKs while others have not is a problem compounded by 
the nature of this cell line designation. MDCK cells are often used in influenza research and 
ƚŚĞƌĞ ĂƌĞ Ă ŐƌĞĂƚ ǀĂƌŝĞƚǇ ŽĨ  ‘ƐƚƌĂŝŶƐ ? ĂǀĂŝůĂďůĞ ŝŶĐůƵĚŝŶŐ D< / ĂŶĚ MDCK II which were 
used in this project. Differences in results between laboratories could be accounted for by 
lack of correct information about the strains used. This problem is discussed 
comprehensively by Dukes et al. 2011. These studies on the H17 and N10 genes, combined 
with the characterisation of internal gene segments by Juozapaitis et al. 2014 , are evidence 
that H17N10 is a functional virus to which we have only just started to culture as a full viral 
entity (Moreira et al. 2016). 
6.1.3 Zoonotic potential 
Due to the nature of influenza A and the risk posed to human and livestock populations 
from reassortant strains with epidemic/pandemic potential, the discovery of novel and 
significantly divergent subtypes of influenza virus was worrying to the influenza community. 
This was reinforced after the publicity surrounding the bat-suspected Ebola outbreak in 
2014. Efforts are now being made to discover whether bats represent a true reservoir for 
influenza viruses, and if there remain further subtypes to be characterised. Due to the large 
diversity in, and widespread nature of bat populations, further studies are required to 
determine the risk of crossover and host susceptibility (Serra-Cobo and López-Roig 2016). To 
further support the importance of this point, a recent study identified influenza H9 cross-
reactive antibodies in a large proportion (30%) of bats in Ghana (Freidl et al. 2015). This 
serological approach may represent a solution, as antibodies may be detectable for longer 
periods post infection than vRNA through consensus RT-PCR.  While similar studies to the 
original H17N10 and H18N11 articles (Tong et al. 2012, 2013) have been carried out in 




Europe on central European bats (Fereidouni et al. 2015; Sonntag et al. 2009), no evidence 
of influenza virus was detected through consensus RT-PCR.  Efforts must be made to 
reproduce these studies worldwide using PCR and serology to map the extent of cross-
reactive immunity and influenza prevalence in bats. Further work on H17 and N10 suggests 
that receptor specificity is not only impeding attempts to study the WT virus, but also acting 
as a major limiting factor for infection due to receptor presence or abundance on different 
cell types (B. Zhou et al. 2014). Zhou et al. 2014 found that the bat viruses were 
incompatible with influenza A or B on a genetic and protein level, reducing the risk of 
reassortment with influenza A or B viruses and subsequently reducing the pandemic 
potential of these viruses.  
6.2 Methods 
6.2.1 Plasmids, Cells and reagents 
The eukaryotic expression plasmid pI.18 (Cox et al. 2002) was used as a backbone for H17 
and N10 (A/little yellow shouldered bat/Guatemala/060/2010) expression plasmids, both 
genes of which were subcloned into pI.18 by a previous student, Dr Francesca Ferrara, at 
the Viral Pseudotype Unit, Medway School of Pharmacy.  
Multiple cell lines were used in this project. Human embryo kidney cells (HEK293T/17) were 
obtained from Dr Davide Corti, Institute for Research In Biomedicine, Switzerland and were 
used for production of PV as well as in titration and neutralisation assays. MDCK cells used 
originate from two sources. MDCK I cells were obtained from Prof Sarah Gilbert, University 
of Oxford. MDCK II, alongside rat intestinal epithelial cells (RIE 1495) were obtained from Dr 
Martin Schwemmle, Institute of Virology, University of Freiberg, Germany. MDCK I, II and 
RIE 1495 cells were utilised in titration and neutralisation assays. mAbs used include CR6261 
(Friesen et al. 2010), CR9114 (Dreyfus et al. 2013) as well as F16-nt and F16-chol which were 
originally described by Corti et al. 2011 and reproduced from the published sequence by 
Lacek et al. 2014. 
Four human sera were used in this project. These were kindly provided by Prof. Sarah 
Gilbert, Jenner Institute Laboratories, University of Oxford. Samples were taken from adult 
human volunteers during an influenza vaccine clinical trial (NP vaccine) in the Oxford area, 
United Kingdom. Two high positive and two low positive (based on pMN neutralising 




antibody titre to CS CHM cHA PV, see chapter 3) were selected from a panel of sera in order 
to interrogate H17N10 PVs, using MDCK II and RIE 1495 as target cells in the neutralisation 
assay. 
6.2.2 Cell culture 
MDCK I, MDCK II and RIE 1495 cells were cultured in T25 or T75 flasks (Thermo Fisher 
Scientific, cat: 156367, 156499).  Cells were subcultured 1:5 on Mondays and Wednesdays, 
1:10 on Fridays. Cell monolayers were washed twice with PBS (without Calcium/Magnesium, 
Pan Biotech, cat: P04-36500) before addition of 2 ml (T25) or 4 ml (T75) Trypsin 0.05 % 
EDTA (Pan Biotech, cat: P10-040100) and incubation for 10-20 minutes at 37°C, 5% CO2. 
Cells were resuspended in a total volume of 5 ml (T25) or 10 ml (T75) whereupon they were 
diluted for use in titration/pMN assays or seeded for future use. 
6.2.3 Production of luciferase PV using H17 and N10 glycoproteins 
Luciferase PVs were produced as in chapter 2, section 2.3.1. Standard reagents were used 
for the production of H17 and H17N10 PV, plasmid quantities are listed in Table 6.1. 
Table 6.1. DNA mix plasmid quantities. H17N10 PV were produced by co-transfection of HEK293T/17 
cells with the following quantities of plasmid per well of a 6-well plate. 





Protease encoding plasmid 125 
 
NA-only PV produced for ELLA were produced in a similar fashion to other PV, with the 
exception that supernatants were harvested 72 h post transfection, in lieu of the traditional 
48 h. Table 6.2 lists plasmid quantities for each preparation of N10-only PV produced. Other 
viruses used in the ELLA were produced previously and using standard methods. These were 
quantified by RLU/luminescence and used in the ELLA as controls (N1-N9) or to determine 
N10 activity (H17N10, H5N10). 
  




Table 6.2. List of plasmid quantities used for N10, H5N10 and H17N10 PV production. Production 
was carried out in 6-well plates, values represent ng per well. Plasmid IDs are shown alongside the 
exact quantities (per well of a 6-well plate) of plasmid used in the transfection mix when producing 
PV. 


















 N10 500 750 1000 1500 2000 3000 250 250 
HA - - - - - - 500 500 
p8.91 500 500 500 500 500 500 500 500 
pCSFLW 750 750 750 750 750 750 750 750 
6.2.4 Titration of H17 and H17N10 on various cell lines 
H17 and H17N10 bearing PV were titrated as described in chapter 2 (section 2.3.2). Multiple 
cell lines were used as targets for these PV: MDCK I, MDCK II, RIE 1495 as well as 
HEK293T/17. 
6.2.5 pMN of H17 and H17N10  
bnmAbs were employed using the pMN assay. Input quantity used was 5000 ng, giving a 
concentration gradient of 5000 to 40 ng after 1:2 serial dilutions, across which the mAbs 
neutralising capacity was measured. mAbs CR9114, F16-nt and F16-chol were tested. A 
subset of samples from the Jenner institute laboratories, University of Oxford (detailed in 
chapter 3 and appendix X1) were also tested on H17N10 PV. 
6.2.6 ELLA using N10 
The ELLA is described in further detail in sections 2.3.5 and 5.2.4. ELLA titration was carried 
out using N10 PV produced under various parameters (Table 6.2) as well as H5N10, H17N10 
and other IAVs (H3N1, H3N3, H3N4, H3N8, H3N9) produced using standard parameters 
(Table 2.6). 
6.3  Results 
6.3.1 Titration of PV preparations using newly acquired cell lines: MDCK II 
and RIE 1495. 
The H17 and N10 glycoproteins were obtained through a gene synthesis service (Genscript, 
USA) and cloned into vector pI.18. These genes were then used to produce H17 and H17N10 
bearing PV. However, the original cell lines tested were not permissive to these PV. Only 




one positive result was obtained which could not be repeated. H17 bearing the pCSGW GFP 
reporter was successfully used to transduce U87 cells after having been produced in the 
presence of TMPRSS2 and HAT proteases. This work was carried out by Dr Stuart Mather 
(Figure 6.2).  
The lack of results with a luciferase reporter and lack of reproducibility with GFP lead to 
cessation of this project until further reagents became available, the starting point of this 
chapter. Upon evaluation of some of these initial preparations on the newly available cell 
lines MDCK II and RIE 1495, a positive signal was obtained (Figure 6.3) for one preparation 
of H17N10 produced with 125 ng of HAT protease encoding plasmid in a 6-well dish format 




Figure 6.2. Transduction of U87 cells by influenza GFP PV. A) H17 produced using pCAGGS-HAT. B) 
H17 PV produced using pCAGGS-TMPRSS2. C) Cell only control. D) H5 (A/Viet Nam/1194/2004) PV 
positive control. Immunofluorescence carried out by Dr Stuart Mather.  
  





Figure 6.3. Titration of initial H17 based PV preparations on HEK293T/17 as well as newly acquired 
cell lines MDCK II and RIE 1495. No positive RLU/ml signal is observed for H17 based PV titrated on 
HEK293T/17 cells when compared to Delta Envelope negative control and A/Vietnam/1194/2003 
(VN1194) and VSV-G positive controls. When using MDCK II and RIE 1495 cells, a positive signal is 
observed for one H17 PV preparation: H17N10 produced with 125ng HAT by Dr Keith Grehan. 
6.3.2 H17 and H17N10 are activated by proteases HAT, TMPRSS2 and 
TMPRSS4. 
Further experiments were planned and carried out to repeat the previous results under the 
same production parameters, and also to produce H17 and H17N10 bearing PV in the 
presence of other proteases available in the laboratory. All experiments from this point 
forward were carried out with co-transfection of 125 ng of protease encoding plasmid per 6-
well plate well, in addition to pI.18-H17, p8.91, and pCSFLW plasmids (+ pI.18-N10 for 
H17N10 PV). It was decided that this plasmid quantity was sufficient for the detection of an 
increased PV titre, based on experiments with other influenza luciferase PV. Our results 
show that TMPRSS2, TMPRSS4 and HAT significantly increase the titres of H17 and H17N10 
PV, titres being several logs higher than baseline cell or delta envelope controls in both 
MDCK II and RIE 1495 cells. There is a disparity between the results obtained between H17 
and H17N10 on MDCK II cells, with H17N10 titres approximately one log higher. Titres 
obtained when transducing RIE 1495 cells were consistently the highest within this set of 
data. VSV-G PVs were used as a cell transduction control, providing us with a maximum 
transduction value due to the fact that this glycoprotein mediates entry with a highly 
ubiquitous LDLR receptor (Finkelshtein et al. 2013). VSV-G PV titres were lower than H17 
titrated on MDCK II, and H17 and H17N10 titrated on RIE1495, possibly indicating that the 
H17 receptor is in greater abundance than LDLR.  H17 and H17N10 PV were also able to 
transduce MDCK I cells after activation via HAT (Figures 6.4 and 6.5). 






Figure 6.4.Transduction of MDCK I cells by H17 and H17N10 PV produced in the presence of HAT. H5 
(A/Vietnam/1194/2004), VSV-G and Delta Envelope PV used as controls. H17 and H17N10 PV both 
show RLU/ml values higher than H5 which is not significantly higher for H17 (p=0.3496) but 
significantly higher for H17N10 (p= 0.0240). H17 and H17N10 titres were both significantly higher 
than Delta Env titres (P=0.0326 and 0.0003 respectively). 
 





Figure 6.5. Luciferase based titration of H17 and H17N10 PV produced in the presence of proteases TMPRSS2 (T2), TMPRSS3 (T3), TMPRSS4 (T4), HAT, KLK5, 
and Furin. Values in RLU/ml. VSV-G bearing PV used as transduction control for high titre PV. Proteases T2, T4 and HAT included in the production stage of 
H17 and H17N10 PV lead to high titre PV due to proteolytic activation of the H17 glycoprotein, with the highest titres observed in RIE 1495 cells.




6.3.3 N10 mediates release of group 1 and group 2 influenza PV. 
Production of PV bearing H5 HA (A/Vietnam/1194/2004) or H7 HA (A/Shanghai/2/2013) and 
the N10 (A/little shouldered bat/Guatemala/060/2010) lead to an increase in RLU/ml titre 
for both PVs when compared to H5-only and H7-only PV produced in the absence of a 
source of NA (Figure 6.6). PV produced without an envelope glycoprotein produced a 
luciferase signal approximately 1-2 logs lower than H5/H7 PV produced without an NA 
source present. 
 
Figure 6.6. N10 releases group 1 (H5) and group 2 (H7) bearing PV. RLU/ml titres for H5 
(A/Vietnam/1194/2004) and H7 (A/Shanghai/2/2013) released with exogenous NA (+ NA), N10 
(+N10) or produced in the absence of NA (-NA). Delta envelope control represents a baseline RLU/ml 
value.  
 
Subsequently, results for multiple different preparations of N10 as well as H17N10 and 
H5N10 bearing PV (Table 6.2) produced negative results in the ELLA. In contrast, control H3 
PVs bearing N1, N3, N4 and N9 were positive for sialidase activity to varying degrees (Figure 
6.7).  Control PV (H3NX) produced by Rebecca Kinsley and Martin Mayora-Neto. 





Figure 6.7. ELLA for PVs bearing N10, H5N10, H17N10 and H3NX (N1, N3, N4, N8, N9) glycoproteins. 
No NA activity is observed for any N10 bearing PV. NA activity is detected for N9, N3, N4, N8 and N1 
PV alongside the H3 glycoprotein (ordered from strongest to weakest NA activity). 
 
6.3.4 H17 is neutralised by bnmAbs targeting the conserved stalk region. 
bnmAb CR9114 strongly neutralised H17N10, giving IC50 neutralising antibody titres of 61.18 
ng/ml on MDCK II cells and 66.41 ng/ml on RIE 1495 (Figure 6.8). F16-nt also neutralised H17 
and H17N10, giving neutralising antibody titres of 12 µg/ml (MDCK II) and 68 µg/ml (RIE 
1495) (Figure 6.9). F16 conjugated to cholesterol (F16-Chol) was much less neutralising, 
antibody titres were  191 µg/ml (MDCK II) and  997 ug/ml (RIE 1495)  (Figure 6.10). CR6261 
did not neutralise H17N10 at any concentration attempted (maximum 100 Ɋg/ml starting 
concentration).  
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Figure 6.8. Neutralisation of H17N10 by mAb CR9114 when transducing MDCK II and RIE 1495 cells. 
CR9114 neutralises H17N10 PV when using both MDCK II and RIE 1495 in the pMN assay. 
Neutralising antibody titres (IC50) for CR9114 on MDCK II and RIE1495 cells were 61.18 and 66.41 
ng/ml respectively. mAbs were tested in duplicate with more consistent neutralisation seen when 
using MDCK II cells in the pMN assay.  
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Figure 6.9. Neutralisation of H17N10 PV by mAb F16-nt when transducing MDCK II and RIE 1495 
cells. F16-nt neutralises H17N10 PV when using both MDCK II and RIE 1495 in the pMN assay. 
Neutralising antibody titres (IC50) for F16-nt on MDCK II and RIE1495 cells were 12 and 68 µg/ml 
respectively. mAbs were tested in duplicate with consistent neutralisation seen when using both 
MDCK II and RIE1495 cells in the pMN assay. 
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Figure 6.10. Neutralisation of H17N10 PV by mAb F16-chol when transducing MDCK II and RIE 1495 
cells. F16-chol poorly neutralises H17N10 PV, using both MDCK II and RIE 1495 in the pMN assay. 
Neutralising antibody titres (IC50) for F16-chol on MDCK II and RIE1495 cells were 191 and 997 µg/ml 
respectively. mAbs were tested in duplicate with more consistent results observed when using RIE 
1495 cells.  
6.3.5 Human sera show neutralising activity against H17N10. 
The subset of human serum samples used in pMN assays on H17N10 PV showed varying 
neutralising titres; titres for sera were between 24 and 289, representing the reciprocal 
dilution point for inhibition of 50% of the RLU input signal. Neutralisation curves are 
displayed in Figure 6.11 and IC50 values recorded in Table 6.3. The most consistent 
neutralisation curves were generated when PVs were used to transduce RIE 1495 cells in the 
presence of serum J136 (IC50: 289). Other sera show a trend towards decreasing 
neutralisation as serum is diluted, but no distinctive curve is produced by nonlinear 
regression analysis, reducing the confidence which can be attributed to these results. 
Nevertheless, neutralisation is observed when compared to negative serum control (FBS).  
Table 6.3. IC50 values for subset of Oxford serum samples assayed against H17N10 PV. Samples J136 
and J56 were chosen as high positive samples while J50 and J170 were chosen as low positive 
samples, based on pMN against CS CHM PV. High and Low positive serum samples behave similarly 
against H17N10 PV. 
Serum ID IC50 (MDCK II) IC50 (RIE1495) 
J136  137 289 
J50 3 78 
J56 191 176 
J170 24 47 







Figure 6.11. Neutralisation of H17N10 PV by Jenner Sera samples (J#). Two high positive (J136 and J56) and two low positive (J50 and J170) as determined 
by pMN vs. CS CHM bearing PV. Serum samples were picked and assayed against H17N10 luciferase PV on both MDCK II and RIE 1495. Neutralisation was 
observed, with high positive samples more efficiently neutralising H17N10 PV than low positive samples when compared to the negative serum control FBS.
Chapter 6  W Development and use of H17 and H17N10 PV 




6.4.1 H17 PV transduce MDCK I, MDCK II and RIE 1495 cells 
By acquiring and employing the new cell lines MDCK II and RIE 1495, an H17 dependent 
luciferase signal from the transduction of these cells by our PV was produced (Figure 6.3). 
This allowed us to study this HA as well as the effect of its matched NA in neutralisation and 
inhibition assays. Our data reinforces the utility of MDCK II and RIE 1495 cell lines in 
characterisation or study of bat influenza viruses (Moreira et al. 2016). After successfully 
performing experiments on MDCK II and RIE 1495 cells (Figure 6.5), Experiments were 
repeated with the MDCK I line, showing successful transduction by H17N10 and H17 
luciferase PV, despite previous lack of results with this cell line (Figure 6.4). 
6.4.2 H17 HA cleaved by proteases 
We have reproduced work showing that TMPRSS2 and trypsin like proteases can activate 
H17, adding to the list HAT and TMPRSS4 which are frequently used for the activation of 
other IAV HAs in the PV production process (Figure 6.5) (Ferrara et al. 2012; M. Hoffmann et 
al. 2016). While we have shown that TMPRSS3, Furin and KLK5 have little to no effect on 
H17 activation in our PV system, it is possible that these proteases are not compatible with 
the current PV production system, they may be incorrectly localised within the cell and 
therefore not have an effect. There is a great deal of further work which could be carried 
out to further understand the susceptibility of H17 to different proteases as well as the 
extent to which these types of proteases are present in the cells susceptible to infection by 
this virus. 
6.4.3 N10 releases group 1 (H5) and group 2 (H7) influenza PV 
ELLA was negative for all N10 bearing PV, despite the production of multiple different 
batches with increasing quantities of the pI.18-N10 expression plasmid, in addition to 
H17N10 and H5N10 which functioned in viral entry assays (Figure 6.7, section 6.3.3). The 
fact is that N10 is not acting as an IAV like sialidase (García-Sastre 2012), the ELLA assay is 
not suitable for detection of N10 enzymatic activity, or that it is unable to detect it. 
However, we have shown that N10 mediates release of group 1 and 2 HA influenza bearing 
PV in the absence of another source of NA (Figure 6.6). This intriguing finding shows that the 




enzyme is acting in an influenza specific manner, but does not help to characterise its 
interactions with the matched H17 glycoprotein. It is possible that the N10 is cleaving 
further down the carbohydrate chain, leaving behind residues that do not allow for HA 
binding, preventing build-up of viral particles on the cell surface and crucially resulting in a 
negative result in ELLA. It is also possible that NA is mediating increased budding of 
influenza PV, leading to the increase in titre observed in this fashion (Barman et al. 2004; B. 
J. Chen et al. 2007; Jin et al. 1997).  
6.4.4 H17 PV neutralised by bnmAbs 
Despite the undecided nature of the pandemic threat posed by exotic viruses such as 
H17N10 (or its related bat virus H18N11), it is encouraging to know that stalk-binding 
bnmAbs are effective at neutralising the H17 glycoprotein (Figures 6.8-6.10). With the ever 
growing number of research groups attempting to produce universal vaccines that elicit 
production of similar stalk-targeting antibodies, any breakthrough and subsequent use in 
vaccination programs or trials should elicit immune responses which cross-react with bat 
influenza viruses, reducing severity of disease and risks of H17 spreading in naïve human 
populations. 
6.4.5 Further work 
In order to strengthen these results, further sets of MDCK derived cell lines should be 
obtained and tested alongside MDCK I and MDCK II cells. This will help to interrogate the 
discrepancy in results seen in the published literature and our work (Maruyama et al. 2014; 
Moreira et al. 2016). This could also encourage stakeholders to further investigate the 
MDCK cell types they use and increase the reproducibility and accuracy of MDCK derived 
results. Also, comparison of the MDCK II, RIE 1495 and HEK293T proteome may help 
characterisation of the H17 receptor and direct future experiments. Much work is required 
on discovery of the H17 receptor as well as the substrate required for N10 activity. It is 
unclear whether H17 requires N10 for viral egress through its action or other effects, such 
as the binding attributes seen in some H3N2 strains (Y. P. Lin et al. 2010). Nevertheless, N10 
is shown to be a functional enzyme having a clear impact on egress and production titres of 
H17 bearing PVs, it would be interesting to discover the substrate in order to be able to 
adapt ELLA to detect its activity and allow further work to be carried out.  
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Chapter 7 : Discussion and conclusions
In this thesis, several objectives were achieved using PV bearing influenza glycoproteins. 
First, a cHA bearing the stalk from the 2009 H1N1pdm strain was produced alongside the 
parental strains and employed in a serological collaboration towards the detection of 
heterosubtypic/broadly neutralising antibodies in human sera.  This not only confirmed the 
increase in bnAbs post H1N1pdm, but represents a useful tool for the further dissection of 
stalk antibody responses from those against the head of future strains through the 
employment of cHA bearing PV. Second, gold standard serological assays (HI, SRH) were 
compared to the pMN assay using two defined sets of sera against both lineages of 
influenza B, showing correlation between assays for the Yamagata but not Victoria lineages. 
Third, the ELLA assay was adapted to the use of PV and optimisation was carried out with 
currently relevant strains towards the generation of high ELLA titre PV preparations as well 
as the generation of reliable and highly reproducible data. Fourth, PV bearing the bat 
influenza H17 glycoprotein were successfully used to transduce cell lines MDCK I, MDCK II 
and RIE 1495, and it was shown that this exotic strain was neutralised by characterised 
bnAbs CR9114 and F16 as well as human sera with high stalk neutralising properties. 
Subsequently it was shown that the bat influenza N10 glycoprotein, while unable to cleave 
FBS derived fetuin in the ELLA assay, was still able to mediate the release of group 1 and 2 
influenza PV in the absence of another source of NA. 
7.1 Chapter 3 
The cHA PV system allowed the generation of large amounts of neutralisation data, 
especially so due to each serum sample being tested on three different HA bearing PV. This 
resulted in data against an exotic group 1 strain (H11), a pandemic strain (H1 CA/09) and the 
chimera, allowing the interpretation of heterosubtypic immunity in each of nearly 200 
patient samples. Serum samples spanned from 2008 to 2016 but unfortunately only 20 
samples were collected from patients prior to the pandemic H1N1 start. Ideally, samples 
would have been obtained in groups pre and post 2009 with known HI data against the 
pandemic strain, allowing the confirmation of bnAb increases due to CA/09 infection. 
However, this was not possible due to the rarity of serum samples which were very kindly 
provided by the Jenner Institute Laboratories. The three virus system is time and resource 




consuming, which is not ideal when low volumes of serum are available. Despite the lack of 
serum samples pre 2009, the available panel performed as expected, with low neutralising 
antibody titres against H11, typical cross-reactive titres against CA/09 and relatively low 
titres against the cHA (Figure 3.19). When bracketed by year (Figure 3.20), an interesting 
pattern is seen in that after 2009 various spikes in neutralising antibody titres are observed, 
raising the average titres for each year respectively. When bracketed by influenza season, 
an even more prominent peak is seen for the 2009 season against all three PV, indicating an 
increase in heterosubtypic immunity in the first pH1N1 influenza season (Figure 3.21). Each 
season following 2009-2010 showed increased neutralising antibody titres against the CS 
CHM. This confirms that circulation of the pH1N1 strain corresponds with increases in 
heterosubtypic immunity. Age bracketing of neutralising antibody titres generated using the 
cHA system (Figure 3.22) showed an increase in bnAbs in the elderly and the younger age 
group (20s) which was hit the hardest by the 2009 pandemic (Dawood et al. 2012; Shrestha 
et al. 2011). The Sports Science Sera evaluated against various different group 1 and group 2 
influenza bearing PV generated interesting data on heterosubtypic protection. Expectedly, 
high neutralising antibody titres were observed against H1 and H3 seasonal strains and 
lower titres against exotic H5 and H7 subtypes (Figure 3.23). However, the data generated 
allowed the pairing of data for high responders against multiple subtypes, enabling us to 
identify the patients in Table 3.4 who display high titres within a group or between groups. 
While this system is also resource heavy, this approach could suit a small scale project using 
a defined set of HA bearing PV. Interestingly, the use of serum samples in ELLA based upon 
their performance in pMN yielded data which correlated remarkably well between the two 
assays (Figure 3.25). This is incredibly useful data when considering that infection with 
pH1N1 will generate an immune footprint against both the HA and NA glycoproteins used in 
these assays. Having near perfect correlation between antibody titres against each 
glycoprotein using influenza PV makes these two assays an excellent choice for future 
projects determining HA and NA directed antibody responses. 
The next step for cHA bearing PV is to troubleshoot the problems with the production of 
group 2 and influenza B cHAs. A starting point could be recreation of successfully published 
cHAs, using this as a platform for the creation of further cHAs through site directed 
mutagenesis or seamless cloning. Following this, further large scale projects should be 
attempted, ideally with serum from universal vaccine candidates which are also being tested 




for immunogenicity by traditional means (ELISA). To this end, RLU titres must be improved 
for cHAs bearing the CA/09 stalk, which has been difficult to produce in high enough titres 
to perform neutralisation assays. Finally, a larger scale project involving CA/09, CS CHM and 
ELLA on a defined serum panel from patients known to be positive/negative to CA/09 would 
be an excellent project to learn more about the strengths and weaknesses of this system.  
7.2 Chapter 4 
Interesting data on the neutralisation of influenza B PV was generated in the projects listed 
in chapter 4. First, a panel of recently characterised mAbs was evaluated against the 
available influenza B PV library, consisting of strains from Yamagata and Victoria lineages as 
well as the pre-lineage strain (Table 4.4). The results with B/Brisbane/60/2008 were 
unexpected (Figure 4.3), as the original article in which the mAbs were characterised 
showed that they were susceptible to Victoria specific mAbs (Verma et al. 2017). The 
evaluation of pMN alongside widely used assays HI and SRH raised some interesting 
questions on the nature of serological assays and influenza virus. Two strains, each from a 
different lineage of influenza B were assayed by HI, SRH and pMN, generating IC50 and IC90 
data for the latter. mAbs behaved as expected for the Yamagata lineage, but not for Victoria 
in the case of B/Brisbane/60/2008 (Figures 4.3 and 4.4). Interestingly, the pre-lineage strain 
was neutralised in a similar manner to the Victoria lineage, being susceptible to mAbs 
generated against cross-lineage epitopes as well as Victoria specific epitopes. The fact that 
in two different cases discordant results have been attributed to B/Brisbane/60/2008 
bearing PV is a cause for concern. Sequencing of this gene revealed no deletions or 
insertions, PVs were functional and fully able to transduce cells through HA based entry of 
the lentivirus, and B/Brisbane/60/2008 antiserum neutralised B/Brisbane with a higher 
potency than other influenza B PVs based on pMN assay (Figure 4.5). It is important to note 
that the B/Florida/4/2006 gene used was human codon optimised whereas the gene for 
B/Brisbane/60/2008 was WT. This could lead to differences in glycosylation patterns, 
masking the target epitopes of the 8E12 or 5A1 mAbs in comparison to the original 
published paper by Verma and colleagues. This is further reinforced by this groups frequent 
use of human codon optimised synthesized genes (personal communications with Dr Jerry 
Weir), and previous work showing the effect of codon optimisation on N-linked 
glycosylation (Ebrahimi and West 2014). Troubleshooting this problem would be facilitated 




by generation of a codon optimised gene for B/Brisbane/60/2008, in order to reduce the 
number of variables between strains of influenza B PV. Testing WT and codon optimised 
B/Brisbane PV side by side would yield interesting data on the effect of codon optimisation 
on influenza HA N-linked glycosylation and whether this causes masking or unmasking of 
epitopes, leading to the results reported in this chapter. Despite the discordant data with 
Victoria lineage strain B/Brisbane/60/2008 (Figures 4.8-4.13), pMN, HI and SRH assays 
correlated well for the Yamagata lineage strain B/Florida/4/2006 (Figures 4.14-4.19). This 
experiment should be repeated in the future with a further set of PV from each influenza B 
lineage. First, this would provide further data to determine whether Victoria lineage strains 
do not correlate well between assays or whether the problem lies in B/Brisbane/60/2008. 
Second, this would allow the establishment of a correlate of protection of pMN data 
generated using influenza B PV, which would lend greater value to future projects involving 
these PV. 
7.3 Chapter 5 
The data presented in chapter 5 represent the establishment and optimisation of ELLA using 
PV as a source of NA in the Viral Pseudotype Unit laboratories. This assay adds a further 
aspect to the use of PV in serology, expanding PV utility in the measurement of 
immunogenicity of vaccines involving an NA component, and enables the user to perform 
experiments against novel NA inhibitors designed to reduce morbidity following infection 
with influenza viruses. Interesting factors affecting the result outputs were tested, such as 
ELLA viral input (OD492 of 2.0 or 90% of titration input) and concentration of PNA-HRPO 
(Figures 5.2 and 5.17-5.18). These two variables, when diluted gave rise to reduced NA titres 
or increased antibody titres (Figures 5.17 and 5.18). Also, we succeeded in producing high 
titre NA only PVs which performed well in ELLA, despite being more easily neutralised than 
PV bearing HA and NA (Figure 5.11). These PVs provide a platform which, alongside HA only 
PVs in the pMN assay, offer a clean measure of antibody potency against the glycoprotein of 
choice  W eliminating the effect of steric hindrance from reported antibody titres. The data 
generated with the various parameters suggested that using more concentrated PNA-HRPO 
(1:500) and a higher viral input resulted in optimal data. Reduction in viral input lead to 
increased values for negative controls, and reduction in concentration resulted in higher 
antibody titres for low positive samples (Figures 5.18 and 5.19). Both of these scenarios 




would be best avoided in future projects using ELLA. The next step for ELLA is utilisation in a 
wide ranging project, alongside pMN values against matched HA bearing PVs. The 
combination of clean HA/NA responses with high correlation observed between the same 
pH1 and pN1 assays in chapter 3 (Figure 3.25), show that these two assays work well when 
carried out side by side, providing a wealth of data which aid interpretation on immunity 
generated against both glycoproteins, without the risk of data being misinterpreted due to 
the effect of steric hindrance. 
7.4 Chapter 6 
In chapter 6 we reported the success in production of H17 an H17N10 bearing PV, and their 
neutralisation by bnAbs (Figures 6.8-6.10). This exotic HA which has yet to be discovered in 
virus form in the wild is nevertheless important in the context of the history of influenza 
viruses and their ability to cross over into humans and contribute to a pandemic. Recent 
work has shown that the risk is low for H17 and H18 bat influenza viruses, due to 
incompatibility between these viruses and traditional strains (B. Zhou et al. 2014). We have 
confirmed that H17 mediates entry though PV based transduction (Figures 6.3-6.5) and also 
shown that N10 is able to act in a NA-like manner in mediating the release of PV bearing HA 
from group 1 and 2 influenza (Figure 6.6). While various research groups have studied the 
N10 protein and concluded that it is not an NA, these results show that it does have a 
similar action which warrants further investigation. Future work on N10 will include the 
testing of different sources of fetuin as it is possible that the N10 utilises a different 
substrate which is not in abundance in the ELLA assay. Attempts must also be made to 
optimise the ELLA environment to the N10 activity, N10 may not function in the same 
conditions as avian or human NAs. Finally it would be worth titrating N1 CA/09 in wells 
previously exposed to N10, to determine whether N10 cleaves fetuin in a manner which 
releases sialic acid but does not expose galactose, the PNA substrate, thus leading to 
negative ELLA results. 
  




7.5 Vaccines, future of PV in serology/vaccines 
While the focus of this thesis is the production and utilisation of PV in a serological setting, 
the technique remains poorly represented among influenza laboratories and published 
articles, giving way to traditional techniques such as HI, ELISA and SRH. This is unfortunate 
as PV based assays have many strengths over these assays, they are safe, sensitive, easily 
manipulated and only work with functional glycoproteins, opening avenues for the 
detection of antibodies or inhibitors not located at the RBS. Some of the problems with the 
use of PVs surround the fact that they only contain influenza glycoproteins and are 
effectively a lentivirus gaining entry to cells in a HA mediated fashion. Also, the issue of 
glycosylation, raised in chapter 4 is an issue, as PVs are exclusively produced in cells 
originating from the human kidney, whereas batches of inactivated virus used in traditional 
assays would have originated from other sources, whether cell or egg grown. As with all 
areas of biology, the idea of standardisation is the goal to be aiming for, and the 
development of consensus protocols and standard reagents in the future would facilitate 
the comparison of results between assays as well as between laboratories. 
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Jenner Sera, obtained from the Jenner institute laboratories, University of Oxford. Serum 
ID#, age at enrolment (if available), date of sample collection as well as pMN neutralising 
antibody titres (IC50) against A/duck/Memphis/546/1974, A/California/7/2009 and CS CHM 
are displayed. 
      Average IC50 
ID# Age at enrolment Sample date H11 CA/09 CHM 
            
1 47 29.07.08 5 2263 194 
2 31 29.07.08 10 3263 287 
3 28 31.07.08 0 2629 68 
4  - 04.08.08 0 2172 136 
5 34 12.08.08 35 2307 512 
6 23 13.08.08 17 2931 174 
7 24 14.08.08 0 2958 149 
8  - 14.08.08 100 3924 1242 
9 43 21.08.08 2 4050 674 
10 21 29.08.08 6 4956 169 
11 32 11.09.08 4 4146 1167 
12 27 15.09.08 0 3275 421 
13 49 16.10.08 0 2085 141 
14 25 05.01.09 0 2389 126 
15 24 05.01.09 10 3271 77 
16 22 22.01.09 0 1716 78 
17  - 28.01.09 0 9274 308 
18 20 10.02.09 0 7388 801 
19 41 19.02.09 45 3321 423 
20 23 7.09.09 0 1116 137 
21 45 16.03.10 1883 13444 3492 
22 35 16.03.10 40 3223 613 
23 18 16.03.10 0 1414 108 
24  - 07.04.10 429 2033 1820 
25 28 13.04.10 10 1757 132 
26 47 13.04.10 423 2374 543 
27 23 15.04.10 0 7171 1217 
28 23 27.04.10 853 6139 2826 
29 29 17.05.10 0 2116 554 
30 51 17.05.10 33 1470 739 
31  - 24.05.10 108 1492 756 




32  - 24.05.10 133 3217 1440 
33 54 15.06.10 851 2943 2887 
34  - 17.08.10 503 3869 1368 
35 66 07.09.10 49 2035 257 
36 63 24.09.10 54 2866 530 
37 50 05.10.10 284 5356 2122 
38 91 26.10.10 126 4208 1540 
39 66 26.10.10 435 3076 1194 
40 54 17.11.10 207 3540 2942 
41 54 17.11.10 93 4109 225 
42  - 17.11.10 95 1616 211 
43 58 17.11.10 288 3143 812 
44 59 14.12.10 1257 7956 1921 
45 63 14.12.10 553 2194 755 
46 54 14.12.10 151 2555 1654 
47 61 14.12.10 336 9401 5420 
48  - 03.08.11 547 3472 1924 
49  - 09.08.11 45 1728 775 
50 59 16.08.11 78 1989 484 
51 62 25.08.11 - 2684 612 
52 59 25.08.11 37 1524 282 
53 78 13.09.11 165 5547 1038 
54 61 13.09.11 157 2267 1058 
55 75 29.09.11 394 3152 863 
56 65 29.09.11 268 4016 2767 
57  - 27.10.11 791 1757 3250 
58  - 01.11.11 3 1802 851 
59  - 02.11.11 107 6219 901 
60 85 15.12.11 68 7505 1103 
61 63 04.01.12 211 4797 2264 
62 60 31.01.12 - 4101 458 
63 58 01.02.12 380 6718 1563 
64 63 01.03.12 428 4623 1656 
65 76 28.03.12 3 3349 786 
66 82 28.03.12 935 7547 3043 
67 56 28.03.12 2 1337 225 
68 72 04.05.12 1429  - 4248 
69 63 04.05.12 398 6729 2547 
70 80 09.05.12 157 3184 1005 
71 75 09.05.12 80 6473 711 
72 83 22.05.12 3 2838 396 
73 60 16.05.12 233 6134 804 
74 40 20.06.12 25 2191 552 
75 58 12.07.12 63 4008 1508 
76 57 12.07.12 132 6236 1071 




77 62 25.07.12 204 4430 6625 
78 28 31.07.12 23 2806 591 
79 26 02.08.12 - 2686 1033 
80 62 02.08.12 539  -- 1632 
81 65 20.08.12 409 3708 1235 
82 24 23.08.12 - 2490 779 
83 29 28.08.12 12 4356 216 
84 26 28.08.12 302 6078 1010 
85  - 30.08.12 401 2528 650 
86 23 12.09.12 - 11547 668 
87  - 12.09.12 - 23954 901 
88 79 12.09.12 272 3011 1120 
89 67 13.09.12 38 6161 1294 
90 42 19.09.12 213 5824 4322 
91  - 20.09.12 89 3770 1350 
92 47 20.09.12 196 3757 2466 
93 53 21.11.12 306  - 722 
94 32 03.10.12 - 1882 524 
95 49 09.10.12 145 1758 653 
96 21 09.10.12 79 684 489 
97 20 31.10.12 9 10636 561 
98 21 31.10.12 1 4586 811 
99 21 31.10.12 - 3738 3277 
100 21 09.01.13 128 3429 775 
101  - 19.08.13 8 5586 138 
102 22 26.09.13 183 6212 1977 
103 22 26.09.13 3 2417 166 
104 20 18.10.13 - 4022 760 
105 22 12.12.13 117 5947 578 
106 21 05.03.14 491 15535 5008 
107  - 19.03.14 340 7964 1071 
108  - 19.03.14 490 6071 435 
109 20 10.04.14 98 7487 724 
110 20 10.04.14 98 7487 724 
111 39 28.04.14 425 5789 1206 
112 22 13.05.14 61 8123 343 
113 21 15.05.14 185  - 312 
114 24 15.07.14 1 3803 53 
115 22 25.09.14 43 6998 106 
116 29 04.11.14 63 5386 484 
117 23 08.01.15 39 8407 440 
118 20 13.01.15 144 7016 1649 
119 64 15.01.15 7 5090 313 
120 27 23.02.15 239 9394 2773 
121 25 26.01.15 - 6179 691 




122 21 28.01.15 8 7687 630 
123 24 04.02.15 9 6208 1524 
124 24 04.02.15 5 8423 485 
125 25 04.02.15 7  - 1021 
126 22 05.02.15 47 8611 2017 
127 22 10.02.15 532  - 8445 
128 25 11.02.15 357 7630 2302 
129 45 11.02.15 39 3560 396 
130 78 12.02.15 3 2347 561 
131 23 18.02.15 7 8166 235 
132 46 04.03.15 72 9743 1297 
133 21 05.03.15 2 4205 439 
134 21 09.03.15 11 6524 475 
135 21 09.03.15 178 6163 1336 
136 58 21.03.15 66 4149 1471 
137 36 26.03.15 93 2742 830 
138 21 26.03.15 3 5628 80 
139 52 26.03.15 493 4760 1111 
140 60 26.03.15 174 2969 1262 
141 61 26.03.15 35 3023 579 
142 62 15.04.15 - 1726 1307 
143 57 15.04.15 549 4207 2528 
144 52 16.04.15 154 7658 3148 
145 65 16.04.15 752 4691 2604 
146 64 16.04.15 6 2735 713 
147 38 23.04.15 97 4203 959 
148 29 24.04.15 45 6531 638 
149 21 3.05.15 - 6084 634 
150 24 20.05.15 15 3384 1009 
151 20 14.05.15 198 8530 1672 
152 22 13.05.15 1 5890 5540 
153 28 19.05.15 3 3991 461 
154 21 13.05.15 7 5833 2160 
155 26 13.05.15 167 5040 1405 
156 24 20.05.15 7 17860 883 
157 19 13.05.15 434 7965 2206 
158 27 27.05.15 84 3382 595 
159 66 11.05.15 387 3249 1338 
160 54 11.05.15 280 4451 3634 
161 68 18.05.15 - 1354 1627 
162  - 18.05.15 143 3279  - 
163 56 11.05.15 705 11462 1856 
164 63 11.05.15 39 4910 1471 
165 70 18.05.15 510 8439 3141 
166 67 18.05.15 382 3581 2633 




167 50 21.05.15 25 1128 229 
168 72 11.05.15 746 17958 6739 
169 55 13.05.15 - 867 226 
170 52 18.05.15 147 1573 2863 
171 63 18.05.15 292 7916 1636 
172 67 21.05.15 236 4075 1333 
173  - 21.05.15 - 3683 363 
174 22 01.06.15 42 7759 1192 
175 22 01.06.15 66 8711 754 
176 22 04.06.15 46 4219 702 
177 23 08.06.15 42 4488 612 
178 54 28.09.16 165 1490 578 
179  - 26.10.16 191  - 923 
 
  





Sports Science Sera, obtained from Dr Glen Davidson, University of Kent. Serum ID# is 
displayed alongside pMN neutralising antibody titres (IC50) against group 1 
(A/Brisbane/59/2007 (H1) and A/Vietnam/1194/2004 (H5)) and group 2(A/Udorn/307/1972 
(H3) and A/Shanghai/2/2013 (H7)) influenza PV. 






ID 0V 12V 
 
ID 0V 12V 
 0 761 752 
 
0 332 123 
1 1504 5122 
 
1 233 262 
2   2404 937 
 
2 102 257 
3 1845 2202 
 
3 531 1126 
4   9188 6515 
 
4 427 518 
5 7013 16548 
 
5 6107 2421 
6 783 1156 
 
6  1209 1039 
7  9226 2823 
 
7  2257 1835 
8   6817 3761 
 
8  1105 7007 
9  7032 2035 
 
9  1256 1211 
11 5309 5035 
 
11 459 355 
12 3161 2825 
 
12 655 665 
13   757 438 
 
13 355 383 
14 690 578 
 
14 382 404 
15   13736 2646 
 
15 1006 1082 
16 1771 2196 
 
16 725 122 
18 2592 4539 
 
18 754 366 
19 3194 4794 
 
19 259 172 
21 2303 2011 
 
21 203 375 
22   6050 2223 
 
22 419 1342 
23   5298 4303 
 
23 1107 1364 
24 2716 3429 
 
24 1047 2074 
26 2600 9783 
 
26 1285 1701 
27   3699 1959 
 
27 171 229 
28 1580 3660 
 
28 413 538 
29 6089 8584 
 
29 1063 688 
30 3832 10660 
 
30 846 545 
31 4251 5016 
 
31 467 639 
32 1301 15391 
 
32 175 161 
34  2100 2537 
 
34 19 41 
35   10275 6095 
 
35 1107 1086 
36 4683 17408 
 
36 62 85 
37  4319 3011 
 
37 1058 828 




38   7181 1986 
 
38 94 63 
39   4255 3561 
 
39 226 137 
40  1661 4148 
 
40 33 23 
41   44354 27972 
 
41 724 584 
42   8286 3528 
 
42 40 25 
44   10186 7586 
 
44 169 175 
45   4013 6750 
 
45 736 386 
46  6091 5213 
 
46 288 763 
47  9125 3779 
 
47 99 187 
48 1450 1953 
 
48 60 52 
49 13533 14031 
 
49 799 415 
50  14443 3830 
 
50 509 628 
51  2221 9298 
 
51 63 109 
53   1415 4478 
 
53 125 6 
54   19333 32973 
 
54 140 3 
55  2137 3694 
 
55 9 34 
56 4016 3747 
 
56 414 670 
57 1650 1614 
 
57 - 5 
58   25325 89154 
 
58 36 25 
59   8931 25241 
 
59 204 206 
60   45409 10518 
 
60 187 1782 
 






ID 0V 12V 
 
ID 0V 12V 
 0   1484 3747 
 
 0  602 914 
1   1535 3249 
 
1  590 921 
2  3106 2482 
 
2  899 483 
3   4437 5858 
 
3   963 1423 
4   1508 1244 
 
4  1760 774 
5   5856 4769 
 
5   412 781 
6   1169 1837 
 
6   917 1623 
7   2401 2622 
 
7  554 507 
8  3084 2441 
 
8  1129 341 
9  8170 5560 
 
9  3323 1797 
11   1511 4293 
 
11  212 153 
12   1618 6789 
 
12  1106 582 
13   1764 3013 
 
13   281 602 
14   1548 7454 
 
14   665 202 
15  2300 1629 
 
15   376 1100 
16   2351 3341 
 
16  21 87 
18   3834 16920 
 
18   243 365 
19   4374 5416 
 
19   121 254 




21   2124 11279 
 
21  211 149 
22  6242 5500 
 
22  226 272 
23   4618 7714 
 
23   416 987 
24  7580 2574 
 
24   402 674 
26   4371 8359 
 
26   782 1423 
27   2379 2151 
 
27  423 378 
28   8138 15213 
 
28   840 2236 
29   3061 4473 
 
29   75 165 
30  4230 3679 
 
30   442 781 
31  6590 5422 
 
31   256 514 
32   4263 8172 
 
32   183 416 
33 - - 
 
33 - - 
34   542 1216 
 
34  102 45 
35  2688 1433 
 
35  246 113 
36   1403 2408 
 
36   187 334 
37  4879 3538 
 
38  347 397 
38  3520 2734 
 
39  252 179 
39  12763 1456 
 
40   160 336 
40   1247 1583 
 
41   1612 2258 
41   5959 9512 
 
42  515 391 
42  17384 5599 
 
44  300 425 
44  6163 4559 
 
45  315 147 
45   2532 3014 
 
46  74 424 
46   939 2417 
 
47  205 690 
47  1420 1210 
 
48  609 521 
48  1920 1591 
 
49  283 201 
49  3009 1770 
 
50  132 84 
50   1093 957 
 
51  118 637 
51   1139 1491 
 
53  293 1070 
53   1515 21139 
 
54  180 260 
54   2231 7856 
 
55  470 96 
55   4974 5001 
 
56  363 412 
56  4793 2836 
 
57  230 505 
57  2014 6418 
 
58  1569 513 
58   6099 5539 
 
59  317 553 
60  14047 2292 
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